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Summary 
Tobacco use continues to be one of the UK's biggest health problems and smoking 
cessation is one area where health professionals can contribute towards the tobacco 
control agenda. The role that dental team members can play in the smoking cessation 
field is largely unevaluated. The work of this PhD thesis encompasses two phases, the 
first was to develop a means of determining smoking status, using analysis of cotinine, a 
nicotine metabolite. The second phase looked at the efficacy of dental hygienist-
delivered smoking cessation advice in a dental setting. 
The aim of the first study was to compare cotinine levels in different biological fluids 
collected from both smokers and non-smokers, and to relate the findings to self-reported 
smoking status. Patients recruited to the study were asked to provide samples of urine, 
blood and saliva (both stimulated and unstimulated). Data collected from patients by 
questionnaire included information on smoking behaviour, such as daily number of 
cigarettes smoked, and environmental exposure to smoke. Following sample collection, 
patients were asked to rate the acceptability of each sampling method. Samples were 
analysed using enzyme immunoassay (EIA) kits. In total, 80 patients participated, with 
49 smokers and 31 non-smokers. There was clear differentiation between smokers and 
non-smokers (p < 0.001) for all the different samples in terms of cotinine concentration. 
A significant relationship was seen between cotinine levels and daily number of 
cigarettes for both salivas and urine (all p < 0.001) but not for serum. Participants found 
serum and urine collection methodologies 'very acceptable' (67% and 66%, 
respectively) whereas 9% found collection of stimulated saliva 'not at all acceptable'. 
Thus, cotinine, as analysed by EIA kits, whatever the collection method, shows good 
differentiation between smokers and non-smokers. Salivary samples have the advantage 
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of being non-invasive. However, collection methodology is important, as cotinine levels 
may vary. 
The second and main phase of this PhD study aimed to examine the feasibility and 
efficacy of a smoking cessation randomised controlled trial, delivered by dental 
hygienists, in a cohort of periodontal patients attending an outpatient dental hospital 
department. Patients were randomised to receiving either smoking cessation advice 
based on the 5As and nicotine replacement therapy (NRT), or 'usual' care, where the 
patients allocated to the control group received 'very brief advice from the recruiting 
consultant. At baseline, infonnation was collected from 116 participants (59 
intervention and 57 controls), on smoking history, level of nicotine dependence and 
motivation to quit. Patients also provided salivary samples for cotinine analysis, and 
exhaled air samples for carbon monoxide monitoring. At baseline, the mean age of trial 
participants was 41.2 years, 71% were female and half of the recruits (50%) were from 
the more deprived areas (DEPCATS 5-7). The median nicotine dependence score for 
trial participants (as measured by Fagerstrom Test for Nicotine Dependence) was 5, 
with a mean pack-years exposure of 21.5 and 24.8 years for the intervention and control 
groups respectively. 
Point-prevalence quit rates are reported, verified by carbon monoxide and cotinine at 3 
and 6 months, with cotinine verification at one year. 
At 3 months, of the patients followed-up (102; 88%), 17.3% of the intervention group 
had quit, compared to 10.0% of the controls. Of patients recruited at baseline, 15.3% of 
the intervention group quit compared to 8.8% of controls. 
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At the 6-month time point, of the patients followed-up (71; 61%), 16.7% of the 
intervention group had quit, compared to 8.6% of the controls. Of the patients recruited 
at baseline, 10.2% of the intervention group had quit, compared to 5.3% ofthe controls. 
Prolonged abstinence figures would indicate that of the patients followed-up at 6 
months, 11.1 % of the intervention group had quit, compared to 8.6% of the controls. 
When prolonged abstinence is considered in terms of all recruited patients, the 
corresponding figures were 6.8% of the intervention group and 5.3% ofthe controls. 
At 12 months, of the patients followed-up (56; 48%), 12.1 % of the intervention group 
had quit, compared to 8.7% of the controls. Of the patients recruited at baseline, 6.8% 
of the intervention group had quit, compared to 3.5% of the controls. 
With regards to secondary outcomes, those patients who were not successful in quitting 
were asked about changes in smoking behaviours. At 3 and 6 months, there was a 
statistically significant higher percentage of intervention participants who reported that 
they had made a quit attempt of one week or more in the preceding 3 months: 37% and 
47% respectively for the intervention group, compared to 18% and 16% respectively for 
the control group. At 3 months, with regards to self-reported median reduction in 
number of cigarettes smoked daily, there was a statistically significant difference 
between intervention and control groups (33% v 0%). When self-reported reduction in 
smoking was associated with reduction in cotinine levels (reduction of smoking 
between baseline and 6 months), a statistically significant higher mean reduction was 
seen in the group who reported reducing smoking, compared to the group who reported 
that they had not reduced. 
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Using patients' self-reported 'Stage of Change' at baseline as a predictor of likelihood 
of quitting at 3 months, of the 14 biochemically validated quitters at this point, nine had 
classified themselves as being in the most ready state i.e. 'preparation stage' at baseline. 
With regards to using 'Stage of Change' as an outcome measure, where 'success' is 
considered to be positive movement through the model itself, at 3 months, there was no 
difference between intervention and control groups regarding numbers moving forward. 
At 6 months, there were slightly more individuals in the intervention group who moved 
forward compared to the controls. 
With respect to efficacy, this thesis has shown that, given training in smoking cessation 
and access to NRT for their patients, dental hygienists in this secondary care setting can 
have a modest effect, with regards to the delivery of smoking cessation, at least in line 
with success rates reported by other health professionals. Further work needs to be 
carried out to determine the most appropriate model for future delivery of smoking 
cessation by dental team members. 
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Chapter 1 Introduction 
1. t General Introduction 
Smoking has long been recognised as one of the most important preventable causes of 
ill-health and premature death, accounting for 13,000 smoking-related deaths per year in 
Scotland alone (Scottish Executive, 2004a). There are currently around 1.4 million 
smokers in Scotland, approximately 30% of the population. Comparable UK figures 
for tobacco-related disease are 120,000 deaths per year, with more than half dying from 
respiratory disease (Britton, 2004). The burden of disease caused by tobacco also has 
considerable financial implications. It is estimated that the NHS in Scotland spends up 
to £ 140 million every year on treating smoking-related disease (Scottish Executive, 
2003a). However, tobacco is not only a UK but global problem, with tobacco use on the 
increase, especially in the developing countries (Abdullah and Husten, 2004). 
The detrimental general health effects of smoking, such as lung cancer and heart disease 
are well known. Scotland unenviably has the highest lung cancer rate in Europe for both 
men and women (NHS Health Scotland and ASH Scotland, 2004). Tobacco use has 
strong links with deprivation, and is one of the main reasons why disadvantaged people 
are more likely to have poorer health and die younger (NHS Health Scotland and ASH 
Scotland, 2004). Around two-thirds of the social class differences in death rates in 
middle age are due to smoking. Smokers die, on average, 10 years earlier than non-
smokers (Doll et al., 2004). 
While there is high public awareness of the general health risks of tobacco, there is 
much less public awareness of the association between smoking and oral problems such 
as oral cancer, or the links with periodontal disease. Scotland also has high rates of oral 
cancer, higher than in England, and this is largely due to the risk factor of smoking 
(Macpherson et ai., 2003). 
The white paper, 'Smoking Kills', released in 1998 (Department of Health, 1998), set 
out the UK agenda with regards to tobacco control. Following devolution, Scotland 
gained responsibility for her own health agenda, and since then, has followed her own 
(though often parallel with England) path with regards to tobacco control policy. The 
Tobacco Action Plan, released in 2004, aimed to move forward this agenda (Scottish 
Executive, 2004a). Key areas were identified, such as preventing young people from 
starting smoking, expanding smoking cessation services to help more smokers quit, and 
taking action around environmental tobacco smoke. 
Smoking cessation is thus only one of the important strands in tobacco control. There is 
strong commitment to try to reduce the number of smokers and in particular to develop 
services to help them quit. It is known that 70% of smokers want to quit, though around 
2% succeed in the long-term each year (NHS Health Scotland and ASH Scotland, 
2004). 
In the field of tobacco control, the volume of literature is vast. This review attempts to 
focus on the topics of most relevance to the study area described in this thesis, i.e. the 
development and planning of a smoking cessation intervention, as delivered by dental 
team members. 
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Information was retrieved from a variety of sources including librarian-delivered 
searches of Medline, self-delivered searches using PubMed, hand searches of relevant 
tobacco research journals and use of electronic sources such as Globalink. 
1.2 Cigarette Smoking: an epidemiological overview 
1.2.1 History of Tobacco Use 
Tobacco (Nicotiniana tabacum L.), a native plant of the American continent, is believed 
to have been growing there since around 6000 BC (Tobacco Advisory Group of the 
Royal College of Physicians, 2000). Historians hold the view that American Indians 
started to use tobacco as early as the 1 st century BC for medicinal and ceremonial 
purposes. By the 15th century, tobacco smoking was widespread among indigenous 
American people. By the end of that century, tobacco was introduced to Europe, with 
Christopher Columbus returning to the continent with it, received as a gift from 
American Indians (Borio, 2004). 
Contrary to the popular myth that Sir Walter Raleigh was responsible for making 
smoking fashionable in Britain in the late 1500's, it was actually Captain Sir John 
Hawkins who first introduced tobacco into English society in 1565 (Borio, 2004). 
During the 16th and 17th centuries, tobacco was commonly smoked in pipes and the 
habit was confined mainly to males in the upper echelons of society (Borio, 2004). One 
of the main reasons for the early growth in popularity of smoking tobacco was that it 
was thought to have healing properties. However, as early as 1604, King James VI of 
Scotland (I England) produced a damning report entitled 'Counterblaste to Tobacco' in 
which he said that smoking was: 
3 
'custome loathsome to the eye, hateful to the nose, harmful to the brain [and] 
dangerous to the lungs' (James VI, 1604). 
In an effort to discourage the habit, he increased the import tax on tobacco by 4000%, 
resulting in a dramatic decline in tobacco consumption (Borio, 2004). For economic 
reasons, however, this punitive tax was not maintained, thus leading to a rise in tobacco 
use agam. 
The first reference to the addictive nature of smoking was reported in 1610, when Sir 
Francis Bacon found it difficult to quit smoking. 
'the use of tobacco ... conquers men with a certain secret pleasure, so that those 
who have once become accustomed thereto can hardly be restrained 
therefrom ... ' (Bacon, 1622). 
By the mid 1660's tobacco use was common among all sectors of society and trade in 
tobacco between America and Europe had become a major business. The popUlarity of 
tobacco smoking continued to increase during the 18th and 19th centuries, particularly in 
the fonn of cigars rather than pipes. It was the invention of the manufactured cigarette, 
however, that transfonned tobacco smoking into a mass habit. Cigarettes originated 
with British soldiers in the Crimean War (1853-1856) copying the habit of hand-rolling 
tobacco from their Turkish allies. The first cigarette factory opened in England in 1856, 
followed by the Wills factory in Bristol in 1871 and the Players factory in Nottingham 
in 1888 (Borio, 2004). These companies are still key suppliers in the tobacco industry 
today. 
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The scale of cigarette production was revolutionised in the 20th century by James Duke, 
a tobacco entrepreneur who introduced the use of cigarette-making machines (Hurt and 
Ebbert, 2002). Sales of manufactured cigarettes began to increase between 1895 and 
1919 and continued to rise during World War I, when cigarettes were included in 
soldiers' rations. As a result, many soldiers returning home from the war were 
established regular smokers. 
Until the advent ofthe Suffragette movement in the 1920's, it was socially unacceptable 
for women to smoke, but following this, substantial numbers of women started smoking 
and the tobacco industry responded by developing marketing strategies aimed at 
increasing the appeal of cigarettes to women. This resulted in a rapid escalation in 
cigarette smoking among both sexes during the 1930s and 1940s. By this time, the 
British tobacco epidemic was in full force. 
1.2.2 UK Trends in Smoking Prevalence 
1.2.2.1 Adult Trends in Smoking 
Although no direct measures of smoking prevalence are available for the first half of the 
20th century, it is thought that smoking rates in Great Britain changed dramatically over 
the last century. Using tobacco consumption as a proxy indicator, a peak consumption 
level of 8.8 g per head of population was seen in 1945/46 (Nicolaides-Bouman et al., 
1993). At that time, an estimated 65% of men and 40% of women were regular 
smokers of manufactured cigarettes (Tobacco Advisory Group of the Royal College of 
Physicians, 2000). 
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In March 1962, when the Royal College of Physicians in England launched its landmark 
report into the tobacco epidemic entitled 'Smoking and Health', it was estimated that 
70% of men and 43% of women smoked (Royal College of Physicians, 1962). 
Since 1972, smoking habits in Britain have been measured biennially, independently 
from the tobacco industry, as part of the General Household Survey (GHS). This survey, 
at all time periods, includes a proportionally representative sample of the Scottish 
population. 
In the first year of the GHS (1972), figures show that 52% of men and 41 % of women 
were regular smokers in Great Britain (Office for National Statistics, 1998). The more 
recent trends from 1984 to 2002 have shown a fall in prevalence amongst men from 
36% to 27% and a corresponding decreased rate amongst women from 32% to 25% 
(Office for National Statistics, 2004). 
Over the same time period, similar trends were seen in Scotland, albeit rates were 
slightly higher. Prevalence amongst males fell from 43% in 1984 to 29% in 2002, with 
corresponding figures for women being 35% and 28% (Office for National Statistics, 
2004). 
Differences in smoking prevalence in Scotland are also apparent with regard to urban 
and rural areas. Adult smoking rates are higher in urban areas, with smoking being most 
common among adults living in Glasgow, Clackmannanshire, North Lanarkshire and 
West Lothian (each 35%) and least common in adults living in East Renfrewshire (17%) 
and East Dumbartonshire (19%) (Scottish Executive, 2003b). 
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Additional information concerning the smoking habits of the Scottish population is 
available from the results of the Scottish Health Survey, carried out in 1995 (Dong and 
Erens, 1997) and 1998 (Shaw et al., 2000). This survey of the population of adults aged 
16-74, living in private households in Scotland, aims to provide information about 
health and health-related behaviour, and is based on a larger sample size than the 
General Household Survey. 
The 1995 Scottish Health Survey found that 35% of Scots (34% men and 36% women) 
smoked cigarettes (Dong and Erens, 1997). In this survey, self-reported smoking status 
was correlated with the participants' serum cotinine levels. Differences in the self-report 
and adjusted levels of smoking was most apparent in younger age groups, with 36% of 
males aged 16-24 years reporting that they smoked, compared with a biochemically 
validated figure of 45%. A similar but less marked relationship was found with the 
females, with a 33% self-reported smoking status being compared to a 36% level, as 
validated by serum cotinine measurements. 
In the 1998 Scottish Health Survey, one third of adults (33%) aged 16-74 years self-
reportedly smoked, with 34% of men and 32% of women saying that they used 
cigarettes (Shaw et al., 2000). There was no change in prevalence for men between 
1995 and 1998, though there was a reduction in smoking prevalence of 4% in women. 
Self-reported smoking behaviour was highest for males aged 16-24 and 25-34 years, 
with a prevalence of 37% and 39% respectively. Prevalence gradually decreased with 
age, to 32% and 20% of men aged 55-64 and 65-74 years, respectively. 
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By contrast, there was no clear relationship between age and cigarette smoking rate for 
women aged between 16 and 64 years, with prevalence varying between 31 % and 36%. 
However, a lower prevalence of25% was seen in women aged 65-74 years. 
In the 1998 survey, measures of self-reported smoking were verified by salivary rather 
than serum cotinine, in an attempt to increase the number of participants willing to 
provide biological samples for cotinine analysis. The findings were similar to those of 
the 1995 survey with regard to under-reporting, this again being most marked in the 
younger age-groups. Men aged 16-24 years under-reported smoking by 11%, as 
verified by cotinine. A similar trend was found in women in the 16-24 age group, with 
an under-reporting level of 7%. 
Although the survey results found that smoking prevalence rates decreased with age, the 
prevalence of heavy smoking increased with age, with heavy smoking being defined as 
more than 20 cigarettes per day. Of those who smoked, only 35% of women were 
heavy smokers, compared to 42% of men. Additionally, more women (22%) were light 
smokers «10 cigarettes per day) compared to men (18%). 
A Scottish Office White Paper, 'Towards a Healthier Scotland' (1999) set a target of a 
reduction to 33% (from 35%) of Scottish adults who smoke, by the year 2005. This was 
in fact achieved by 2001. A further target of reducing the percentage of the Scottish 
population still smoking to 29% by 2010 still stands (Scottish Executive, 2004a). 
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1.2.2.2 Trends in Smoking Rates in Children 
Information on smoking rates in children in the UK is available vIa the survey 
'Smoking, Drinking and Drug Misuse in Young People' (The Scottish Office, 2000). 
The first survey was carried out in 1982 and has taken place biennially ever since. 
Results from the first Scottish study indicated that 29% of 15-year-old boys smoked, 
compared with 26% of girls. Prevalence for this age group peaked in 1996 with 30% of 
both boys and girls smoking. 
In addition, further information on smoking amongst Scottish teenagers is available for 
children aged 11-15 years via the 'Health Behaviours l?! Scot/ish Schoolchildren' (Todd 
et al., 1999). In addition to smoking, these surveys looked at a variety of self-reported 
behaviours including, diet, exercise and toothbrushing. 
These two surveys have been superceded by the 'Scottish Schools Adolescent Lifestyle 
and Substance Use Survey' (SALSUS) which continues the biennial series of surveys 
used to monitor national trends in smoking, drinking and drug use in young people. 
The first survey using this format was carried out in 2002 (Currie et aI., 2003). 
This study indicated that 8% of 13-year-olds and 20% of 15-year-olds reported regular 
smoking (> 1 cigarette per week). In both age groups, girls were more likely to report 
being regular smokers than boys. Of the girls, 9% of 13-year-olds smoked, compared 
to 6% of 13-year-old boys. Prevalence rose with age, with 24% of 15-year-old girls 
smoking regularly, compared to 16% of 15-year-old boys. 
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When looking at patterns of smoking in 2002, 15-year-old boys reported smoking 
slightly more cigarettes per week than girls (38 v 34). With regard to dependency in this 
age group, the majority (71%) of regular smokers had been smoking for more than a 
year. Most pupils who smoked regularly reported that they would like to give up 
smoking (73% of those who had been smoking for> 1 year). Almost one third (32%) 
of regular smokers reported that it would be 'very difficult' to give up smoking 
altogether, with a further 36% indicating that it would be 'fairly difficult' to stop. 
Overall, of the regular smokers, 70% reported that they had tried to give up smoking. 
National targets have been set for this group, with the aim being to reduce the 
proportion of 12-15 year olds who smoke from 14% (1995 level) to 12% by 2005 and to 
11% by 2010 (The Scottish Office, 1999). Currently, around 12% of 12 to 15-year-olds 
smoke (Scottish Executive, 2004a). 
1.2.2.3 Trends in Smoking amongst Pregnant Women 
During the first antenatal hospital appointment, information is collected which allows 
measurement of the prevalence of women who smoke during pregnancy. Little change 
has been seen in the prevalence of women who smoke at the start of pregnancy over the 
6-year period between 1995 and 2001, with prevalence dropping from 29% to 25% 
(Scottish Executive, 2001). 
Pregnant women who smoke are seen to be a priority group and national targets have 
been set for a reduction from 29% (1995 level) to 23% and 20% by 2005 and 2010 
respectively (The Scottish Office, 1998). 
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1.2.2.4 Risk Factors and Determinants of Cigarette Smoking 
Gender, age and socioeconomic status all have a bearing on smoking prevalence. 
a) Gender 
The effect of gender on the likelihood of smoking is changing. As previously 
described, for most of the 20th century, smoking in Britain was more common in men. 
However, today, rates for adults are almost equivalent in males and females. 
A trend towards increased female smoking rates has been evident for several years in 
schoolchildren, and the gap between the sexes has been increasing. Therefore, for some 
time, females have accounted for the majority of young smokers entering the smoking 
population. Future prevalence of smoking in young males and females will depend on 
uptake and cessation rates in both sexes during the later teenage years. 
b) Age 
Smoking is very uncommon in children up to and including the age of 11 years, but 
increases rapidly between the ages of 12 and 15. As previously described, among 
adults, smoking prevalence is greatest for men in the 25-34 age group and thereafter 
decreases progressively with age. For women, there is a lower prevalence in the older 
age group of 65-74 years. 
c) Socioeconomic Status 
Strong links are seen between smoking prevalence and socioeconomic status. Data 
extracted from the General Household Survey show trends in smoking by 
socioeconomic grouping (SEG) between 1976 and 1998 (Appendix 1). 
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There is a strong social gradient in prevalence of cigarette smoking, with those in 
manual social classes being much more likely to smoke than those in non-manual 
classes. In 1998, at the UK level, 15% of men and 14% of women in SEG 1 smoked 
compared to 45% of men and 33% of women in SEG 6. 
For Scotland, data from the Scottish Health Survey also show a strong social class 
gradient in prevalence of cigarette smoking. In this study, The Registrar-General's 
classification of social grouping is used. In 1995, those from unskilled occupational 
groups were much more likely to smoke (58% men, 54% women) than those in 
professional occupations (17% men; 19% women). As shown in Appendix I, between 
1995 and 1998, smoking prevalence among professional men reduced by 3%. A similar 
but more marked trend was exhibited by professional women, with a reduction of 10% 
between 1995 and 1998. Over the same time period, smoking prevalence in men from 
the unskilled occupations fell by 10% from 58% to 48%, whilst prevalence in women 
from the unskilled occupations actually increased, rising from 54% to 59%, i.e. 6 in 10 
women in this social group used cigarettes. 
When comparing figures from the Scottish Health Survey 1998 (Shaw et al., 2000) with 
data from the General Household Survey 1998 (Office for National Statistics, 2000), 
with the exception of the professional occupations (SEG 1), smoking prevalence is 
higher in Scotland than the UK as a whole. This is most marked in women from the 
partly skilled lunskilled occupations. 
While tobacco use has halved among the affluent, those living in the most deprived 
circumstances have continued to smoke at the same high rate as in the seventies. 
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Disadvantage, inequality and hardship experienced by low-income individuals causes 
them to be more likely to smoke than those from better-off families. Over 70% of two-
parent households on Income Support buy cigarettes, spending about 15% of their 
disposable income on tobacco (Acheson, 1998). 
1.3 Tobacco - Types of Product and Physiopharmacology 
1.3.1 The Constituents of Cigarettes 
Cigarettes are extremely well-designed and efficient delivery systems for enabling the 
speedy uptake of nicotine by the consumer. 
Cigarettes consist of paper tubes containing chopped up tobacco leaf, usually with a 
filter at the mouth end. Cigarette tobacco is blended from two main leaf varieties; 
'yellowish bright', also known as 'Virginia' which contains 2.5-3% nicotine and 
'burley' tobacco which contains a higher nicotine level of 3-4% (British American 
Tobacco, 2004). 
In addition to tobacco, cigarettes contain fillers made from the stem and other 
components of waste tobacco. These are mixed with water and flavourings such as 
vanilla to make the product more appealing to the consumer (British American 
Tobacco, 2004). 
The nicotine and tar delivery can be modified by the type of paper used in the cigarette. 
The use of more porous paper allows more air to dilute the smoke, thus reducing the 
amount of tar and nicotine reaching the smoker's lungs. Filters are made of cellulose 
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and also trap some of the tar and smoke particles from the inhaled smoke. Filters also 
cool the smoke, making it easier to inhale. 
1.3.2 The Constituents of Cigarette Smoke 
Tobacco smoke consists of mainstream and sidesteam smoke. Mainstream smoke is the 
smoke taken into the mouth by the smoker and sidestream smoke is the smoke which 
comes off the lit end of the cigarette. Many toxins are present in higher concentrations 
in sidestream smoke than in mainstream smoke, and nearly 85% of smoke in a room 
results from sidestream smoke (USDHHS, 1984). 
Cigarette smoke is composed of volatile and particulate matter. Some 500 gases, 
including carbon monoxide, nitrogen, carbon dioxide, ammonia, hydrogen cyanide and 
benzene, have been identified in the volatile phase. This accounts for 95% of the 
weight of cigarette smoke, the other 5% being particulate (Tobacco Advisory Group of 
the Royal College of Physicians, 2000). 
There are approximately 3,500 different compounds in the particulate phase, the major 
one being the alkaloid nicotine (Hoffman et al., 1997). The particulate matter, without 
its alkaloid and water content, is called tar. Many carcinogens, including hydrocarbons 
and aromatic amines, have been identified in cigarette tar. 
1.3.3 Nicotine Physiopharmacology 
Nicotine is distilled from burning tobacco and small droplets of tar-containing nicotine 
are inhaled and deposited in the small airways and alveoli. Nicotine is a weak base and 
thus its absorption across cell membranes depends on the pH. When nicotine from 
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cigarette smoke reaches the small airways and alveoli, it is buffered to physiological pH 
and rapidly absorbed into the pulmonary alveolar and capillary circulation and then 
directly into the systemic arterial blood (Tobacco Advisory Group of the Royal College 
of Physicians, 2000). 
From the time of smoking, it takes about 10-19 seconds for nicotine to reach the brain. 
Levels of nicotine in the plasma, as well as the brain, decline rapidly as a result of 
distribution to peripheral tissues. When smokers smoke throughout the day, there are 
oscillations between peak and trough plasma nicotine levels. However, because of its 
half-life of two hours, nicotine accumulates over 6-8 hours reaching levels in the plasma 
ranging from 20-40ng/ml which then fall progressively through the night (Benowitz et 
al., 1982). There is considerable variation between people, both in their plasma nicotine 
levels and their intake of nicotine from a cigarette (Benowitz et al., 1997). This can be 
manipulated by smokers who change their puff volume, the intensity of puffing and the 
depth of their inhalation. 
Nicotine in mammals binds to the acetycholine receptors in, amongst other regions of 
the central nervous system, the ventral tegmental area (Health Scotland and ASH 
Scotland, 2004). This leads to a burst of firing by cells in the mesolimbic dopamine 
pathWay and release of a neurotransmitter called dopamine in the nucleus accumbens. 
This represents a basic 'teaching signal' which in effect tells the animal to repeat the 
action that immediately precedes it. Thus nicotine is tapping into the basic and ancient 
'reward pathway' which evolved to enable animals to learn to adapt to a complex 
environment. Nicotine acts as a 'primary positive enforcer '. Nicotine ingestion also 
leads to neuroadaption so that when the body becomes depleted of nicotine, a range of 
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unpleasant physical and psychological withdrawal symptoms emerge. Nicotine 
withdrawal is discussed in Section 1.8.1. 
1.3.4 Smokeless Tobacco 
Smokeless tobacco (ST), which refers to both moist ground tobacco and chewing 
tobacco, is an important public health issue worldwide. This topic is currently at the 
protocol stage, awaiting a full Cochrane Review (Ebbert et al., 2003). 
Smokeless tobacco is especially important in the Indian sub-continent and in some areas 
of the UK with a high indigenous ethnic population. However, for the purposes of this 
literature review, a brief summary only will be presented, as it does not relate directly to 
the topic under study. 
Smokeless tobacco can be defined as tobacco that is taken orally and so is not smoked. 
There is a huge variety of different types of tobacco being used globally, and it is not a 
homogenous product. Care, therefore, must be taken in comparing different types of 
tobacco and in interpretating different studies from various regions. 
A national survey in the US reported that, among individuals aged 18 and over, 6.6% of 
males and 0.4% of females reportedly used ST 'in the last month' (USDHHS, 2001a). 
In India, an estimated 22% of males use ST solely and 8% use ST and smoked tobacco 
together (WHO, 1997). In the Sudan, about 40% of males and 10% of females use a 
type ofST known as Toombak (Idris et ai., 1994). 
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The main forms of smokeless tobacco include chewing tobacco of which there are many 
types in the US and Asia, particularly India. In this latter location, tobacco is often 
locally produced and can have other compounds added to improve flavour such as 
spices and sugars. Other added ingredients such as lime, betel and areca nut, have been 
shown to have potentially carcinogenic properties of their own (Merchant et al., 2000; 
Phukan et al., 2001). There is also a commercially produced form of tobacco known as 
paan masala. 
With respect to the UK, the main users are predominantly members of the Indian, 
Pakistani and especially Bangladeshi communities. Recently, guidelines for health 
professionals including dentists were released in England, regarding delivery of 
smokeless tobacco cessation advice to those individuals who use this form of tobacco 
(West et al., 2004). 
In Europe, there is an oral type of snuff available in Sweden, known as snus. It is a 
moist, ground oral tobacco product that is typically placed behind the upper lip, either 
as loose ground tobacco or contained in sachets appearing like small tea bags. The snus 
is typically held in the mouth (without chewing) for approximately 30 min before being 
discarded. Approximately 30% of Swedish males are reported to use snus (Rodu et al., 
2002). The habit is particularly prevalent among young males and is rare in young 
women (Wickholm et al., 2003). 
Currently, within the ED, snus can only be legally sold in Sweden, though there is 
increasing interest in the role that it could play in harm reduction. At present, Sweden 
has the lowest rates of smoking amongst all European countries (around 17%) and is the 
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only country to have reached the World Health Organisation's goal of less than 20% 
daily smoking prevalence by the year 2000 (Fagerstrom and Schildt, 2003). There is 
some debate as to whether the existence and use of snus in this country has contributed 
to this low prevalence of cigarette use, and whether snus could be used as an aid to 
reduce or quit smoking (Gilljam and Galanti, 2003). 
1.4 Tobacco Induced Conditions 
The health concerns associated with tobacco use are widely known. A recent expansive 
and detailed 900-page report from the US Surgeon-General, entitled the 'The Health 
Consequences of Smoking' (USDHHS, 2004) aims to set out the current evidence-base 
with respect to tobacco use and its adverse health outcomes. The report particularly 
focuses on the concept of 'causality of association', and looks to standardise the 
approach to evidence in the fonn of (1) sufficient to infer a causal relationship, (2) 
suggestive but not sufficient to infer a causal relationship, (3) inadequate to infer the 
presence or absence of a relationship, or (4) suggestive of no causal relationship 
(USDHHS, 2004). 
Amongst other conditions, the US report links smoking with cancer, cardiovascular 
disease and respiratory disease, and the body of evidence pertaining to these chapters is 
large and detailed. In this brief review, there is focus on the diseases and conditions 
which fall within category (1). 
The US Surgeon General report specifies that smoking is causal in the following 
cancers: bladder, cervical, oesophageal, renal, laryngeal, lung, oral, pancreatic, stomach, 
and acute myeloid leukaemia. 
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With respect to cardiovascular disease, smoking is causal in abdominal aortic aneurism, 
atherosclerosis, coronary heart disease and stroke. 
With regards to respiratory disease, tobacco use is causal in chronic obstructive 
pulmonary disease, pneumonia in adults and accelerated age-related decline in lung 
function. Smoking during childhood and adolescence produces significant respiratory 
health problems among young people including early onset symptoms including 
coughing and wheezing. With respect to respiratory disease in neonates, maternal 
smoking during pregnancy is associated with reduced lung function in infants. 
In addition to the above serious health consequences, there are reproductive effects of 
smoking (British Medical Association, 2004). There are causal effects of sudden infant 
death syndrome and maternal smoking during pregnancy. Low birthweight, and 
premature rupture of the membranes leading to preterm delivery are also causal. Cleft 
lip and palate has also been linked with maternal smoking in the first trimester of 
pregnancy (Little et al., 2004). 
Smoking also leads to infertility in women (USDHHS, 2001b). The report lists other 
causal health outcomes: cataract, hip fracture, low bone density and peptic ulcer disease. 
The report also includes a section on the dental effects of smoking, including 
periodontal disease. These did not feature in the last report published in 1964. 
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1.5 Tobacco Induced Oral Conditions 
Whilst many of the general health concerns associated with tobacco are well known, the 
detrimental effect of tobacco use on the mouth is less often acknowledged. Oral 
problems associated with smoking can range from cosmetic concerns such as staining 
and halitosis, through to conditions with significant morbidity and mortality. 
Non-malignant smoking-related oral conditions are common in smokers and are 
discussed in Section 1.5.1. 
Potentially malignant conditions are dealt with in Section 1.5.2, with oral cancer, 
possibly the most important disease to affect the oral cavity, being discussed in Section 
1.5.3. 
There is increasing interest being shown in tobacco use as a risk factor for periodontal 
disease, and this is covered in Section 1.5.4. 
Smoking delays wound healing and one of the outcomes of this is increased rejection of 
dental implants. This is reviewed in Section 1.5.5. 
1.5.1 Non-Malignant Smoking-Related Conditions 
Aesthetic considerations include staining of the teeth, dental restorations and dentures, 
while side-effects of smoking include impairment of smell and taste, as well as halitosis 
(Johnson and Bain, 2000). With regard to oral mucosal conditions, nicotinic stomatitis, 
or smokers' palate, occurs in heavy smokers, especially those who smoke a pipe (Sham 
et aI., 2003). Melanic pigmentation (or smokers' melanosis) of the oral mucous 
membrane, especially on the attached gingivae, can be seen in 30% of heavy smokers 
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(Winn, 2001). There can also be overgrowth of the papillae on the dorsum of the 
tongue which can become stained with nicotine (black hairy tongue). All these 
conditions are not considered to be premalignant, and are reversible on smoking 
cessation (Reibel, 2003a). 
In contrast to the conditions described above which are more prevalent in smokers, 
aphthae tend to occur less frequently in those who use tobacco (Tuzun et al., 2000). 
Smoking cessation may result in an increase in the prevalence of aphthous ulcers and 
this can be a temporary, if unpleasant, side effect of quitting (Ussher et al., 2003). 
1.5.2 Potentially Malignant lesions 
1.5.2.1 Leukoplakia 
Of the potentially malignant lesions of the mucous membrane, leukoplakia or white 
patches are the most common type. Leukoplakia can be defined as a 'white patch that 
cannot be characterised clinically or pathologically as any other disease' (Kramer et al., 
1978). It is a clinical term and has no histological connotations (Lamey and Lewis, 
1997). The clinical presentation of leukoplakia can vary from minimal localised lesions 
to extensive involvement of the mucosa. 
The prevalence of leukoplakia can vary among populations, often being between 1 and 
6% (Lim et al., 2003). Leukoplakia is associated with the risk factors of tobacco and 
alcohol (Van der Waal et al., 1997), and can occur six times more frequently in smokers 
than non-smokers (Baric et al., 1982). There seems to be a strong relationship between 
smoking and the development of leukoplakias in the floor of the mouth (Schepman et 
al., 2001). 
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There is debate around the malignant transformation rate of leukoplakia to oral cancer, 
with some researchers stating a rate of around 0.6% to 5% annually (Silvermann et aI., 
1984; Lee et aI., 2000, Greenspan and Jordan, 2004), and others reporting a higher rate 
of 15% (Tradati e/ aI., 1997). 
Reducing or cessation of tobacco use may result in the disappearance of leukoplakia 
(Gupta et aI., 1986; Chad-Martin et aI., 1999). 
1.5.2.2 Erythroplakia and Speckled Leukoplakia 
Erythroplakia (red patches) and speckled leukoplakia (white patches with a red 
component) are much less common in the population than leukoplakia. Studies quote a 
prevalence of 0.09% to 0.83% (Hashibe et aI., 2000). Erythroplakia are red lesions, 
velvety in texture and the margins may be sharply defined (Cawson and Odell, 2002). 
Speckled leukoplakia consist of white flecks or fine nodules on an atrophic 
erythematous base. They can be considered to be a transition between leukoplakia and 
erythroplakia (Cawson and Odell, 2002). 
Both erythroplakia and speckled leukoplakia should be viewed with greater suspicion 
than leukoplakia, having a much higher potential for development of cancer. Estimates 
of malignant transformation rates vary, with one study finding 91 % of lesions to be 
either dysplasia, carcinoma in situ or cancer (Shafer and Waldron, 1975), while another 
found that 20% of cases progressed to cancer within 10 years, despite treatment (Trock, 
2000). 
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1.5.2.3 Oral Candidosis 
It is now thought that smoking, either alone or in combination with other factors, 
appears to be a predisposing factor for oral candidosis. After antimycotic therapy, the 
condition may relapse if the patient continues to smoke, though there may be instances 
where the condition disappears with no drug treatment following smoking cessation 
(Johnson and Bain, 2000). It is thought that candidal infection not only causes 
epithelial hyperplasia, but may also induce epithelial atypia, leading to malignant 
change (Sitheeque and Samaranayake, 2003). It is not clear whether candida! infections 
are a cause of leukoplakia or whether there is a superimposed infection in a pre-existing 
lesion (Cawson and Binnie, 1980; Reibel, 2003b). 
1.5.3 Oral Cancer 
Approximately 90% of oral cancers are squamous cell carcinomas (Neville and Day, 
2002). The most common oral cancer sites are the tongue and floor of mouth (Johnson 
et al., 1993). In addition, oral cancer patients have an increased likelihood of developing 
a second primary tumour elsewhere in the aerodigestive tract (Crosher and McIlroy, 
1998). 
1.5.3.1 Tobacco as a Risk Factor for Oral Cancer 
Smoking is a key risk factor for the development of oral cancer. Tobacco smoke has a 
direct carcinogenic effect on the epithelial cells of the oral mucous membranes (EU 
Working Group on Tobacco and Oral Health, 2000). In recent years, much attention 
has been given to smoking-related mutations in a tumour suppressor gene coding for the 
protein p53. This protein is important in regulating cell proliferation and has a role in 
the repair of DNA damage (Nylander et al., 2000). 
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There has been a well-demonstrated dose-response relationship for tobacco use and risk 
of development of oral cancer, with the risk significantly increasing with the number of 
cigarettes smoked and the duration of smoking (La Veccia et al., 1997). Individuals 
who smoke and do not drink alcohol, have a two to four-fold increased risk of 
developing oral cancer (Johnson and Bain, 2000; Winn, 2001). When the risk factor of 
alcohol is added into the equation, the relationship becomes synergistic, with a smoker 
who consumes two packs of cigarettes and take more than four alcoholic drinks per day, 
having a 35-fold increased risk of oral cancer development (Blot et aI., 1988). 
However, increasing interest is being shown in the higher reported number of cases 
presenting at an earlier age and their likely aetiological factors (Rodriguez et al., 2004). 
A study in the south east of England, looking at survivors of oral cancer (aged under 45 
years), found that a quarter of the cases had no links to the traditional risk factors of 
tobacco and alcohol (Llewellyn et aI., 2003). Likewise, in a survey of 38 oral and 
pharyngeal cancers in Scotland, 32% of cases described themselves as never-smokers 
and 13% as never-drinkers (Mackenzie et al., 2000). Thus, whilst tobacco use remains 
the major risk factor for oral cancer generally, further studies are required to looked 
more closely at other possible aetiological factors and mechanisms of development 
including genetic susceptibility, viral, psychological and occupational variables. 
With respect to smokeless tobacco, the product, as used by the Pakistani and especially 
Bangladeshi communities, carries with it an increased risk of oral cancer (West et al., 
2004). The most commonly used form is tobacco mixed with lime, with additional 
psychoactive compounds such as areca nut. The resulting quid is chewed or held in the 
mouth. In the US and Sweden, smokeless tobacco in the form of snuff is used. Snuff 
24 
habits as used in these countries carry lowered but still important risk of serious health 
hazards, including oral cancer (Johnson, 2001). Further information on all types of 
smokeless tobacco is to be found in Section 1.3.4. 
1.5.3.2 Incidence of Oral Cancer 
With regards to the epidemiology of oral cancer, its incidence varies markedly world-
wide. Globally, it is the sixth most common malignant tumour for both genders 
(Johnson,2001). There are high rates in the Indian subcontinent, where it accounts for 
up to 40% of all malignancies (Johnson, 2001). This figure is related to ethnic and 
religious practices regarding the use of smokeless tobacco. In Scotland and the UK, 
such products are limited to the relevant ethnic groups (Khan et at., 2000). 
When looking at European incidence rates, France has the highest level of oral cancer, 
and this is related to high smoking and alcohol intake levels (Andre et at., 1995). With 
regards to incidence in Scotland, currently, around 500 new cases of oral cancer are 
diagnosed each year (Macpherson et al., 2003). 
In Scotland, oral cancer is twice as common amongst males as females, and the 
incidence rate of approximately 12 per 100,000 in males and 5 per 100,000 in females is 
almost double the rates in England (Quinn et at., 2001). Approximately 85% of new 
cases occur in people aged 50 and over. There is a clear association between social 
deprivation and incidence rates of oral cancer (Macpherson et at., 2003). This 
relationship is stronger in males. There has also been an increase in the number of cases 
over the last 30 years, and this may be linked to patterns of smoking and alcohol 
consumption. 
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1.5.3.3 Tobacco-Related Advice Concerning the Prevention of Oral Cancer 
Infonnation to the general public concerning the prevention of oral cancer includes 
advice not to smoke, or if a current tobacco user, to give up smoking, and to drink 
within accepted limits (Macpherson et al., 2000). It has been reported that cessation of 
smoking eliminates the increased risk of development of oral cancer within 5-10 years 
(Blot et al., 1988). 
1.5.4 Periodontal Disease 
1.5.4.1 Relationship Between Smoking and Periodontal Disease 
In recent years, the relationship between smoking and periodontal disease has been 
investigated extensively, with over 200 papers appearing in the literature during the past 
few years (Rivera-Hidalgo, 2003). Reviews of this body of work indicate that there is 
strong evidence from cross-sectional, case-control and other longitudinal studies that 
smokers are more likely to be affected by periodontitis than non-smokers and that 
response to periodontal therapy is compromised in the fonner group (Kinane and 
Chestnutt, 2000; Johnson and Slach, 2001; Rivera-Hildalgo, 2003; Johnson and Hill, 
2004). 
The evidence shows that, in general, smokers are approximately three times more likely 
than non-smokers to have periodontitis and that the relationship between smoking and 
periodontitis is even stronger among those more severely affected by the disease 
(Johnson and Hill, 2004). For example, a large US-based epidemiological study 
reported recently that for adults aged 20-49 years, the odds ratio of attachment loss 
associated with current smoking was 2.29 for loss of up to 2mm, but for attachment loss 
of at least 3mm, the odds ratio was over 18 (Hyman and Reid, 2003). 
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Recent reviews of the smoking-related periodontal literature indicate that numerous 
studies show that, after adjusting for plaque levels, smokers have more severe bone loss, 
more attachment loss, deeper probing depths and fewer teeth than non-smokers (Rivera-
Hidalgo, 2003; Hilgers and Kinane, 2004; Johnson and Hill, 2004). 
The case for smoking being an important risk factor for periodontal disease is further 
strengthened by the fact that a dose-response relationship is seen between the number of 
cigarettes smoked and the severity of periodontal disease. Grossi et al. (1995), in a 
study involving 1361 adults, found that in relation to the risk of experiencing severe 
bone loss, the odds ratio ranged from 3.25 to 7.28 for light and heavy smokers 
respectively. A similar dose-response relationship has been seen in other studies 
(Norderyd and Hugoson, 1998; Bergstrom, 2003). 
1.5.4.2 Sociological factors and Periodontal Disease 
A case-control study of the relationship between life events and periodontitis has shown 
smoking to be statistically associated with periodontal disease, after controlling for oral 
health behaviours and sociodemographic variables (Croucher et al., 1997). This work 
confirmed earlier findings that periodontal disease experience is influenced by social 
and behavioural factors, and that smoking is independent of other factors (Locker and 
Leake, 1993). 
1.5.4.3 Pathogenic Effects of Smoking 
With regard to the pathogenic effects of smoking on the periodontal tissues, a number of 
mechanisms are thought to be involved. These include direct damage to the tissues 
from smoking-related toxins, changes to the microbial composition of subgingival 
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plaque, alterations to the host innate and immune responses to plaque and changes to 
tissue vasculature influencing blood flow (Kinane and Chestnutt, 2000; Johnson and 
Slach, 2001; Rivera-Hildalgo, 2003; Johnson and Hill, 2004; Hilgers and Kinane, 
2004). These theories and proposed mechanisms result from a vast amount of work in 
this area in recent years. There is still ongoing debate and controversy in relation to 
some of these areas, e.g. the effect on the plaque microflora, and studies into the 
specific effects of smoking on the host's inflammatory and immune responses continue 
to be very active areas of research. An in-depth review of this literature is outwith the 
scope of this thesis. 
1.5.4.4 Effects of Smoking Cessation on Periodontal Status 
Importantly, the literature provides evidence that stopping smoking can have a positive 
impact on periodontal status (Hilgers and Kinane, 2004), with the progression of the 
rate of periodontal destruction decreasing following smoking cessation and recent non-
smokers responding to periodontal treatment in a manner similar to that of non-smokers 
(Johnson and Hill, 2004). 
1.5.4.5 Effects of Smoking on Periodontal Treatment Outcome 
It has been reported that poorer outcome to periodontal treatment, both mechanical and 
surgical, occur in smokers compared to non-smokers (Grossi et al., 1997; Kinane and 
Radvar, 1997; Scabbia et aI., 2001). These poorer outcomes extend also to oral surgery 
with Meechan and co-workers (1988) showing, in a large sample of extraction patients, 
significant reductions in post-extraction socket blood fill and more painful extraction 
sockets in tobacco users. 
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1.5.4.6 Cotinine and Periodontal Disease 
Relatively few studies have looked at the relationship between cotinine and periodontal 
disease. Gonzalez and co-workers (1996) found that the severity of bone destruction in 
periodontal disease, as measured either as clinical attachment level or crestal bone 
height, was positively correlated with serum cotinine levels. Similarly, Machtei et aZ. 
(1997) found that the severity of periodontal attachment loss was positively correlated 
with serum cotinine levels. 
Gunsolley and co-workers (1998) looked at patients who had minimal periodontal 
destruction and found that smoking patients, as verified by serum cotinine, showed 
greater levels of recession. However, by contrast, Chen et aZ. (2001) found neither 
salivary cotinine concentration, nor GCF cotinine levels to be significantly correlated 
with probing depth, attachment loss or tooth loss. 
1.5.5 Effect of Tobacco Use on Dental Implants 
Johnson and Hill (2004) report that the majority of studies show the failure rate of 
implants in smokers to be at least twice that in non-smokers. Wallace (2000) found a 
failure rate after four year of 16.6% in smokers, compared to 6.9% in non-smokers, with 
increased failure rates in smokers also having previously been reported by other 
researchers including Bain and Moy (1993) and De Bruyn and Collaert (1994). 
The impact of smoking on implant failure rates is not equal for upper and lower jaws, 
with a much higher rate being associated with the maxilla. For the maxilla, Bain and 
Moy (1993) reported failure rates of 17.9% and 7.3% in smokers and non-smokers 
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respectively. There was less of a difference in the mandible, with a failure rate of 4.6% 
in smokers and 2.4% in non-smokers. 
Bain (2001) emphasised the importance of quitting smoking in his analysis of 223 
Branemark implants in 78 patients. In this prospective study, smokers were requested 
to quit smoking for 9 weeks; one week prior to surgery and for eight weeks thereafter. 
Of the 57 smokers who underwent surgery, 51 (89.5%) started on the cessation protocol 
and 48 (84.2%) completed the nine weeks without smoking. It was shown that there 
was a statistically significant higher failure rate in smokers compared to non-smoking 
controls and quitters. However, there was no statistically significant difference in 
failure rates between non-smokers and quitters. When looking at the longer-term 
smoking cessation outcomes at 3 months, 6 months and 1 year, the success rates were 
70.2%, 43.9% and 40.4% respectively. However, these outcomes were not 
biochemically validated by cotinine. 
1.6 Overview of Tobacco Control 
Smoking cessation interventions targeting individual smokers (the research area of this 
thesis) are only part of a much broader spectrum of strategies which comprise the 
tobacco control agenda. 
Recently, there have been some major developments in this area with the production of 
a treaty addressing tobacco as a global public health problem. In 2003, WHO developed 
the First Framework Convention on Tobacco Control, which has been adopted by a 
number of member countries (WHO, 2003). The framework covers a wide range of 
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issues including measures relating to the demand for and the supply of tobacco (Shibuya 
et aI., 2003). 
The first series of recommendations within the framework look at reducing the demand 
for tobacco products. Another major area of importance addresses the issue of 
environmental tobacco smoke and looks at enabling the legislation and public health 
agenda in encouraging public places and workplaces to be smoke-free (Scottish 
Executive, 2004b). Restrictions of this kind are thought to increase the number of 
smokers who quit, as well as providing protection for others from passive smoking. 
Ireland recently banned smoking in public places (l April 2004) and Scotland is 
currently looking at introducing this public health measure. 
A further area addressed in the framework is the price of tobacco, as this is thought to 
be one of the strongest influences on tobacco consumption. In the UK, an increase in 
price of tobacco products of 10% has been found to cause a fall in smoking of 4% in 
adults and 6% in children, thus reducing prevalence while increasing revenue 
(Jamrozik,2004). 
Public education, including general and school education, as well as the use of mass 
media have a direct influence on prevalence of smoking and are most effective when 
delivered as part of a comprehensive tobacco control policy (NHS Health Scotland and 
ASH Scotland, 2004). The recent round of advertising by the British Heart Foundation, 
using a visual dripping cigarette, led to very high awareness of the message by the 
general public (British Heart Foundation, 2004). 
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Comprehensive bans and restrictions on tobacco advertising, promotion and 
sponsorship are important strands of a tobacco control policy (Saffer and Chaloupka, 
2000). Norway was the first country to ban tobacco advertising (1970), whereas in the 
UK, tobacco advertising has only been banned from 14 February 2003 (Jamrozik, 
2004). Indirect advertising, for example, sponsorship of sports such as motor racing is 
due to end in 2006 and is just as important as the direct form of advertising. Equally 
important, are promotion of tobacco products through product placement in film and 
other media (Sargent et al., 2001). Point-of-sale advertising also needs to be closely 
monitored and banned, with preferably legislation adopted which requires tobacco 
products to be stored out-of-sight, underneath the counter (Scottish Executive, 2004a). 
Regulation of tobacco products is a thorny area. Cigarettes are highly toxic, though in 
most countries, they have remained exempt from food, drug or consumer protection 
legislation. Smokeless tobacco, though safer, is banned on health grounds in all EU 
countries with the exception of Sweden, whereas medicinal nicotine, in the form of 
patches or other products, is subject to drug legislation and the accompanying 
restrictions. 
Cigarette packaging and labelling is a further issue, with increasingly visible and visual 
warnings about the dangers of cigarettes being adopted as standard in many countries 
(Aftab et al., 1999). Canada was the first to lead with visual warning including graphic 
pictures of oral cancer. Currently in the UK, text-only warnings are being used. 
There are two measures which relate to reducing the supply of tobacco. The first is 
elimination of the illicit trade of tobacco products and the UK government is committed 
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to trying to reduce this (HM Customs and Excise, 2000). The second area for attention 
is the restriction of sales to and by minors (under 16s). In Scotland, test-marketing 
schemes have been set up to ensure shopkeepers are not disregarding the law (NHS 
Health Scotland and ASH Scotland, 2004). 
One further strand of policy, emphasised by the WHO Framework, and of particular 
relevance to the developing world, is to address the problem of finding economically 
viable alternatives for the current tobacco growers to plant and harvest, to ensure their 
economic survival. 
Tobacco cessation and dependence measures which help treat smokers are discussed 
elsewhere in this chapter (Sections 1.9 and 1.10). 
1. 7 Measurement of Smoking Status 
There are two main methods of determining smoking status. The first method, known 
as self-report, involves asking the individual. The second method is to use some form of 
biomarker to validate the information given by the individual. It is now generally 
accepted that in smoking cessation trials, it is essential to use some form of biochemical 
validation (Gariti et a/. , 2002). 
1. 7.1 Self-Report 
When asking about an individual's recent exposure to tobacco, questionnaires are often 
used to determine cigarette intake and environmental exposure. The use of pack-years is 
discussed in Section 1.7.2 below. 
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In addition, self-report can be used to detennine whether an individual has stopped 
smoking, or not. Once this infonnation has been collected, there are a number of ways 
of using this infonnation to detennine abstinence, and these measures are discussed in 
Section 1.7.3 below. 
1. 7.2 Self-Reported Pack-Years 
Another use of self-report is to measure a person's lifetime exposure to tobacco 
products over a number of years. One method of measuring this is the use of 'pack-
years' (Alpagot et al., 1996). Self-reported data obtained from the patient, assessing the 
number of cigarette packs (20 cigarettes per pack) smoked per day for a number of 
years can be used to categorise the risk into high, medium and low. Weighed pack-years 
can also be utilised in order to allow for hand rolled cigarette consumption (Schlecht et 
al., 1999). There is use of this measure in the dental literature, particularly 
periodontally-related, and in coronary care and respiratory medicine (Chen et al., 2001; 
Chambless et at., 2003; Patel et al., 2004). 
1. 7.3 Measures of Abstinence in Smoking Cessation Trials 
Self-report can be used as a means of determining smoking status after a smoking 
cessation intervention (Velicer et al., 1992; Velicer and Prochaska, 2004). There are 
three measures which can be used: point prevalence, prolonged abstinence and 
continued abstinence. These three measures are discussed below. 
Point prevalence abstinence can be defined as the proportion of subjects not smoking at 
a point in time. 
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Prolonged abstinence is defined as the proportion of participants not smoking after an 
initial grace period where the smoker is allowed to lapse, usually one or two weeks just 
after the quit date. 
Continuous abstinence is defined as the proportion of people not smoking at all since 
the occurrence of the intervention or critical event such as the quit date. 
The arguments for using point prevalence include the fact that biochemical validation of 
this measure is possible, depending on the timeframe selected (Velicer and Prochaska, 
2004). In addition, point prevalence measures are often collected, and can contribute to 
a meta-analysis. Point prevalence rates, if measured sometime after the event or 
intervention, such as 6 or 12 months, can include smokers who take delayed action and 
quit. Therefore, they also tend to be more accurate in that the immediacy of the 
measure does not rely on participants self-reported recall of smoking some time 
previously, as in prolonged abstinence (Velicer and Prochaska, 2004). The 
disadvantages of point prevalence include the fact that this measure is not as stable as 
continuous abstinence, and given the high rate of relapse during the first 3 months 
following quitting, it is predictable that individuals who are counted as former smokers 
at one point in time, will be current smokers at the next point in time. 
Prolonged abstinence measures reflect a combination of continuous and point 
prevalence abstinence rates. Individuals are counted as former smokers if they have 
been continuously abstinent for a prolonged period of time, such as 3, 6 or 12 months. 
Prolonged abstinence rates are able to include people who make delayed or repeated 
quit attempts following an intervention. This measure also allows smokers a grace 
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period, and is thought to more accurately reflect what happens during smoking 
cessation. Research has shown that a number of trial participants who successfully quit, 
may have a lapse very early on in the quit attempt (Hughes et aI., 1992). By including a 
grace period, this allows for this smoking behaviour, without automatically counting 
this behaviour as a failure. 
Continuous Abstinence is the strictest measure and allows no smoking from the quit 
date. The advantage of this measure is that it is more stable over time and across studies 
than point prevalence rates. The longer the period of continuous absence, the less the 
probability of relapse. This measure has a number of disadvantages which include a 
requirement that the point of intervention has to be clearly defined. This may be 
possible in a pharmacological study, but is much more difficult in a self-help study 
where the timing of a cessation attempt is under the control of the subject. Also few 
smokers make the transition to non-smokers without any lapses and relapses (Velicer 
and Prochaska, 2004). 
Trials may vary in the measures they report. Hughes and co-workers (2003) 
recommend that trials report multiple measures of abstinence, and as a minimum, 
smoking cessation trials should report prolonged abstinence as the preferred measure, 
coupled with point prevalence as the secondary measure. Two trials reporting recently 
used continuous absence and point prevalence (Molyneux et al., 2003; Tonneson et al., 
2003), whereas another used sustained absence and point prevalence (Borland et al., 
2003). Hughes et al., (2003) do not recommend the use of the term sustained 
abstinence. 
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1.7.4 Use of Biomarkers in Measuring Tobacco Smoke and Environmental 
Tobacco Smoke 
Assays can provide measurement of the concentration of substances in biological tissues 
and secretions. An example of this is the level of a tobacco constituent in exhaled air, 
saliva, blood, urine, hair or other body part (Shields, 2002). Such biomarkers can be 
used to determine internal exposure, estimate a biologically effective dose or used to 
determine the level of potential harm that a compound may have. They are of 
importance in many fields, but this review confines itself to those of relevance as 
validators of smoking status in cessation trials (Gariti et al., 2002; Rebagliato, 2002). 
Examples of such biomarkers are cotinine and nicotine levels in a variety of tissues 
including blood and saliva, and carbon monoxide measurements in exhaled air. 
Additionally, biomarkers such as cotinine can be used to determine an individual's 
exposure to passive or environmental tobacco smoke (ETS) (Benowitz, 1996; Philips et 
al., 1999). 
1. 7.5 Cotinine 
Some studies have used nicotine to measure tobacco exposure. However, as nicotine 
has a short half-life of around 2 hours, results are very dependent on time of sampling 
(Feyerabend and Russell, 1990; Benowitz, 1999). Thus, while nicotine levels may be 
measured, this is usually in conjunction with another means of testing exposure. 
Cotinine, a metabolite of nicotine, is currently regarded as the best biomarker for 
exposure to tobacco smoke (Rebagliato, 2002). Since the early 1980's, it has been used 
to determine an individual's exposure to tobacco (Feyerabend and Russell, 1980). It is 
distributed throughout extracellular fluid and is excreted through the kidneys and 
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salivary glands (Benowitz, 1982). Cotinine has a half-life of approximately 20 hours 
and is gradually excreted from the body over 3-4 days (Jarvis et at., 1988). 
As a biomarker, cotinine has the advantage of being almost specific to tobacco smoke. 
There are, however, a number of exceptions, including occupational exposure to 
tobacco leaves, particularly during harvesting (Quandt et at., 2001), the use of 
smokeless tobacco (Andersson et at., 1994) and the use of nicotine replacement therapy, 
including gum, patches and other smoking cessation aids. Additionally, low levels of 
cotinine have been found in the diet, particularly in vegetables such as tomatoes, 
cauliflower and black tea. However, the dietary impact from such foodstuffs on cotinine 
levels can be regarded as insignificant (Benowitz, 1999). 
1. 7 .5.1 Choice of Biological Sample for Cotinine Sampling 
Cotinine can be measured in a variety of body constituents including blood, urine, 
saliva, amniotic fluid, cervical mucus and hair (Vine et al., 1993; Poppe et al., 1995). 
The choice of sample may depend on a number of factors including the setting in which 
the study or intervention takes place and the acceptability of the method of collection to 
both participants and the professionals undertaking the work. 
Blood or serum is often the sample of choice, especially when a sample of blood is 
taken for routine purposes, such as in antenatal clinics (Tappin et at., 2000). Urine 
collection is easier in some settings such as schools and worksites, though there may be 
some concerns about detecting illicit drug use (Leiria et at., 1999). In such 
circumstances, salivary collection may be preferable (Etzel, 1990). A review of the 
types of biological samples used for measurement of cotinine is detailed in Chapter 2. 
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1.7.5.2 Methods of Analysis ofCotinine 
Several chromatographic methods have been used for the analysis of cotinine: gas 
chromatography (GC) (McAdams and Cordeiro, 1993), gas chromatography-mass 
spectroscopy (GCMS) (Shin et al., 2002; Torano and van Kan, 2003) and liquid 
chromatography-mass spectroscopy (LCMS) (Bernert et al., 2000). 
The advantages of GC-based methodologies include accuracy: with higher levels of 
sensitivity and specificity than other methods, especially when looking at levels of 
exposure associated with passive smoking. Such assays can also deal rapidly with large 
sample numbers. One disadvantage of chromatographic-based methods of analysis, 
however, is cost. This is due to the high capital costs of the equipment required and the 
time involved in preparation and extraction of the materials. 
A number of immunoassays, including radioimmunoassay (RIA), have also been used 
for cotinine analysis. More recently, enzyme-linked immunoabsorbant assay (ELISA) 
kits have become available both in the US (OraSure) and UK (Cozart). The kits are 
largely unevaluated in the UK. The advantages of the kits include accessibility; they 
do not require costly equipment and are relatively easy to handle. A fuller discussion of 
the advantages and disadvantages of the kits is given in Chapter 2. 
A number of studies have compared the different methods of analysing cotinine. A 
study, comparing ELISA screening kits with gas chromatography-mass spectrometry 
and using urine samples, found conflicting results depending on the laboratory used for 
analysis. 
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An initial study found poor agreement with the two methods of analysis (Gariti ef al., 
2002). However, in a later study, samples from the same patients were analysed blind 
(Alterman et ai., 2002) and on this occasion the ELISA results showed almost total 
agreement with the GeMS findings. 
1.7.5.3 Determining Cut-Offs for SmokerslNon-Smokers 
Studies comparing non-smokers and smokers have consistently found that measurement 
of cotinine in urine, serum or saliva can distinguish active smokers from non-smokers. 
Active smokers almost always have serum or saliva levels higher that lSng/ml and 
sometimes greater than SOOng/m!. Non-exposed, non-smokers have cotinine levels of < 
1ng/ml with non-smokers exposed to ETS having levels of cotinine in the range of 1-
lSng/ml (Rebagliato, 2002). Difficulty may arise in differentiating between a non-
smoker, who is heavily exposed to ETS, and a light, occasional smoker. 
Self-reported non-smokers, who seem to be smokers on the basis of biochemical 
measurements, are generally considered 'deceivers' of their true smoking status 
(Archbold et al., 1995). 
When making comparisons of levels of self-reported smoking misc1assification across 
studies, it can be difficult to directly compare results because of differences in a) 
analytical techniques (gas chromatography compared with radioimmunoassay) and b) 
populations studied (Rebagliato, 2002). 
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A study investigating the effect of ethnicity, found that serum cotinine levels were 
higher amongst black smokers than white or Mexican American smokers (Caraballo et 
ai., 1998). This was thought to be due to slower clearance rates in black smokers and a 
higher nicotine intake per cigarette in this population (Perez-Stable et ai., 1998). 
1. 7.5.4 N ear-Patient Testing of Cotinine 
A disadvantage of the cotinine assay method outlined above is that instant feedback to 
the patient is not possible. One new technique, attempting to address this issue, is the 
development of a 10-minute disposable near-patient saliva test. This consists of a 
plastic device, containing dried reagents to measure nicotine and its cotinine metabolite, 
by a colorometric assay (Cope et ai., 2000). This technique gives a semi-quantitative 
assessment of tobacco consumption by monitoring the colour change in the sample and 
by comparing it to a reference chart and the results can be fed back to the patient. 
Alternatively, the test can be quantified by measuring the light absorbency with a 
colorimeter and a concentration of nicotinic metabolites obtained with reference to a 
cotinine standard. With this latter technique, however, instant feedback to the patient is 
lost. A similar test exists for use with urine (Cope et ai., 1996). As they are relatively 
new to the market, their full potential has still to be determined. 
1.7.6 Carbon Monoxide (CO) 
The most widely used biomarker, both to determine tobacco exposure, and to 
biochemically validate quitting in smoking cessation interventions, is carbon monoxide 
(CO) (Middleton, 2000). Exhaled air samples are measured for CO using a hand-held 
monitor. 
41 
The advantages of using such a monitor include economic considerations, with such 
equipment being much cheaper per head to use than cotinine sampling (Jarvis et al., 
1986). Additionally, these monitors are not difficult to manipulate and staff can easily 
be trained to use them. The readings can also be taken quickly and the CO measurement 
fed back to the patient. This can be an important motivational tool to use during a 
patient's quit attempt (Hajek and Belcher, 1991). Other advantages include its use to 
verify smoking status when the individual is using some form of nicotine replacement 
therapy (Scott et al., 2001). 
Limitations of CO readings include the fact that they are not specific for tobacco, as 
there are a number of non-tobacco sources, such as vehicle exhaust fumes, which might 
affect levels, especially in urban areas. Carbon monoxide also has a short half-life of 4-5 
hours, so cannot detect a patient's exposure over a longer time period. 
There is also some debate as to the cut-off level to be used to differentiate smokers from 
occasional smokers and non-smokers. A cut-off of between 6 and 10ppm is often used 
(Gariti et aI., 2002; Tonnesen et al., 2003). 
A number of papers comparing the specificity and sensitivity of methods using carbon 
monoxide and cotinine assays are discussed in Section 1.7.7. 
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1.7.7 Comparison of Different Methods used to Determine Smoking Status 
A key issue for smoking cessation researchers concerns the confinnation of self-
reported abstinence. A relatively small inflation in abstinence rates, detennined by 
self-report, that is not biochemically validated, can have significant implications for the 
evaluation of the efficacy of a given treatment (Gariti et ai., 2002). 
A number of studies have compared the use of carbon monoxide, cotinine and self-
report (Murray et ai., 2002). In one of the first (Murray et aJ., 1993), at one-year follow-
up, cotinine and carbon monoxide monitoring detected smoking in 17% and 10% 
respectively of self-reported non-smokers. This large, population-based study, the 
'Lung Health Study', was a randomised trial in 10 centres, involving 3923 participants 
in a smoking cessation programme and 1964 usual-care participants. Smoking was 
assessed at the first annual check-up. Sensitivity (percentage of smokers detected) and 
specificity (percentage of non-smokers detected) were calculated by comparing each 
biochemical measure with the self-report. For cotinine compared with self-report, the 
sensitivity was 99.0% and the specificity was 91.5%. For carbon monoxide compared 
with self-report, the sensitivity was 93.7% and the specificity was 87.2%. 
A smaller, though more recent study, examined smoking cessation outcomes in a group 
of 240 participants who had participated in a trial that compared the efficacy of different 
intensities of psychosocial treatments, coupled with 8 weeks of patch treatment (Gariti 
et aJ., 2002). Treatment outcomes were assessed 9, 26 and 52 weeks from initial 
treatment, and data on self-report, carbon monoxide and urinary cotinine were collected. 
Carbon monoxide measurements taken at 9 weeks found two (1.9%) trial participants 
who reported being non-smokers, with readings at the level consistent with exposure to 
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tobacco smoke. Cotinine measurements detected a higher yield of 22 (23.2%) who 
could be classified as being 'deceivers'. There were similar, if less marked, findings at 
26 weeks (1.6% and 14.8%) and at the I-year interval (1.7% and 6.8%). The authors 
concluded that cotinine analysis was by far the best measure to verify self-report of 
abstinence, especially when examining short-term treatment outcomes. They also 
suggested that a less costly, onsite, readily accessible measure of nicotine use, but with 
greater validity than carbon monoxide, would be a great asset for researchers. One 
example of this may be the near-patient cotinine test, discussed in the previous section. 
1.7.8 Other Biomarkers Used in Smoking Cessation 
A number of other biomarkers have been used to determine smoking status. 
Thiocyanate is one, though it is not so widely used as other biomarkers. If used, it is 
often combined with other tests such as CO (Hurt et al., 2000), serum cotinine 
(Seersholm et al., 1999) or both serum cotinine and CO (Waage et al., 1992). As 
thiocyanate is not a nicotine metabolite, it has been used to determine smoking status in 
the presence of nicotine, either in the form of nicotine inhalers (Hurt et al., 2000) or to 
discriminate smokeless tobacco users from cigarette tobacco users (Holiday et al., 
1995). 
1.7.9 Use ofCotinine in Measurement of Environmental Exposure to Tobacco 
Environmental exposure to tobacco is of increasing concern, particularly from a public 
health perspective. There are issues around children being exposed to passive smoking 
in the home, particularly if the child is asthmatic. Occupational exposure in public 
places, such as bars and restaurants, has recently been the focus of attention, and urinary 
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cotinine has been used to quantify the risks to individuals (Akbar-Khanzadeh, 2003; 
10hnsson et aI., 2003). 
1.7.10 Summary 
It is now accepted that to measure smoking status, especially in smoking cessation 
trials, in addition to collecting data by self-report, it is essential to biochemically 
validate the findings. Carbon monoxide monitoring is the most frequently used means 
of verifying smoking status due to cost considerations. However, problems with this 
methodology include its short half-life and lack of specificity. Cotinine measurement 
provides the most sensitive means of detecting exposure to nicotine and can be 
measured in blood, urine and saliva. Whilst it is considered the best biomarker for 
exposure to tobacco smoke, its cost may continue to be a barrier to its more widespread 
use, except in the area of research. 
1.8 Psychological Aspects of Smoking Cessation 
Individuals generally do not stop smoking without first deciding that this is a desirable 
outcome. There are two factors which can give an indication of the likelihood of an 
individual smoker stopping smoking: addiction (compulsive smoking characterised by 
dependence, both physiological and psychological) and motivation (desire/intention to 
stop smoking) (Foulds, 1996). 
I.S.1 Addiction 
Tobacco is now considered to be a drug of addiction. Historically, the term drug 
addiction meant that tolerance developed to the effects of a drug during repetitive use, 
and that after cessation, withdrawal symptoms emerged (termed physical addiction) 
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(Benowitz, 1992). A more modern definition regarding addiction is that is can be 
defined as 'a drug or stimulus which has unreasonably come to control behaviour' 
(WHO, 1992; American Psychiatric Association, 1995). In essence, the terms addiction 
and dependence are used interchangeably, in the literature (Tobacco Advisory Group of 
the Royal College of Physicians, 2000). 
There is no doubt that many tobacco smokers become nicotine dependent. However, 
researchers agree that individual smokers differ in the degree to which they become 
dependent (Shiffman, 1991). There is good evidence that the degree of dependence is 
closely related to frequency of smoking (Etter et al., 1999). It would appear that adults 
who consistently smoke fewer than five cigarettes per day on at least four days per 
week, over a long period of time are non-dependent. Non-dependent smokers, who are 
able to increase/decrease their consumption of nicotine are known as 'chippers' 
(Shiffman, 1989). These smokers report no signs of nicotine withdrawal after overnight 
abstinence. However, chippers' nicotine absorption per cigarette and nicotine 
elimination rates have been found to be similar to those of heavy smokers (Shiffman et 
al., 1992). 
It has been suggested that vulnerability to nicotine dependence is related to genetically-
based high sensitivity to nicotine (Pomerleau et al., 1993). Consistent with this is the 
finding that people who become highly dependent smokers have been found to have 
experienced more pleasurable sensations at their initial exposure to tobacco (Pomerleau 
et al., 1998). 
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One feature of addiction is when the substance or stimulus is removed, the individual 
can suffer from withdrawal symptoms. This leads to a set of signs/symptoms caused by 
the abstinence of nicotine to which the individual has physiologically adapted. Nicotine 
withdrawal is now a recognised disease and is included in the Diagnostic and Statistical 
Manual of Mental Health Disorders (DSM - IV) (American Psychiatric Association, 
1994). 
Nicotine withdrawal can be recognised by patients suffering from at least four of the 
withdrawal symptoms listed below: 
depression or dysphoric mood 
anxiety, tension 
restlessness 
insomnia 
increased appetite or weight gain 
irritability,frustration or anger 
feeling light-headed 
diffiCUlty in concentrating 
decreased heart rate 
urge to smoke 
Symptoms usually reach a peak of intensity about 48 hours after smoking cessation and 
then gradually decline over 3-4 weeks (Hughes and Hatsukami, 1986). Craving and 
hunger may continue for several months. When smokers quit, even if they don't 
increase the amount of food they eat, they may put on weight. This is because nicotine 
is a stimulant which increases the metabolic rate and helps to burn calories. 
The single most important element of the withdrawal syndrome is the urge to smoke. It 
has a direct relationship with failure to quit, and is predictive of subsequent relapse to 
smoke (West et al., 1996). 
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1.8.2 Measuring Nicotine Addiction 
Nicotine dependence consists of both physical and behavioural components. Most 
research has addressed the concept of physical addiction. Two widely-used nicotine 
dependence assessment instruments that determine the extent to which nicotine controls 
behaviour are the Fagerstrom Test for Nicotine Dependence (FTND) (He atherton et al., 
1991) and its predecessor, the Fagerstrom Tolerance Questionnaire (Fagerstrom, 1978). 
A shortened version, used to look at physical dependence, is the Heaviness of Smoking 
Index. This is a two-question instrument which looks at number of cigarettes per day 
and time to first cigarette of the day (Kozlowski et al., 1994). These two questions are 
thought to be the most important in determining tobacco dependence of individuals. 
There are other instruments which can be used to measure dependence, such as the 
screening questionnaire for tobacco dependence according to lCD-10, DSM-III R and 
DSM IV, as developed by Kawakami and co-workers (Kawakami et al., 1999). These 
more recently developed instruments are not so widely used as the FTND. 
1.8.3 Motivation 
A smoker's motivation defmed as 'the drive, intention or desire to smoke' is clearly 
critical in whether the individual succeeds or not in stopping smoking (Foulds, 1999). 
Smokers differ in their motivation to quit, and these differences are thought to affect 
likelihood of quitting. There is some merit in assessing level of motivation in smokers 
with a view to helping those who at the time are more highly motivated, rather than 
targeting an intervention at those smokers who currently have no intention of stopping 
smoking (Foulds, 1996). 
48 
1.8.4 Measuring Motivation to Quit 
There are two commonly used methods of assessing motivation. The first method 
consists of asking smokers a few simple questions about strength of desire to stop 
smoking, focusing on how much they want to stop altogether and if they could quit 
easily, would they do so (Foulds, 1996). A higher score is thought to be predictive of 
greater likelihood of quitting. 
Another method of assessing motivation to change is that implicit in the 'Stage of 
Change' model of human behaviour. The 'Transtheoretical' Model, advanced by 
Prochaska and DiClemente (1983), provides a theoretical structure for assessing these 
changes. This model recognises that smokers go through a series of stages (not 
necessarily linearly) on the way to achieving non-smoking status. The stages are as 
follows: precontemplation: currently smoking and not seriously considering quitting 
within the next six months, contemplation: currently smoking and seriously considering 
quitting within the next six months (but not within the next 30 days), preparation: 
currently smoking and seriously intending to quit within the next 30 days, or had a quit 
attempt of 24 hrs or more in the last year, action: not currently smoking, having quit 
within the last six months, maintenance: not currently smoking, having abstained for 
over six months. It is suggested that progress through the stages is driven by a series of 
10 processes, specific to different stages, including consciousness raising (seeking 
information about the problem behaviour) and stimulus control (controlling situations 
that may trigger relapse into old behaviour) (Whitelaw et al., 2000). 
If smokers relapse, they return to an earlier stage in the model. This model also 
acknowledges that smoking cessation is often a cyclical activity, rather than one 
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individual, discrete event and that a smoker may go round the cycle several times before 
succeeding in quitting (DiClemente et aI., 1991). Basic research would indicate that in 
populations of smokers, 40% are in precontemplation, 40% in contemplation and 20% 
in the preparation phases (Prochaska and Velicer, 1997). 
This method of assessing motivation has been used to predict the likelihood of making 
an attempt to quit. It can also be used to measure progress through the different stages 
of change, for those smokers still smoking, but thinking more seriously about quitting. 
This model has been used extensively in smoking cessation research in a variety of 
settings and with different client groups (Bunton et al., 1999). 
Some evidence is available which indicates that smokers in the earlier stages are not as 
successful at quitting as smokers who are in later stages (Prochaska et al., 1993). There 
is also some evidence that interventions, designed to link with a motivational stage, lead 
to better outcomes than do non-tailored interventions of equal intensity (Prochaska et 
al., 1993; Ashworth, 1997). 
Though this model is used extensively in the smoking cessation field, a number of 
researchers are critical of some of its applications (Bunton et al., 2000; Littell and 
Girvan, 2002). A review, commissioned and published by the Health Education Board 
for Scotland, outlines some of the methodological problems and limitations of the 
'Stage of Change' (Bunton et al., 1999). Around 1000 papers were identified as using 
or mentioning the model, of which 300 were examined in detail. The largest sub-group 
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of references were in the field of substance use/misuse including smoking, though other 
areas such as diet, exercise, sexual and mental health were identified. 
In this detailed critique, Bunton and co-workers identified problems both with the 
internal structure of the model with regard to the descriptors of the stages, and its 
external validity (its application) in health promotion. 
Other researchers raise concerns regarding a lack of consistency regarding the 
questionnaires used in the different studies (Etter and Sutton, 2002; Littell and Girvan, 
2002). Unlike the Fagerstrom Test for Nicotine Dependence where there is one 
standard research instrument, with 'Stage of Change', researchers often have to design 
their own and this will lead to lack of standardisation and inconsistency. 
Despite the contrasting views of researchers, it cannot be disputed that its widespread 
use in health promotion, especially with regard to substance misuse, has had an impact, 
and further evaluation and validation is required to determine its full potential. 
1.9 Strategies for Smoking Cessation 
1.9.1 Policy Documents including Evidence-Based Guidelines 
A number of evidence-based documents have influenced policies with regard to 
smoking cessation in the UK. In the USA, in the mid 1990's, the Agency for Health 
Care Policy and Research (AHCPR) released guidelines on treating tobacco dependence 
(Fiore et ai., 1996). These were updated in 2000 (Fiore et ai., 2000). The AHCPR 
guidelines are based on evidence from 300 selected articles which have been 
extensively reviewed and subjected to meta-analysis. They provided guidance for three 
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key audiences, primary care clinicians, tobacco cessation specialists and health care 
administrators. 
Other key influences on evidence-based policy are the systematic reviews conducted by 
the Cochrane Tobacco Addiction Review Group in the UK (the Cochrane Library 
reviews). These reviews present evidence, results and conclusions based on meta-
analysis and systematic reviews of randomised clinical trials selected from the literature 
according to strict inclusion criteria. However, they do not make recommendations. 
Both the AHCPR Guidelines and Cochrane Reviews have influenced the development 
of policy documents in both Scotland and England. In Scotland, the 'Smoking 
Cessation Guidelines for Scotland,' were released in 2000, and aimed to set out 
guidance on the delivery of smoking cessation within the context of the National Health 
Service (ASH Scotland & Health Education Board for Scotland, 2000). This document 
was adapted from the English Guidelines, 'Smoking Cessation Guidelines for Health 
Professionals' (Raw et al., 1998). The recommendations given in both these documents 
are targeted at three levels; the primary care team, all health professionals and smoking 
cessation specialists. Due to rapid changes occurring, especially with regard to health 
care policy, the English guidelines were updated and republished in 2000 (West et al., 
2000). More recently, the Scottish guidelines have also been rewritten and were 
published in September 2004 (Health Scotland and ASH Scotland, 2004). 
Two further Scottish documents, released in 2004, reinforce the current tobacco agenda. 
These are entitled 'Reducing Smoking Related Harm' (NHS Health Scotland and ASH 
Scotland, 2004) and 'A Breath of Fresh Air for Scotland - Tobacco Action Plan' 
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(Scottish Executive, 2004a). The former document identifies three areas of priority, 
namely: a more intensive approach to discourage children and young people from 
smoking, a marked expansion in smoking cessation services, and the development of 
further ways to make public and work places smoke-free. The Tobacco Action Plan 
follows through with an agenda to address these three priority areas. 
1.9.2 Community Approaches to Smoking Cessation 
The Cochrane Group has undertaken a systematic review of community interventions 
for reducing smoking among adults (Secker-Walker et al., 2004). The aims were to 
ascertain whether community-based interventions reduced smoking as measured by 
prevalence, cigarette consumption and quit rates, when compared to no intervention in 
comparison communities. It further aimed to detail what characteristics of the studies 
related to their efficacy. A community intervention was defined as a coordinated 
multidimensional programme aimed at changing adult smoking behaviour, involving 
several segments of the community and conducted in a defined geographical area. The 
size of the communities varied, with the population ranging from a few thousand to over 
100,000 people. 
The reviewers identified 32 studies for inclusion within the review. Nineteen 
interventions (59%) aimed at cardiovascular risk factor reduction, with nine (28%) 
aimed solely at reducing tobacco use. In 20 studies, there was a description of the 
process of community involvement. A variety of pUblic events, such as lectures or 
health fairs were used in 28 studies (88%). Mass media was used in 26 studies (81 %), 
18 (56%) used radio, with 11 (34%) using television spots. Posterslbillboards were 
used in 21 studies (66%). Interventions aimed specifically at smoking included 
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materials such as quit-kits in 18 (56%) studies, cessation groups in 16 (50%), individual 
counselling in nine (28%), audiotapes/videotapes in nine (28%) and quitlines in four 
(12%) of the projects. 
Cross-sectional follow-up was used to evaluate the interventions in 14 studies (44%) 
and cohort follow-up in 10 (31 %), and both cohort and cross-sectional follow-up in the 
remaining eight (25%). Questionnaires were administered in person in 20 studies 
(63%), by telephone in 13 (41%) by both methods in three and by mail in two. 
Biochemical testing was obtained in 10 studies (31 %), and examples of this included 
exhaled carbon monoxide and serum or salivary cotinine. 
Twenty seven (84%) studies reported differences in smoking prevalence as their main 
outcome, 14 studies (45%) reported changes in number of cigarettes and 16 studies 
(50%) reported quit rates. 
When looking at the changes in smoking prevalence, the estimated net decline ranged 
from -1.0% to 3.0% for men and women combined (10 studies). For women, the 
decline ranged from -0.2% to +3.5% per year, and for men the decline ranged from 
0.4% to + 1.6% per year. In one of the most rigorously conducted studies, the US 
COMMIT (Community Intervention for Smoking Cessation), there were 11 pairs of US 
and Canadian communities with a combined population of 2,000,000, which 
participated in a randomised control trial of a variety of community smoking cessation 
interventions. This study showed evidence of a limited effect, with no difference in 
prevalence between intervention and control, and there was no significant difference in 
the quit rates of heavier smoker, who were the key target intervention group. Dentists 
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were surveyed within the test areas concerning their tobacco control activities and it was 
found that, in general, their activities lagged behind those of the physicians, with 48% 
of the dentists counselling their patients, compared to 94% of the physicians (Jones et 
al.,1993). 
In conclusion, the failure of the largest and best-conducted community-based study to 
detect an effect on prevalence of smoking is disappointing. Though such approaches 
will continue to be part of tobacco health promotion policies, future studies will need to 
take account of this limited effect and consider other options (Secker-Walker et al., 
2004). 
1.9.3 The 'Stepped Care Approach' 
Following its 1996 and 2000 reviews, the US Agency for Health Care Policy and 
Research (AHCPR) proposed a 'stepped approach' to smoking cessation. This involved 
the provision of 'brief low cost interventions for smokers who could stop without 
extensive support, moving up to the provision of specialist smoking cessation clinics for 
the most dependent smokers. A similar approach was adopted in Scotland, where the 
intensity of the intervention was matched to the smokers' level of motivation and 
addiction (ASH Scotland & Health Education Board for Scotland, 1998). All health 
professionals were seen to have a role in delivering smoking cessation advice, including 
general medical practitioners, practice nurses, health visitors, pharmacists, dentists, 
dental hygienists and health promotion specialists (ASH Scotland & Health Education 
Board for Scotland, 2000). 
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Evidence for this multi-professional approach, came from a meta-analysis of 108 
interventions used in 39 control trials of smoking cessation in medical practice. It was 
found that the greatest success was achieved when there were multiple interventions 
given by multiple health care providers on multiple occasions (Kottke et al., 1988). 
The policy recommended that each smoker should be targeted with the least expensive 
treatment that was likely to enable that person to stop smoking (ASH Scotland & Health 
Education Board for Scotland, 2000). There were four steps, each of which were 
appropriate for smokers with particular levels of addiction. 
1. The first level of intervention involved the provision of health education and 
other information designed to increase motivation to quit. This could be 
delivered relatively cheaply to the population via the mass media. 
2. The second level was provision of very brief advice (up to three minutes) on 
stopping smoking by a health professional, including dentists and hygienists. 
3. The third level was for healthcare workers to offer nicotine replacement therapy, 
plus a follow-up appointment. This could take up to 20 minutes of a 
professional's time. 
4. The fourth level involved the provision of intensive treatment in a specialist 
clinic, for the most highly addicted of smokers. Specialist counselling, group 
therapy, as well as intensive support including NRT may be used. 
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1.9.4 Individual Approaches to Smoking Cessation 
There are a number of approaches that can be used to give individual advice to smokers 
(Fiore et aI., 1996). Two factors govern the delivery of smoking cessation advice; 
length of time taken to deliver a clinician-patient interaction, and number of sessions 
that a patient may receive with respect to smoking cessation advice. The greater the 
input in time and number of sessions, the higher the success rate (Fiore et al., 2000). 
Individual advice can vary from 'very brief' advice, where attention is drawn to the 
smoker's habit, and there is advice given to quit which lasts no more than 3 minutes. 
The main effect of this advice would be to motivate attempts at quitting, rather than to 
increase cessation rates (Health Education Board for Scotland and ASH Scotland, 
2001). Most of the advice on smoking cessation, delivered in the dental setting will be 
within the timeframe of this category. With respect to the success rate expected with 
this type of intervention, it is stated that at 6-months, around 2% of smokers given this 
type of advice would quit (NHS Health Scotland and ASH Scotland, 2004). 
'Brief advice' to stop smoking may be structured, and can last around 10 minutes. 
Examples of this approach would include the 4/SAs, and is covered in detail in Section 
1.9.5 below. The length of this approach will make it suitable for delivery within a 
dental setting. The success rate expected with this type of intervention, dependent on 
whether NRT is used, would be around 5-12% of smokers quitting the tobacco habit 
(NHS Health Scotland and ASH Scotland, 2004). 
More detailed counselling /psychosocial interventions will take a longer period of time, 
ranging from 10 to 30 minutes to deliver to the patient. Examples of this type of 
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intervention would include motivational interviewing and its derivatives, 'brief 
motivational interviewinglbehavioural change counselling'. Motivational interviewing 
is covered briefly in Section 1.9.6 below. As the training required to deliver 
motivational interviewing is considerable, and the time available in a dental setting for 
the delivery of smoking cessation advice will be restricted, there is probably limited 
application for this technique within the general dental practice setting. 
1.9.5 'Brief Advice' 
Much of the smoking cessation advice in primary care is thought to focus around 'brief 
advice' which should be provided routinely with some infonnation on NRT and how to 
use it, and a follow-up visit (Fiore et al., 2000). The method of delivery varies, from 
flow charts with the essential elements of asking the patient about their smoking and 
advising them to quit, to more structured protocols which attempt to give the health 
professional more guidance in delivering such advice (Health Education Board for 
Scotland and ASH Scotland, 2001). 
One such protocol, known as the 4As, appears in the dental literature (Christen et al., 
1990; Chestnutt, 1999). The 4As are:- Ask about smoking at every opportunity, Advise 
all smokers to stop, Assist the smokers to stop, and Arrange follow-up and appropriate 
referral if required. This structured method of giving advice was used in one smoking 
cessation trial in general dental practice in the UK (Smith et al., 1998). Trials in other 
settings, such as general medical practice and in secondary care with pregnant women, 
have used this approach (Kviz et al., 1995; Melvin et al., 2000). 
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More recently, the 5As have been used to help professionals provide smoking cessation 
advice for their patients (Fiore el aI., 2000; Health Education Board for Scotland and 
ASH Scotland, 2001) This methodology was first outlined for use by physicians, but is 
suitable for use by all health professionals (DiClemente et aI., 1991). In addition to the 
4As as detailed above, the fifth 'A' makes reference to Assessing the patient with 
regards to readiness to quit This acknowledges that not all patients are ready to quit, 
and tailors advice on cessation to an individual patient, dependent on the patient's 
'Stage of Change'. There have been no trials in the dental field using this particular 
model of structured smoking cessation advice. The 5As have been used in general 
medical practice, particularly in the US and Australia, and with pregnant smokers (Litt, 
2002; Solberg et aI., 2002; Dept of Health Australia, 2004.) 
There is one group where there is no evidence that the use of 5As is efficacious, and this 
is with cancer patients (Schnoll el aI., 2003). It was concluded that this group required 
more personalised advice, which reflected and addressed their individual situations. 
1.9.6 Motivational Interviewing 
Motivational interviewing is a more patient-centred approach for use with helping 
individuals change their behaviour. Motivational interviewing can be defined as 'a 
directive, client-centred counselling style for eliciting behaviour change by helping 
clients explore and resolve ambivalence' (Rollnick and Millar, 1995). Motivational 
interviewing is influenced by 'Stage of Change' and has self-efficacy and patient-
centred counselling as key concepts (Rollnick et aI., 1999). 
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There has been recent interest in the technique, especially when used with pregnant 
smokers (Tappin et al., 2000; Velasquez et a/., 2000). 
A systematic review looked at the effectiveness of behavioural interventions, adapting 
the principles and techniques of motivational interviewing (MI) in the four behavioural 
domains of substance abuse, smoking, HIV risk and diet/exercise (Dunn et al., 2001). 
In total, 29 studies were identified and monitored. Sixty per cent of the 29 studies 
yielded at least one significant behaviour change element. There was evidence that MI 
can be an effective substance abuse methodology when used by clinicians who are non-
specialists, but there was inadequate evidence to evaluate the effect of MI in other 
domains including smoking. 
In a study which aimed to reduce passive smoking exposure in low income households 
with young children, there was some evidence that the intervention group who had a 
motivational interviewing session from a trained counsellor and telephone follow-up 
had lower nicotine levels than those from the self-help group (Emmons et al., 2001). 
In another study looking at group counselling for smoking cessation, cognitive/skill 
training therapy (CBT) and motivational interviewing (MI) therapy were compared with 
'brief intervention' (BI) in a sample of 677 smokers (Smith et al., 2001). All 
participants received 8 weeks of nicotine patch therapy. Neither the MI nor the CBT 
improved long term abstinence rates relative to the 'brief intervention' (BI). 
Motivational interviewing is a relatively new methodology and requires further research 
and evaluation to examine its future potential in the field of smoking cessation. 
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1.9.7 Specialist Approaches to Smoking Cessation including Group Therapy 
Specialist smoking cessation services are now a key strand in the provision of smoking 
cessation. It is to these services that those individuals who are most heavily dependent 
on tobacco should be referred for treatment. Usually, a specialist smoking cessation 
clinic will offer individual counselling as well as group therapy, dependent on a client's 
individual preference. The individual will also be encouraged to use nicotine 
replacement therapy (NR T) if required. 
Both Scottish and English smoking cessation services use group counselling which 
focuses on group processes rather than the therapists educational or counselling input 
(Hajek and West, 1998). This withdrawal-orientated therapy is based on the premise 
that smokers fail because of the severity of withdrawal symptoms, and if one can 
address this problem, the likelihood of success is higher (Hajek, 1989). This treatment 
methodology has been pioneered at the Maudsley Clinic in London. Participants are 
registered with a view to attending weekly for six weeks, where they meet and receive 
professional advice, as well as social support from each other. 
Since 1998, England has developed smoking cessation services in all of its regions, 
following the release of the White Paper 'Tobacco Kills' (Department of Health, 1998). 
Evaluation of the specialist smoking cessation clinics in England has resulted in 
extremely encouraging results (Department of Health, 2003). Figures released for 
specialist services, April 200l-March 2002, indicated that 227,300 users had set a quit 
date and of those, about 142,300 (63% of those setting a quit date) received free NRT. 
At the 4-week follow-up, 119,800 (53%) said that they had quit (self-report). This is 
considerably in excess of success rates associated with the 'brief intervention', though 
61 
direct comparison is difficult, as results of other smoking cessation studies often report 
quit rates at 3 and 6 months, rather than at 1 month. 
With respect to the Scottish Specialist Smoking Cessation Services, these have been 
developed more recently, and what is available varies geographically. Greater Glasgow, 
for example, runs mainly group counselling sessions, whereas Tayside offers only 
individual counselling. Currently, no evaluation figures are available for Scottish 
specialist smoking cessation services. Partnership in Action on Tobacco and Health 
(PATH), part of ASH Scotland, are currently developing data collection tools to be used 
in the evaluation of all Scottish Cessation Services. 
1.10 Therapeutic Aids to Smoking Cessation 
1.10.1 Nicotine Replacement Therapy 
Nicotine Replacement Therapy (NRT) is used to replace the nicotine from cigarettes in 
smokers who wish to quit smoking. This reduces the withdrawal symptoms associated 
with smoking cessation (Royal College of Nursing, 2001). It minimizes many of the 
physiological and psychomotor withdrawal symptoms, and therefore its use increases 
the likelihood of motivated smokers quitting and remaining abstinent (Hughes et al., 
1990). All forms of NRT use routes of absorption other than gastric, as nicotine is 
rapidly broken down in the acidic environment of the stomach (Tang et al., 1994). 
A Cochrane Review provides evidence, from over 35,600 smokers, that offering NRT 
products to dependent smokers is more effective in helping them stop smoking than if 
NRT is not offered or if a placebo is used (Silagy et al., 2004). The review identifies 
110 trials of which 96 were associated with a non-NRT control group. The main 
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outcome measure was abstinence from smoking after at least six months of follow-up. 
The odds ratio for abstinence with NRT compared to control was 1.74 (95% confidence 
interval, 1.64-1.86). The odds ratios for the different forms ofNRT were 1.66 for gum, 
1.74 for patches, 2.27 for nasal spray, 2.08 for inhaled nicotine and 2.08 for nicotine 
sublingual tablet. The odds were largely independent of the duration of the therapy, 
intensity of additional support provided or the setting in which the NRT was used. 
1.10.2 Nicotine Gum 
The first type of NRT to be developed was chewing gum in 1967 (Royal College of 
Nursing, 2001). This was prompted by a request from the Swedish Navy to a 
phannaceutical firm regarding the problems they had with their submarine crews 
suffering from nicotine withdrawal, when they were on board ship. 
The nicotine resin complex is presented in a buffered chewing gum base which enables 
the nicotine to be absorbed directly through the buccal mucosa resulting in plasma 
concentrations approximately half that produced by smoking a cigarette (Russell et af., 
1976). 
Nicotine gum was first launched in the UK as a prescription-only 2 mg gum, followed 
thereafter by a 4 mg gum for use with more highly dependent smokers. Currently, both 
formulations are available on the general list and can be bought in supermarkets in a 
similar manner to toothpaste or sugar-free gum. 
The first randomised controlled trial (RCT) trial of nicotine gum was carried out in the 
early 1980s (Jarvis et ai., 1982). One hundred and sixteen subjects who were smoking 
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between 26 and 30 cigarettes a day were recruited, and told to use unrestricted amounts 
of the 2 mg gum. Of the 58 participants who received the nicotine gum, 27 (47%) were 
not smoking at I year, compared to 12 (21 %) of the placebo gum users. 
In a recent trial, 608 smokers were characterised into high and low nicotine dependence 
(Garvey et al., 2000). Subjects were assigned to placebo, 2 mg or 4 mg nicotine gum 
groups. Brief behavioural counselling was also used. At 1 year, post-cessation quit 
rates were 11.2%, 19.5% and 18% for the low dependence group using placebo, 2 mg 
and 4 mg gum respectively. For the more highly nicotine dependent group, quit rates 
were 6.1%, 15.7% and 20.7% for placebo, 2 mg and 4 mg gum respectively. Other 
variables relating to quit rate at one year were longer period of abstinence on a prior quit 
attempt, being married, higher educational status and having a non-smoking partner. 
Side effects of gum can include hiccups, gastrointestinal upset, jaw pain and oro dental 
problems (Palmer et al., 1992). 
1.10.3 Nicotine Patches 
The nicotine patch consists of a self-adhesive transdermal delivery system (Royal 
College of Nursing, 2001). Two types of patch are available: a 24 hour patch designed 
to be worn day and night, and a 16 hour patch which is applied first thing in the 
morning and removed at bed time. There is no difference in efficacy between these 
dosage regimes (Silagy et al., 2004). 
The patch works by slowly releasing a controlled amount of nicotine over a 16 or 24 
hour period, i.e. all the time it is worn. Properties of nicotine make it ideal for 
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transdennal delivery. Being lipophilic, it can penneate through the stratum corneum, 
and its hydrophilic properties also mean it can pass through the deeper layers of skin 
and reach the systemic circulation. This produces lower levels of nicotine than smoking, 
but high enough to prevent withdrawal symptoms such as irritability, restlessness and 
anxiety. 
Nicotine patches were first launched in the UK in 1992. In a study of 1200 heavy 
smokers (defined as > 15 cigarettes per day) attending general medical practice, 
participants received 'brief' GP advice, a booklet and 16hrs/day patches, either active or 
placebo (Stapleton et at., 1995). Outcomes were measured at follow-ups at weeks 1, 3, 
6, 12, 26 and 52 by self-report and biochemical validation. It was found that nicotine 
patch treatment doubled the rate of continuous abstinence, up to one year. 
1.10.4 Other Forms of Nicotine Delivery 
There are other fonns of nicotine delivery, namely lozenges, tablets, inhalator and nasal 
spray (Royal College of Nursing, 2001). Choice of product is often dependent on the 
preference of the individual making the quit attempt. Nasal sprays may be more suitable 
for those who are more highly dependent, as they have the most rapid nicotine delivery 
system of all the nicotine replacement therapies. 
One study, in which smokers were randomised to nicotine gum, patch, spray or inhaler 
found no significant differences in abstinence rates after 12 weeks (Hajek et al .• 1999). 
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1.10.5 Combination of NRT therapy 
There is some evidence that using a combination of NRT products is better than one 
product alone (Silagy et al., 2004). For those patients unable to quit on a single type of 
NRT, updated US Clinical Practice guidelines recommend use of nicotine patches with 
another form ofNRT as a second-line therapy, or with bupropion (Fiore et al., 2000). 
Currently, NRT products are not licensed for use in this way in the UK. 
1.10.6 Non-Nicotinic Preparations used in Smoking Cessation 
1.10.6.1 Zyban (Bupropion) 
Sustained-release bupropion (amfebutamone) is a non-nicotinic agent that is indicated 
as an aid to smoking cessation. Its smoking cessation properties were discovered when 
it was noted that some smokers, using the drug for antidepressant reasons, quit smoking. 
Its mechanism of action in smoking cessation is not fully understood, but it may be 
mediated by raising the concentration of dopamine in the brain (Ascher et al., 1995). 
In two large clinical trials, use ofbupropion (300mg/day) for 7-9 weeks, was associated 
with significantly higher smoking abstinence rates than placebo at 6 and 12 month 
follow-ups (Hurt et al., 1997; Jorenby et al., 1999). Point prevalence rates at 12 months 
in the two studies were 23.1% and 30.3% with bupropion, compared to 12.4% and 
15.6% for the placebo. Continuous abstinence rates at 12 months in the second trial 
were 18.4% with bupropion and 5.6% with placebo (Jorenby et al., 1999). However, 
some side-effects were noted, and insomnia and dry mouth were reported by a number 
of the patients. A seizure rate of 0.1 % of patients using this drug has been reported 
(Hurt et al., 1997). 
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When looking at the efficacy of bupropion and NRT patch, versus placebo and NRT 
patch, it was found that the combination therapy of bupropion and nicotine patch 
provided a slightly higher abstinence rates than NRT alone (Jorenby et al., 1999). 
1.10.6.2 Other Drugs Used in Smoking Cessation 
Other drugs such as nortriptyline and clonidine have been used in smoking cessation 
(Tobacco Advisory Group of the Royal College of Physicians, 2000). Further research 
is required to investigate their full potential. 
1.11 Involvement of Primary and Secondary Health Care in Smoking 
Cessation 
1.11.1 Smoking Cessation Advice Delivered by Physicians 
A vast amount of information is available concerning the delivery of smoking cessation 
advice by a medical practitioner and a systematic review, using Cochrane methodology, 
has been carried out (Silagy and Stead, 2004). 
Selection criteria included the use of randomized controlled trials with at least two 
groups and assessment of abstinence, at least 6 months after the advice was given. 
This review did not look at the effect of adding NRT to advice, as the effectiveness of 
this was addressed in a separate Cochrane review. 
The review had as its primary objective, to determine whether giving advice was more 
effective than not giving advice and whether the effect was greater if the advice was 
more intense and followed-up. The review also examined the effect of supplementation 
of advice with various aids such as self-help manuals and CO monitoring and looked at 
67 
whether motivational interviewing was more effective than simple advice. Studies 
where advice was provided (with or without a leaflet) during a consultation lasting less 
that 20 min and with up to one follow-up visit was defined as a 'minimal' intervention. 
Any trial where the intervention involved a greater time commitment at the initial 
consultation, or used additional materials was defined as an 'intensive intervention'. 
The Cochrane review identified 34 trials, conducted between 1972 and 1999 and 
including over 27,000 smokers, which met the criteria. Some of the populations were at 
risk of specific diseases, including asthma, ischaemic heart disease and diabetes. Most 
trials were set in primary care, though other settings included hospital wards and 
outpatient clinics. 
The primary outcome measure was that of smoking cessation, rather than smoking 
reduction. Validation of all self-reported cessation by biochemical analysis of body 
fluids or measurement of CO was reported in nine of the studies (26%). No 
biochemical validation was reported in the remaining 21 studies (62%). It is rather 
surprising that the number of studies using validation was so low. 
When all 16 trials of brief advice (as part of a minimal intervention) versus no advice 
(or usual care) were pooled, the results demonstrated a statistically significant increase 
in the odds of quitting [OR 1.69,95% CI 1.45-1.98]. When the effectiveness of more 
intensive advice was compared to no advice/control, there was a trend towards a larger 
effect, but there was evidence of heterogeneity between the trials. A direct comparison 
between intensive and minimal advice in 15 trials suggested a small but significant 
advantage of more intense advice. 
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Even though motivational interviewing appeared to increase the likelihood of making a 
quit attempt, a single trial produced insufficient evidence to support the benefit of 
motivational counselling compared to brief advice on cessation rates (Butler ef al., 
1999). 
1.11.2 Smoking Cessation Advice Delivered by Nurse Practitioners 
A further Cochrane review looked at nursing interventions for smoking cessation (Rice 
and Stead, 2004). The aim of this review was to determine the effectiveness of nursing-
delivered smoking cessation interventions, in comparison to no intervention. Additional 
areas examined were the intensity of the intervention, and whether the intervention was 
more effective if it included follow-up or other aids to smoking cessation. 
Criteria for inclusion were that there had to be at least two treatment groups and 
allocation to treatment groups had to be stated as random. Types of participant were 
adults of either gender, but specifically excluding pregnant women (this is the subject of 
a separate Cochrane review). Follow-up of patients had to be at least to 6-months. 
Advice to stop smoking was defined as verbal instructions from the nurse to stop 
smoking. Low intensity interventions were defined as trials where advice was provided 
(with or without leaflet) during a single consultation lasting 10 min or less, (half the 
time used in the physician review), with up to one follow-up visit. High intensity 
interventions were defined as trials where the initial contact lasted for more than 10 
min, or where there were additional materials or strategies other than simple leaflets and 
participants usually had more than one follow-up contact. As with the physician review, 
studies using NR T were specifically excluded. 
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Outcome measures were smoking cessation or reduction in the number of cigarettes 
smoked. Where biochemical validation was used, only those subjects meeting the 
biochemical criteria were regarded as quitters. 
The reviewers identified 22 trials between 1987 and 2000 in seven different countries. 
Twenty trials recruited hospitalised patients or primary care patients and two studies 
used community-based adults. Eight studies focussed on adults diagnosed with 
cardiovascular problems, one study each with patients with diabetes or respiratory 
disease. 
Sixteen studies, involving 8192 people, contributed to the main comparison of nursing 
advice versus control. In these 16 studies, comparing a nursing intervention to a control 
or usual-care group, it was found that allocation to the intervention significantly 
increased the odds of quitting [OR 1.50 95% CI 1.29-1.73]. There was no evidence 
from indirect comparison that interventions classified as more intensive were more 
effective than less intensive ones. There was limited evidence that interventions were 
more successful for hospital inpatients with cardiovascular disease than for other 
conditions. Interventions in non-hospitalised patients also showed evidence of benefit. 
Five studies, not included in the main analysis, involving nurses giving smoking 
cessation counselling during a screening health check, showed some, albeit a lesser, 
effect. 
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1.11.3 Smoking Cessation Advice Delivered by Community Pharmacists 
For a variety of reasons, community pharmacists are increasingly being seen as an 
important group to promote smoking cessation. They have contact with smokers on a 
day-to-day basis and are the key interface for the distribution of nicotine replacement 
therapy. 
No Cochrane review data are currently available for this group. A protocol has been 
developed and the completed review is due to be published later in 2004. However, a 
recent review of the pharmacists' role in reducing the risk factors in coronary heart 
disease included smoking (Blenkinsopp et al., 2003). 
Two RCTs, one in Scotland and one in Northern IrelandILondon were identified, 
together with three non-randomised experimental studies (Sweden, Germany and 
Switzerland). 
The Scottish ReT involved 492 subjects and 62 community pharmacists. At 9 months, 
12% of the intervention and 7% of the controls had reportedly quit. Surprisingly, for a 
more recent study, self-reported quitters were not biochemically validated, the authors 
stating that they found doing this untenable. 
In contrast, the NIlLondon trial did use validation, in the form of cotinine, to determine 
smoking cessation. This study involved 484 subjects, with 124 community pharmacists 
taking part. However, only 44% of these managed to recruit patients into the study. At 
1 year, 14.3% of the intervention group were abstinent, compared to 2.7% of the 
controls. 
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1.12 Involvement of the Dental Team in Smoking Cessation 
With respect to guidance for the dental team regarding the delivery of smoking 
cessation advice, a number of resources have been developed which focus purely on this 
topic (Watt and Robinson, 1999; Beaglehole and Watt, 2004). One guide includes 
smoking cessation advice under the auspices of oral cancer prevention (Macpherson et 
ai., 2003). 
With regards to the role of the dental team in smoking cessation, this topic has not been 
the subject of a Cochrane review, and no other systematic reviews cover this subject 
area. 
This section will therefore review interventions concerning the delivery of smoking 
cessation advice by primary and secondary care dental team members. 
The majority of the available literature examines dental professionals' attitudes and 
practices regarding the provision of smoking cessation advice. Some papers address 
issues to do with training received by dental team members or the perceived need for 
training by dentists and hygienists. A smaller body of literature assesses smoking 
cessation rates/reduction in cohorts of dental patients recruited to trials. Two papers 
examine the patients' perspective regarding the involvement of the dental team in 
promoting smoking cessation. 
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1.12.1 Dentists and Dental Hygienists Attitudes to Promoting Smoking Cessation 
Surveys of dentists concerning their attitudes to promoting smoking cessation have been 
carried out in the US, UK, Canada, Sweden, Finland, Italy, Germany, the Netherlands, 
Jordan, Australia and New Zealand, over the last two decades. Some studies in the UK 
and US surveyed similar groups of dentists 5 years apart, enabling secular trends to be 
examined with regards to smoking cessation activity (Logan et ai., 1992; John et ai., 
2003). With respect to dental hygienists, surveys have been carried out in the US, 
Canada, UK and Italy. 
The size of the surveys vary, from several thousand questionnaires in some of the US 
and one UK study, to around one hundred in some of the smaller research projects. 
Response rates also differ, with some researchers obtaining responses of at least 70% 
(Telivuo et al., 1991; Logan et al., 1992; Chestnutt and Binnie, 1995) while others 
obtained response rates as low as 12% (Warnakulasuriya and Johnson, 1999; Reichart et 
ai., 2000). The quality of the responses therefore may vary, depending on the project 
methodology. Some surveys, despite having a large number of questionnaires, may still 
have a low overall response rate, and issues to do with bias and selectivity have to be 
borne in mind. 
The surveys also differ in the approaches taken, with some asking about smoking 
cessation under the banner of oral cancer prevention. However, there are a number of 
recurring themes. 
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1.12.2 Dentists' and Dental Hygienists' Roles and Current Practices with respect 
to Smoking Cessation 
One of the main areas examined has been whether dental health professionals consider 
themselves to have a role in smoking cessation. Most surveys would indicate that high 
numbers are of the opinion that dentists and dental hygienists should participate in this 
area, albeit under the auspices of oral cancer prevention. 
In the UK (Scotland), Chestnutt and Binnie (1995) found that 55% of dentists said that 
they had a role in promoting smoking cessation. Other surveys asking comparable 
questions found slightly higher results in the region of 70% (Campbell and Macdonald, 
1994; Warnakulasuriya and Johnson, 1999). With respect to the dental hygienists, there 
were similar findings in the region of 60-80% of hygienists feeling that they had a role 
in this area (Fried and Rubenstein, 1990; Gussy ef aI., 1996; Syme et aI., 2001). 
By contrast, in one of the most recent studies, carried out in Sweden, half the dentists 
(49%) and around a third of the hygienists did not perceive that assisting people with 
tobacco cessation was part of their job (Helgason et aI., 2003). 
Differing categories of dentists have varymg perceptions of their role in tobacco 
counselling. One group, where advice is most often offered, is the category of 
periodontist, and this is likely to be due to the role that tobacco plays in the aetiology, 
prevalence and response to treatment of periodontal disease (Dolan et aI., 1997). 
The attitudes of paediatric dentists to tobacco intervention work with children and 
adolescents have been studied, and though high numbers thought they had a role, half 
(48%) did not feel confident in undertaking this work (Shenkin, 2003). 
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Some surveys asked the dental health professionals about their own smoking habits. The 
prevalence of smoking amongst dentists varied from continent to continent. A 
relatively high number of dentists in Northern Italy and Jordan smoked, with around 
one in three (33% and 35% respectively) reporting being current smokers (Lodi et al., 
1997; Burgan, 2003). This is high compared to rates of Scottish (12%), English (9%), 
Swedish (16%), American (6%) and Canadian dentists (4%) (Logan et aI., 1992; 
Campbell and Macdonald, 1994; Chestnutt and Binnie, 1995; Halling et aI., 1995; John 
et aI., 1997). The reported prevalence of tobacco use by dental hygienists was 7% in 
both the UK and US (Fried and Rubenstein, 1990; Gussy et aI., 1996). 
1.12.3 Asking Patients about Tobacco Use 
On examining whether the dentists Asked their patients about their smoking status, 
studies often differentiated between asking all or most of their patients, or asking some 
of their patients. 
High numbers of dentists ask at least some of their patients about their smoking status: 
90% in the US (Logan et al 1992; Dolan et aI., 1997), 80% in Canada (Campbell and 
Macdonald, 1994), 85% in Scotland and England (Chestnutt and Binnie, 1995; John et 
aI., 2003). Lower numbers of dentists report routinely or always asking about smoking. 
In England, 48% routinely recorded their patients' smoking status, with 27% always 
discussing smoking with their patients (John et al., 2003). Comparable figures are 19% 
in Scotland (McCann et al., 2000) and 33% in the US (Dolan et aI., 1997). In Northern 
Ireland, only 14% of the dentists said that their patients' records routinely contained 
information about smoking habits (Cowan et aI., 1995). 
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If there were signs or symptoms of oral disease, such as potentially malignant lesions or 
periodontal disease, dentists felt happier about raising the issue of smoking (John et aI., 
1997; Clover et aI., 1999). 
With respect to dental hygienists, Halling et al. (1995) found that 68% of hygienists in 
Sweden routinely took a tobacco history compared to 32% of the dentists. A recently 
published survey of Italian dental hygienists found that 94% reported asking about 
patients' tobacco use (Nicotera et al., 2004). 
1.12.4 Advising Patients about Tobacco Use 
Few dentists always advise their smoking patients to quit, with a larger number advising 
at least some of their patients to quit. Several studies found around 60% of dentists were 
likely to advise at least some of their patients to quit (Logan et al., 1992; Dolan et at., 
1997). 
With respect to dental hygienists, a similar or slightly higher number were likely to 
routinely advise their patients to quit, with 60% of Iowa hygienists routinely, and 67% 
of Eastern US hygienists almost always or often advising patients to quit (Fried and 
Rubenstein, 1990; Chambers and Corbin, 1996). 
As with asking patients about tobacco use, a number of studies have reported that 
dentists find it easier to advise their patients if there is dental pathology present (John et 
a/., 2003). In addition, Martin and co-workers (1996) reported that dentists were more 
likely to advise patients who smoked heavily (2 packs a day) than smokers who smoked 
more lightly (a pack or less per day). With respect to dental hygienists, Parker (2003) 
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postulated that the reason that dental hygienists found it easier to advise patients to quit 
smokeless tobacco was due to the high prevalence of intraoral lesions in such patients. 
1.12.5 Assisting Patients with Smoking Cessation 
The literature shows that dentists and hygienists are much less likely to actively assist 
their patients in trying to quit, than they are to ask and advise on smoking matters 
(Warnakulasuriya, 2002). 
Practitioners have been asked whether they helped patients to set a quit date, whether 
they gave information about nicotine replacement therapy and whether they referred 
patients in need to specialist services. Clover and co-workers (1999) in her Australian 
study found that only 5% of the dentists surveyed helped their patients set a quit date. In 
a recent Canadian study, less than 10% of dentists provided any method of assistance, 
such as resources, quit date or referral, for most patients interested in quitting 
(Brothwell and Armstrong, 2004). In the US, Dolan and co-workers (1997) found that 
periodontists were the category of dentist most likely to give their patients help in this 
area. 
With respect to dental hygienists, this group were more likely to be proactive than the 
average dentist, with 24-27% of US hygienists discussing specific strategies to stop 
smoking with patients (Hastreiter et al., 1994; Chambers and Corbin, 1996). 
It has been suggested that even where dentists were willing to participate in smoking 
cessation, their activities were not systematic and there was a need for further education 
and training (Wood et al., 1997). 
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1.12.6 Issues associated with Competency and Perceived Training Need 
Many of the studies outlined above asked practitioners to rate their levels of confidence 
and competence in delivering smoking cessation advice. In many studies, practitioners 
expressed a need for further training (Chestnutt and Binnie, 1995, Warnakulasuriya, 
2002; John et a/., 2003). 
Within the US, one study reported only 24% of dentists (Texas-Mexico Border) felt 
adequately trained to provide tobacco cessation education (Alonge and Narendran, 
2003), while another showed that less than 10% reported a good knowledge ofNRT or 
Bupropion (John et a/., 2003). Block and co-workers (1999) found that 60% of dentists 
reported a desire for further tobacco education. 
With respect to dental hygienists, the concerns cited were similar to those of the 
dentists, with low confidence in the training already received, especially in the UK 
(Gussy et a/., 1996; Dykes et a/., 2001). 
A number of surveys have looked at the state of tobacco education in the undergraduate 
curriculum and found it to be insufficient (Chestnutt and Binnie, 1996; Dykes et a/., 
2001; Rikard-Bell et ai., 2003a). These studies suggest that further structured training at 
undergraduate level for both dentists and hygienists is essential. 
Gelskey (2002) detailed a systematic training approach to tobacco education involving 6 
hours of training, which would be suitable for dental health professionals. 
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1.12.7 Barriers to Participating in Delivering Smoking Cessation Advice 
A number of barriers to participating in smoking cessation have been cited by dental 
health professionals. Lack of confidence, limited resources, doubt about their 
effectiveness and skills in assisting patients in making a quit attempt, not knowing 
referral routes for detailed counselling and lack of patient materials were recurring 
themes in the different surveys (Chestnutt and Binnie, 1995; Wamakulasuriya, 2002; 
John et al., 2003). Lack of time was mentioned by several studies (Chesnutt and Binnie, 
1995; Albert et at., 2002; Watt et al., 2004) and hygienists voiced similar concerns with 
respect to the barriers mentioned above (Chambers and Corbin, 1996; Gussy et al., 
1996). McCann et al (2000) cited fear of adversely affecting the dentist-patient 
relationship. Lack of remuneration for this work was also mentioned in some studies 
(Chestnutt and Binnie, 1995; John et al., 1997) though others reported that this was not 
a strong barrier (Chambers and Corbin, 1996; Dolan et ai., 1997). 
1.12.8 Patients' Perceptions of Smoking Cessation as delivered by Dental Team 
Members 
In the UK, there is no research into patients' opinions and attitudes regarding smoking 
cessation therapy in a dental setting. One Canadian and one Australian study address 
this topic area. 
In rural areas of Alberta, Canada, staff in 52 dental offices were recruited and provided 
demographic and professional information about their tobacco counselling practices as 
well as information about their views regarding the patients' opinions of providing such 
a service (Campbell et ai., 1999). Additionally, a random sample of patients, seen 
during one month at these dental offices, were interviewed over the telephone about 
their last dental visit. In all, data were collected from 3,088 dental patients of whom 
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58.5% believed that the dental team should provide tobacco cessation services. This 
was in contrast to the data collected from the dentists: 61.5% did not think that patients 
expected such services, and dentists cited patient resistance (94.3%), the fact that 
patients might leave their practices (53.9%), and lack of confidence in practitioners' 
ability to provide effective services (90.4%) as barriers. 
A more recent study (Rikard-Bell et al., 2003b) looked at Australian patients' views of 
the counselling they received from their dentist in the field of smoking cessation. 
Seventy-eight dental practices agreed to allow patients to be approached to collect data. 
A total of 2,451 patients were contacted, of which 1,160 agreed to participate and to fill 
in pre-consultation questionnaires. Of this group, 302 (26%) were current smokers. 
Most patients who smoked reported that they would not change their dentist if asked 
about their smoking status at every opportunity (61 %). Within this group, nearly half 
of all smoking patients were not seriously intending to quit (46%) and only 79 (26%) 
were considering quitting. Less than one third of smokers (30%) surveyed stated that 
they would try to quit if their dentist suggested that they should try. 
Patients were also asked to complete questionnaires after their dental consultation. Of 
the 849 who agreed, 623 returned the postal questionnaires. Of this cohort, only 17% 
recalled being asked about their smoking status at their most recent visit. With regards 
to smokers, only 35% recalled any type of smoking cessation advice being given. 
Though this was an interesting approach to what amounts to an audit of the delivery of 
smoking cessation advice, a number of flaws in the methodological approach may be 
inherent, resulting in potential bias. Only 58% of dentists agreed to allow patients to be 
80 
approached, and only 623 (out of a possible 2,451 patients initially approached) 
completed post-consultation questionnaires. The authors also state that smokers were 
significantly more likely not to return the post-consultation questionnaires. 
1.12.9 Clinical Trials involving Dentists and Smoking Cessation 
In the US and UK, dentists have been involved in a limited number of smoking 
cessation trials and are recognised increasingly as having a small but significant impact 
upon cessation rates (Gordon and Severson, 2001; Warnakulasuriya, 2002). Two US 
and two UK trials are discussed below. 
In a randomised control trial, Cohen (1997) found that by attaching stickers to the front 
of the casenotes of patients who smoked, a doubling occurred in the percentage of 
smokers (36% v 18%) who were asked about their smoking by the clinician. 
In previous work, Cohen carried out a randomised control trial involving private 
dentists in the US (Cohen et al., 1989). Each of the 50 dentists recruited was assigned 
to one of four experimental legs: 'reminder' group where two prompts on patients' 
notes reminded the clinician to ask about smoking and to set a quit date; 'gum' group 
where patients were offered free nicotine gum; 'both' group where patients had both 
information and free nicotine gum; and a 'control' group who received neither 
information nor gum. Smoking cessation outcomes were determined at 6 and 12 
months, with biochemical validation of smoking status available for 428 participants at 
6 months and 374 at 12 months. At 6-months, those patients in the ' gum' leg had a 
cessation rate of 18.2%, compared with 7.1 and 7.4% for the 'control' and 'reminder' 
groups. Those patients in the 'both' group had a quit rate of 9.4%. At the 12-month 
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mark, the rates of quitting for the 'gum' group had fallen slightly to 16.3%, whereas the 
patients who received 'both' had a success rate of 16.9%. The 'control' and 'reminder' 
groups had a rate of7.7% and 8.6% respectively. Despite this trial being around fifteen 
years old, there is little recently published literature involving the use of NRT in a 
dental setting. Christen and Christen (1992) described how NRT in the form of nicotine 
patches could be used within the oral care setting, but no data were presented regarding 
their effectiveness of such an approach. 
In the UK, there have only been two clinical trials reported involving dental team 
members and the provision of smoking cessation advice. The first study took place in a 
hospital periodontal department. A group of 98 smokers were given smoking reduction 
advice, combined with dental health instruction and periodontal care, delivered by one 
periodontist (Macgregor, 1996). A control group of 33 individuals were given dental 
health instruction and periodontal care, but no smoking cessation advice. Follow-ups of 
patients varied, between 3 and 12 months. In the intervention group, 50% reported 
reducing their consumption of cigarettes to half or less, and 13.3% reported giving up 
smoking completely. In the control group, 29% reported some reduction in their 
smoking, with 5.3% of the participants giving up completely. No details were presented 
regarding the nature of the smoking cessation advice, nor was there any biochemical 
validation of the smoking status of the patients, with all data regarding giving up 
smoking or cutting down being self-reported. 
In the first UK trial of smoking cessation in a general dental practice setting, Smith and 
co-workers (1998) found a smoking cessation rate of 11 % at 9 months. This study did 
not have a control phase and there were difficulties associated with recruitment of 
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patients in some of the practices. Though 54 practices agreed to participate in the study, 
only 22 (41 %) took part, with two practices managing to recruit over one-third of all the 
patients. A total of 159 patients were recruited to the study. Patients were given 
counselling based on the 'brief intervention from the dentists, and they were also 
offered NRT (nicotine patches at cost price) if they so wished. Smoking status was 
biochemically validated at baseline and at 9 months using cotinine. Seventeen (out of a 
total of 159) had stopped smoking at the 9-month mark, and of these seven attributed 
their success to the help and advice given by the dental team, with ten patients 
attributing their success to the use of nicotine patches. The main criticism regarding 
this study was the lack of an ReT design. Other areas of concern include the lack of 
quality control regarding the actual nature of the smoking cessation intervention, nor 
was there any formal training of the dental team members involved. 
1.12.10 Trials involving Smoking Cessation and Dental Hygienists 
There have been a number of tobacco cessation trials reported involving dental 
hygienists giving advice to smokeless tobacco users; in general these have not been 
reported in this thesis as they are outwith the area of this study. 
No UK trials have been reported involving the use of dental hygienists to give smoking 
cessation advice to patients. Two US trials, carried out during the 1980's and 90's, have 
involved dental hygienist-delivered smoking cessation advice. 
The first US trial was carried out by Secker-Walker et aZ. (1988). Dental hygienists 
were trained to deliver the smoking cessation intervention during routine care. The 
intervention consisted of providing 'brief counselling', self-help material and direct 
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advice to quit. A total of 51 smokers were recruited. A telephone follow-up 
questionnaire, administered 6 months after counselling, revealed that 14.6% of the 
counselled patients quit smoking. Data were collected by self-report and there was 
neither biochemical validation nor a control group within this trial. The authors state 
that the best predictors of quitting smoking included an initial high intention of quitting 
soon, fewer pack-years of smoking and two or more visits to the dental hygienist. 
Clearly, methodologically, any future trials would have to be more robust, with an RCT 
design, and quitting validated by some form of biochemical means such as cotinine or 
CO. 
A randomised clinical trial to test a brief intervention in fee-for-service practices was 
carried out in Oregon (Severson et al., 1998). This intervention principally used dental 
hygienists. The intervention was targeted at both smokeless tobacco users as well as 
cigarette smokers. This was the largest trial to date, involving dental team members, 
and data were available for 3,068 cigarette smokers and 469 smokeless tobacco users 
recruited into the trial and followed-up at both 3- and 12-months post-intervention. 
For the cigarette smoker, three types of intervention were used: 'Usual Care', 'Minimal 
Intervention' and 'Extended Intervention'. For smokeless tobacco users, two groups 
were used: 'Usual Care' and 'Extended Intervention'. Minimal Intervention in this trial 
was defined as, asking about their patients' smoking habits, giving feedback to the 
patients regarding any smoking-related oral conditions, giving advice to quit and some 
resources for the patient including a pack of educational materials. The 'Extended 
Intervention' was defined as all of the above and in addition, setting a quit date with the 
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patient, giving a motivational video and telephone follow-up regarding the patient's 
progress. 
Two types of outcome measures were used for the cigarette smokers: absolute quit rate 
and secondary measures looking at quit attempts. The percentages of trial participants 
who quit at 3-months were 5.1 % and 5.6% for Minimal and Extended interventions 
respectively, with the Usual Care (control group) having a success rate of 4.7%. At the 
12-month mark, there was little difference between the groups with the percentages for 
Minimal, Extended and Usual Care (control) being 2.5%, 2.6% and 2.4% respectively. 
Secondary outcomes looked at 'readiness to quit', having attempted to quit in the 
previous 12 months and thinking about quitting in the next 30 days. Those in the 
Extended Intervention group were significantly more likely to have tried to quit in the 
last 12 months and to be thinking of quitting in the next 30 days, than either the 
Minimal Intervention or Usual Care groups. 
With regards to the smokeless tobacco intervention, the results were more encouraging: 
17.8% of the users had quit at 3 months with the levels falling to 10.4% at 12 months. 
The authors felt that smokeless tobacco users were more successful in quitting because 
they may not have been subjected to the same barrage of health messages and 
environmental restrictions as cigarette smokers and were more receptive to the whole 
concept. 
Problems with this study include no biochemical validation of the smokers' self-
reported quitting, and the units of randomisation were also the practices, rather than the 
patients. 
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1.12.11 Summary 
Whilst a relatively large number of studies have investigated dental team members' 
views regarding their involvement with smoking cessation activity, very few smoking 
cessation trials have been undertaken in the dental setting. Methodological concerns are 
associated with most of these trials, suggesting that further work in this area, using a 
randomised controlled trial design and appropriate validation of smoking status, is 
required. 
86 
Chapter 2 
The Validation of Self-Reported Smoking Status by Analysing 
Cotinine Levels in Stimulated and Unstimulated Saliva, Serum and 
Urine 
2.1 Introduction 
As outlined in the previous chapter, when assessing the effectiveness of smoking 
cessation interventions, there is increasing emphasis being placed on the use of 
biochemical validation as a means of determining those individuals who have stopped 
smoking, and to weed out 'deceivers', ie those individuals who self-report that they are 
non-smokers, but whose biochemistry would indicate that they are still smoking (Gariti 
et at., 2002). 
As detailed in Chapter 1, the biochemical marker used increasingly to determine 
exposure to nicotine is cotinine. This nicotine metabolite can be used for determining 
exposure to tobacco via various biological fluids including blood, saliva, cervical 
exudate, semen and urine (Etzel, 1990; Vine et at., 1993; Poppe et at., 1995). In 
addition to using cotinine as a means of biochemical verification of a patient's self-
reported smoking status, it can also be used to assess a non-smoker's exposure to 
environmental tobacco smoke (Cummings et at., 1990). 
The following sections discuss measurement of cotinine in saliva, serum and urine, 
those fluids most often used in smoking cessation trials. 
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2.2 Use of Saliva 
The main advantage of using saliva is that it is non-invasive to collect, easily accessible 
and requires no facilities for its collection. Cotinine has been shown to be stable in 
saliva, thus samples can be sent by post, enabling its use in outreach settings such as 
dental practices (Greeley et al., 1992). Samples are also able to be frozen with no 
detriment to the cotinine analysis (Foulds et al., 1994). 
Some minor disadvantages of saliva are that it can be more difficult to work with than 
other sample types in the laboratory, as food intake can affect its consistency and 
appearance. Saliva also contains non-food particulate matter, such as oral squames and 
mucopolysaccharides which can contribute to its stringy or sticky consistency 
(Schramm et aI., 1992; Bernert et al., 2000). Salivary collection can sometimes be 
difficult for those subjects who suffer from 'dry mouth', either idiopathic or drug-
induced. Additionally, Trudgill and co-workers found that increasing daily cigarette 
consumption was associated with lower salivary bicarbonate concentration and a 
reduced salivary flow rate (Trudgill et al., 1998). 
There are a number of methods that can be used to collect saliva for cotinine analysis 
(Schramm et al., 1992; Bernert et al., 2000). Schneider and co-workers (1997) looked 
at salivary cotinine levels as a function of the collection method (Schneider et al., 
1997). Unstimulated salivary cotinine levels were compared with saliva collected by 
stimulation with a) sugar cubes and b) paraffin wax. In the sugar-stimulated saliva, 
cotinine levels were 26% below unstimulated levels, while wax-stimulated saliva 
yielded levels 6% below those of unstimulated saliva. The authors postulated that the 
reason for the difference may lie in the pH changes which alter with the salivary flow 
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rate. Cotinine has a pKa close to the pH of saliva and plasma. As the pH of 
unstimulated saliva is less than that of stimulated saliva, a basic compound such as 
cotinine would be influenced by the flow. Under more acidic conditions such as those 
produced by unstimulated saliva, there would be higher concentrations of cotinine 
available. Thus, as flow rate is increased with stimulation, less of the substance would 
be captured for measurement. 
Although salivary cotinine is used in smoking cessation trials, often details of collection 
methods are not given, and it is not possible to determine whether the saliva collected is 
stimulated or unstimulated. 
2.3 Use of Serum 
Serum was probably the first medium to be used in cotinine analysis. The main 
disadvantage of serum is that it is invasive to collect, though it may be the sample of 
choice in most clinical settings, especially if patients are having blood taken for other 
reasons (Scott et aI., 2001). Serum samples have been used to determine smoking status 
in head and neck cancer patients (Hald et aI., 2003), follow-up care for patients with 
myocardial infarct and angina (Jolly et al., 1999) and patients attending a bronchoscopy 
clinic (Lewis et aI., 2003). 
Serum samples can be used to detect cotinine at low levels, such as that found through 
environmental exposure, though as previously stated, it can be invasive to collect. 
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2.4 Use of Urine 
Urine is often the sample of choice in passive smoking studies, particulary if related to 
children (Blackburn et al., 2003). Venepuncture is considered unsuitable and it may be 
difficult to obtain a salivary sample, especially in young children. 
Urine sample collection is affected by diurnal rhythm, with lower excretions observed 
in the morning (de Weerd et al., 2002). Urine measurements therefore have to be 
subject to creatinine/cotinine correction, expressed as a ratio (ng/mmol creatinine). 
2.5 Patients' Acceptability of Sampling Methodology 
With regards to the patients' perspective, no published work has previously investigated 
patient acceptability of the different sampling methods used to collect biological 
samples for cotinine analyses. 
2.6 Method of Analysis of Cotinine 
The initial methods developed for cotinine analysis included gas-chromatography (GC) 
and gas-liquid chromatography, and these have been discussed in Chapter 1. 
In the last decade, a microplate enzyme immunoassay (EIA) kit has become available in 
the UK (Cozart, UK). The advantages of these kits are they do not require large, 
expensive equipment such as GC, and are relatively easy to handle. However, they are 
largely unevaluated in the UK. 
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2.7 Aims 
The main aim, therefore, of this study was to measure and compare cotinine levels using 
the microplate enzyme immunoassay technique in a variety of biological fluids, 
collected from a group of patients, both smokers and non-smokers, recruited in an 
outpatient dental hospital department. Further aims were to:-
a) Correlate self-reported smoking exposure data with the biochemical 
determination of cotinine levels, in the various body fluids, and to 
b) Compare levels of patient acceptability concerning the differing methods of 
sample collection. 
2.8 Methods 
2.8.1 Recruitment 
Following approval from the Greater Glasgow Area Dental Ethics Committee 
(Appendix 2), recruitment was via patients attending the Oral Medicine outpatient clinic 
at Glasgow Dental Hospital and School. Copies of the patient information and consent 
forms are shown in Appendix 3. Initially, smokers were invited to participate, and non-
smokers were then recruited, in an attempt to match age and gender to the first group. 
Data were collected over a 3-month period in early summer, by two student researchers 
and one academic researcher. A convenience sample was used, with as many patients 
recruited as possible within the available timeframe. The age range for the participants 
was 16 to 75 years. 
Exclusion criteria included medical conditions such as an incipient diagnosis of oral 
carcinoma or medication affecting salivary function. For smokers, only those who used 
cigarettes were included in the study. Those individuals who smoked a pipe or used 
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cigars were excluded, as were any individuals currently using nicotine replacement 
therapy. 
2.8.2 Self-reported Smoking Status 
Participating patients were asked to fill in a questionnaire about their tobacco smoke 
exposure (see Appendix 4). The questionnaire sought information on daily number of 
cigarettes smoked, time of first cigarette of the day, inhalational habits and brand and tar 
levels of current cigarettes used. The time elapsed since the most recent smoking 
occasion was also noted. For non-smokers, information on exposure to tobacco smoke 
both at home and in the workplace was collected. Additionally, details relating to 
tobacco smoke exposure in the last 24 hours were recorded. 
2.8.3 Sample Collection 
Samples were then collected from each patient in the following order: 
1) an unstimulated sample of saliva was collected by asking the patient to drool 
into a universal container (minimum volume of 3ml was collected). 
2) a sample of stimulated saliva was collected by asking the patient to chew the 
cotton wool roll from a Salivette collection device (Sarstedt Aktiengesellschaft 
& Co, D-51588 Numbrecht, Germany). When saturated, this was removed 
from the mouth and placed into the salivette. 
3) a sample of blood (5ml) was collected in a plain container using standard 
venepuncture techniques. This was collected by the student researchers and 
clinic nurse who was experienced in venepuncture. 
4) a sample of urine (25ml) was collected in a plain universal container. 
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2.8.4 Patient Acceptability 
Patients were then asked to fill in a short questionnaire concerning the acceptability of 
the four different methods of sample collection (see Appendix 4). A four-point Likert 
Scale was used which asked the respondents to rate the sample collection from 
'completely unacceptable' to 'completely acceptable'. 
2.8.5 Storage of Samples 
Blood samples were stored in a fridge overnight, to allow clotting before the serum was 
separated and stored at -20°C. Stimulated saliva samples, collected using the Salivette 
devices, were centrifuged at 3000 rpm at 1200g for 10 min. The supernatant was then 
removed and stored at -20°C. The unstimulated saliva and urine samples were stored at 
-20°C. On the day of analysis, the unstimulated saliva was thawed and centrifuged and 
the supernatant transferred to inert plastic tubes. 
2.8.6 Measurement of Cotinine 
Cotinine concentrations were measured using a microplate enzyme lmmunoassay 
(Cozart Biosciences Ltd, Abingdon.UK). 
Different versions of the assay, with appropriate standards, were used for each of the 
three biological matrices. Quality control material was prepared by spiking cotinine-
free serum, urine and saliva with a cotinine standard (Sigma Chemicals) to give two 
levels, low and high within each standard range for each matrix. Where required, 
dilutions of the patients' samples were made using cotinine-free serum, urine and in the 
case of saliva, deionised water. Serum and salivary cotinine concentrations were 
expressed as ng/ml. Urine creatinine was measured by the kinetic Jaffe reaction on an 
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Olympus 640 analyser (Olympus UK Ltd, Southall, UK). To take account of urine 
dilution, all urine cotinine results were expressed as a ratio (ng/mmol creatinine). 
A cut-off of 15ng/ml of cotinine was used to differentiate smokers from non-smokers in 
serum and saliva. For the urine sample analysis, a cut-off of 50ng/ml of cotinine was 
used to determine smokers. 
2.S.7 Statistical Analysis 
2.S.7.1 Comparisons ofCotinine Levels 
When comparing smokers and non-smokers, it was necessary to logarithmically 
transform the data, due to greatly differing variances in the cotinine levels. Subsequent 
analysis was performed on the transformed data and reported confidence intervals to 
compare smokers and non-smokers are for the ratios of the geometric means. Similar 
analysis was required when comparing non-smokers who were exposed/not exposed to 
smoke. 
For smokers and non-smokers separately, a repeated measures analysis of variance was 
used to determine whether there were any significant differences between the four 
collection methods in terms of mean cotinine levels. Subsequent follow-up multiple 
comparisons were carried out to identify which methods differed significantly. 
Generalised linear models were used to identify which self-reported factors, for smokers 
and non-smokers separately, had a significant effect on the cotinine levels, again with 
suitable follow-up multiple comparisons where necessary. 
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2.S. 7.2 Analysis of Patient Acceptability Questionnaire 
Simple column percentages of the responses of the trial participants with regards to 
'very acceptable', 'moderately acceptable' 'tolerable' and 'not acceptable', with respect 
to each of the four collection methods were calculated. 
2.9 Results 
In total, 80 patients were recruited. Of the participants, 49 (25 male, 24 female) were 
smokers (61 %) and 31 (15 male, 16 female) were non-smokers (39%). The mean age of 
the smokers was 44.0 years (SO 18.0 years) and for the non-smokers 46.5 years (SO 
16.7 years). Thirty-eight (48%) of the participants were from relatively atlluent 
backgrounds, i.e. residing in OEPCAT 1-4 areas (21 smokers and 17 non-smokers). 
2.9.1 Comparison of Smokers v Non-Smokers 
The mean cotinine level for the four fluids, for smokers and non-smokers separately, is 
shown in Table 2.1, together with the 95% confidence interval for the ratio of the 
geometric mean cotinine levels (smokers / non-smokers). Corresponding p-values from 
the 2 sample t-tests of mean levels of cotinine in smokers and non-smokers are also 
given. 
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Table 2.1 Mean Levels of Cotinine (nglml) for Smokers and Non-Smokers for 
each Sampling Method 
Smokers Non-Smokers 
(n=49) (n=31) 95% CI** 
Mean (stdev) Mean (stdev) (S INS) p-value 
Serum 328.4 (207.5) 3.6 (2.8) (59.7,111.7) <0.001 
Stimulated Saliva 194.3 (122.5) 2.0 (0.9) (28.5, 105.4) <0.001 
Unstimulated Saliva 314.0 (171.9) 1.6 (1.2) (120.8, 235.5) <0.001 
Urine* 302.5 (244.0) 1.1 (1.9) (224.9, 776.3) <0.001 
*Units are ng/mmol 
* *CI is for ratio of geometric mean of Smokers to geometric mean of Non-Smokers 
A clear differentiation between the smokers and non-smokers was seen (with p<O.OOI 
for all fluids) with confidence intervals illustrating the much greater mean cotinine 
levels of smokers. The mean level of cotinine in non-smokers in all the fluids was 
below 10ng/ml, whereas the mean level of cotinine in the smokers varied from 
194nglml in stimulated saliva to 328nglml in serum. 
2.9.2 Comparison of Collection Methods 
Repeated measures ANaVA indicated that there were significant differences in the 
mean cotinine levels between the four collection methods, for both smokers and non-
smokers (both p<O.OOI). Subsequent multiple comparisons indicated that, for smokers, 
the cotinine levels in serum, urine and unstimulated saliva were significantly greater on 
average than the levels found in stimulated saliva (Table 2.2). For non-smokers, where 
cotinine was being measured in very small amounts, there were significant differences 
between the serum and all other types of sample, with the mean serum level being 
significantly higher. When comparing the urine and stimulated saliva in non-smokers, 
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the mean level in the stimulated saliva was significantly higher. This last finding is the 
opposite relationship to that found with these two samples in smokers, where the mean 
level of cotinine in urine is higher than that found in the stimulated saliva. 
Table 2.2 Multiple Comparisons of Sampling Methods for Smokers and 
Non-Smokers 
95% Simultaneous CI for Difference 
in Average Cotinine Levels 
Fluid - Fluid Smokers (n=49) Non-Smokers ~n=31) 
Serum 
-
Stim. Saliva (59.7,217.7) 10.9, 2.~ 
Serum - Unstim. Saliva (-63.7,93.2) (1.2, 2.~ 
Serum 
-
Urine (-52.0, 103.9) 11.8,3.'!l 
Urine 
-
Stim. Saliva (33.7, 191.8) (-1.7, -O.n 
Urine 
-
Unstim. Saliva (-89.7,67.3) (-1.3,0.3) 
Unstim. Saliva 
-
Stim. Saliva (44.4, 203.5) (-1.2,0.4) 
2.9.3 Relationships between Self-Reported Data and Cotinine levels for Smokers 
Results from generalised linear models, incorporating number of cigarettes smoked per 
day «10, 10-20 or >20), tar level of cigarettes smoked (low, medium or high) and 
inhalational habits (slightly, moderately or deeply) for each of the collection methods 
separately, suggested that the only factor having a significant influence on the smokers' 
cotinine levels was number of cigarettes smoked per day (NoeS). The boxplots shown 
in Figure 2.1 show a cotinine dose-response relationship with NOeS. This dose-
response relationship between cotinine level and NOeS was statistically significant for 
stimulated saliva, unstimulated saliva and urine (all p<O.OOl) but was not statistically 
significant for serum (p=0.291). 
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Figure 2.1 Cotinine Dose-response for Smokers Categorised as Low, 
Medium and Heavy, in Stimulated & Unstimulated Salivas, 
Serum and Urine 
(a) Serum (b) stimulated Sal ... 
leXXl 1000 
E ~ 
'" '" 5 5 .. .. 
c c 
·c 500 ·c 500 g :g :g $ U u '0 '0 a; a; ~ > > .. .. -' -' 
0 0 
.-
< 10 10 - 20 > 20 < 10 10 -20 >20 
CogslOay CogsIOay GlgSIOoy CigslOay CigstOay Gigs/Day 
(e) Unstrnulated Sal ... 
(d) Urine 
1000 
1000 -
"0 
E 
E E 
'" '" 5 $ 5 .. $ ., c c 500 ·c 500 ·c :g 15 g u E3 u '0 '0 a; a; > > .. ., -' -' 0 0 
> 20 
< 10 10 -20 >20 
< 10 10 - 20 CigslDay GigslDay 
CigslOay CigslDay GigsIDay GigslDay 
For stimulated saliva, the mean cotinine level for <10 cigarettes/day was significantly 
lower than that for 10-20 cigarettes/day and >20 cigarettes/day, but there was no 
signjficant difference between the mean cotinine level for 10-20 and that for >20 
cigarettes/day. For unstimulated saliva, there was a significant difference between each 
of the three categories of NOeS. For urine, there was no significant difference between 
the average levels of cotinine for <1 0 and 10-20 cigarettes/day, but both of these had on 
average lower levels of cotinine than the >20 cigarettes/day category. 
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2.9.4 Relationships between Self-Reported Data and Cotinine levels for 
Non-Smokers 
For non-smokers, generalised linear models were used to determine which of the three 
factors - exposed to passive smoke at home (yes or no), at work (yes or no) and 
exposed to passive smoke in the previous 24 hours (yes or no) - had a significant 
influence on the mean cotinine level, for each of the four collection methods in turn. 
For each of the fluids, the most dominant factor was exposure to smoke at home. This 
factor had a significant effect on the average cotinine levels of stimulated saliva, 
unstimulated saliva and urine (all p<0.05). For each of these fluids, exposure to smoke 
at home significantly increased on average the mean level of cotinine, compared to the 
mean level of cotinine of participants not exposed to smoke at home (see Table 2.3). 
Table 2.3 Mean Levels of Cotinine (nglml) for Non-Smokers for each Sampling 
Method by Exposure to Smoke at Home 
Exposed to Not Exposed to 
Smoke at Smoke at 95% CI** 
Home (n=10) Home (n=21) (Exposed I 
Mean (stdev) Mean (stdev) Not Exposed) p-value 
Serum 5.4 (4.7) 2.9 (0.8) (0.4, 1.4) 0.25 
Stim. Saliva 2.7 (1.4) 1.7 (0.4) (0.5,0.9) 0.02 
U nstim. Saliva 2.5 (1.9) 1.3 (0.4) (0.4, 1.0) 0.04 
Urine* 2.3 (2.0) 0.6 (1.5) (0.1,0.5) <0.01 
*Units are nglmmol 
**CI is for ratio of geometric mean of Exposed to geometric mean of Not Exposed 
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2.9.5 Patient Acceptability of Each CoUection Method 
Figure 2.2 gives the percentages of patients who found each of the four collection 
methods ' very acceptable', 'moderately acceptable', 'tolerable' and 'not at all 
acceptable ' . 
Figure 2.2 Patient Acceptability of Collection Methods 
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There was no difference between the patterns of acceptability of smokers and non-
smokers. High numbers of patients found both serum and urine collection 
methodologies ' very acceptable' (67% and 66% respectively), significantly greater than 
that for the stimulated saliva collection (45%). No participant rated the serum or urine 
collection methods as being 'not at all acceptable' , whilst almost 1 in 10 (9%) found 
collection of the stimulated saliva 'not at all acceptable'. The unstimulated saliva fared 
better than the stimulated saliva, with 51 % of the participants rating the former 
collection method as 'very acceptable' and only 1 % 'not at all acceptable'. 
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2.10 Discussion 
2.10.1 Recruitment 
In total, 80 patients were recruited, 49 smokers and 31 non-smokers. It is acknowledged 
that the utilisation of a convenience sample may have resulted in recruited participants 
not necessarily being representative of the typical oral medicine patient population. 
Although a reasonable number of participants were recruited, the matching of non-
smokers and smokers was incomplete due to time constraints, resulting in an unequal 
number of patients in the two groups. 
2.10.2 Sample Collection 
For monitoring purposes within a smoking cessation trial, usually only one type of 
biological sample would be collected. This study was more unusual in that a variety of 
samples were collected which allowed examination of the inter-relationships between 
the different fluids. This study was also cross-sectional and was not being used to 
verify quit attempts. 
2.10.3 Differentiation between Smokers and Non-Smokers 
Using the appropriate microplate enzyme immunoassay kit for each type of sample, 
there was clear differentiation between smokers and non-smokers in this study. This 
agrees with the findings of previous studies (Velicer e/ al., 1992). 
2.10.4 Comparison ofCotinine in Different Samples 
With regard to the relationship between the two methods of salivary collection, the 
mean level of cotinine in smokers was found to be greater in the unstimulated 
(314nglml) compared to the stimulated (194ng/ml) saliva. These findings were 
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consistent with those of Schneider et al. (1997) who postulated that the reason for the 
difference may lie in the pH changes which alter with salivary flow rate. 
A number of papers have compared cotinine levels in different biological samples. The 
half-life of cotinine in saliva and serum is approximately the same, and cotinine 
concentrations in these two matrices have previously been found to be correlated. 
Bernert and co-workers (2000) looked at the relationship between serum and saliva 
(collected via salivette devices) and found a simple linear relationship of serum cotinine 
levels being 10% above or below the given salivary levels. 
However, in the present study, serum levels were found to be more closely correlated 
with unstimulated than stimulated saliva. For smokers, the serum cotinine was on 
average 4% and 41 % greater than the unstimulated and stimulated saliva respectively. 
McAdams and Cordeiro (1993) looked at determining the level of cotinine in serum, 
urine and oral samples. Salivary samples in this study were collected using the OrasSure 
system (North et al., 1993). This collection device consists of an absorbent paddle, 
which is placed in the patient's mouth, and once the pad is saturated it is inserted into 
the collection tube ready for storage, prior to analysis. 
The authors stated that the results of the assignments in all three matrices matched the 
self-reported smoking status perfectly. However, this was a small study with only 20 
participants, both smokers and non-smokers, and the focus of the paper was on the 
development of a gas-chromatography method of analysis. No attempt was made to 
look at the relationship between the cotinine in the three samples. 
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An older study compared serum, saliva and urine in non-smokers, passive and active 
smokers (Wall et aI., 1988). This study had a sample of 98 subjects. More unusually, 
these individuals were asked to collect samples of their saliva and urine in their own 
homes. Such samples are usually collected for quality assurance purposes under the 
supervlSlon of the researchers, who, in this study, took blood for serum cotinine 
estimation. Serum and saliva cotinine results could not discriminate between non-
smokers and passive smokers. Mean urine cotinine was higher in passive smokers than 
non-smokers but there was a great deal of subject overlap. Cotinine in all body fluids 
could separate active smokers from the other groups. Additionally, among smokers, 
light smokers had lower levels than heavier smokers. 
2.10.5 Cotinine Dose-Response 
A cotinine dose-response relationship to nicotine exposure is important as it helps to 
quantify the relative risk that patients are undergoing. In this study, the two salivary 
samples and urine samples were able to differentiate between categories of light, 
medium and heavy smoker, whereas serum samples were not able to exhibit this 
finding. Machacek and Jiang (1986) found similar results, with little association 
between cotinine concentrations in plasma and number of cigarettes smoked. With 
regards to saliva and cotinine levels, Etter et al. (2000) found cotinine concentration to 
be moderately associated with the number of cigarettes per day. 
In longitudinal studies of smoking cessation or reduction in smoking, the ability to 
differentiate between the categories of smoking may be of use in looking at reduction in 
nicotine exposure. It could be used to differentiate between those smokers who say they 
have reduced, but continue to compensatory smoke by inhaling more deeply or by 
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smoking more of their cigarettes, compared to those who cut down their smoking prior 
to quitting totally 
As discussed previously, this work was cross-sectional in nature, and exhibited a dose-
response on a population basis. With regards to smoking cessation or reported 
reduction, a further longitudinal study is required to see whether the cotinine levels at 
baseline for a cohort of patients correlates with patients' self-reported smoking exposure 
at further time points such as 3 and 6 months. 
2.10.6 Patient Acceptability 
Patient acceptability of the different methods of sample production provided some 
unexpected findings. It was postulated that patients might rate venepuncture least 
favourably because of the invasive nature of the technique, when surprisingly they rated 
the stimulated saliva collection most negatively. Some participants found the chewing 
of the cotton wool roll an unpleasant sensation and, in extreme cases, felt nauseous, 
which may have led to a poor acceptability rating being recorded. Using a cotton wool 
roll to collect saliva in this way is not the most common method, though previous 
published work has used this methodology (Roy el aI., 1996; Croucher el al., 2002). A 
more usual method to stimulate saliva would be the use of paraffin wax to induce 
salivary flow (Kivela et aI., 2003). From a participant's point of view, the unstimulated 
saliva appeared to be the more acceptable of the two salivary collection methods, and 
hence would be the choice for any future work. However, acceptability levels associated 
with alternative means of stimulating saliva would require further investigation. 
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The high acceptability of the blood sampling methodology may be related to the setting 
in which this cross-sectional study took place: a dental hospital oral medicine 
department where venepuncture is often a routine part of investigation. It was decided 
to carry out this work in an oral medicine setting because it was felt that it was more 
ethical to recruit patients who were undergoing this procedure anyway as part of their 
treatment planning. It is postulated that work carried out in a different dental setting 
such as general dental practice or a periodontal clinic may yield differing results in 
terms of patient acceptability of collection methods. 
The operator effect has yet to be investigated. Samples were collected by the student 
researchers who had undergone special training in venepuncture and with increasing 
practice would have become more proficient at the techinique. The nurse who routinely 
carried out this procedure could be expected to be skilled in this area. It is postulated 
that in a different setting such as general practice, dental practitioners who are not 
routinely used to taking blood samples may not want or feel they have the skills to use 
this technique. 
2.10.7 Suitability of Kits 
One aim of this study was undertaken to determine whether EIA kits could be used to 
determine the smoking status of patients, recruited to a future smoking cessation trial 
within a dental hospital setting. The immunoassay kits provided an acceptable means of 
analysing cotinine in this current sample of patients. The advantages of these kits 
included availability (currently there is no access to GC facilities for cotinine analysis in 
Scotland) and economic considerations. These kits were sufficiently sensitive to 
distinguish between categories of smoker and non-smoker. 
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2.11 Conclusions 
For future smoking cessation work, baseline verification of cotinine levels, followed by 
cotinine assessment once smoking cessation interventions have taken place offer a good 
means of monitoring and evaluating the process of smoking cessation interventions as 
they are delivered. 
All matrices, including serum, urine and the two methods of collecting saliva, were 
successful in differentiating between smokers and non-smokers. 
The use of EIA kits proved to be a suitable alternative to GC analysis on the basis of 
performance, cost, accessibility and the sample size involved in this study. 
With regards to choice of sample for oral health staff, salivary samples, whether 
stimulated or unstimulated would appear to be the most appropriate for use within a 
dental setting. Levels of cotinine obtained with unstimulated saliva were higher, and 
sample collection was more acceptable to the patient. Stimulated saliva yielded lower 
levels of cotinine and was less acceptable to the patients. If stimulated saliva sample 
collection was required, it may be necessary to look at other methods of stimulating 
saliva, such as the use of paraffin wax. 
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Chapter 3 
Smoking-Related Behaviour Change in Periodontal Patients given 
'Brier Smoking Cessation Advice and Nicotine Replacement Therapy, 
Delivered by Dental Hygienists: A Randomised Controlled Trial 
3.1 Introduction 
Tobacco use is the single biggest contributor to ill health, and is the most important 
preventable cause of death in the UK (Callum, 1998). As outlined in Chapter 1, in 
addition to being implicated in coronary heart disease, lung and other cancers, smoking 
also has a profound effect on the oral tissues. Cigarette smoking is associated with 
increased prevalence and severity of periodontitis and smokers suffer from more tooth 
loss (Krall et al., 1997; Tonetti, 1998). In addition, the risk of oral cancer and 
potentially malignant lesions is higher amongst smokers compared to those who have 
never smoked. Patients who smoke have a six-fold increased risk of developing oral 
leukoplakia compared with non-smokers (Baric et al., 1982). 
There is growing awareness and interest in the role that dental health professionals can 
play in helping their patients quit the tobacco habit, whether in secondary or primary 
care (Chestnutt & Binnie, 1995; Macgregor, 1996; McCann et al., 2000; Watt & Daly, 
2003; John et al., 2003). Most research has focussed on dentists and their contribution, 
but increasingly interest is being shown in the role that dental hygienists can play 
(Chestnutt & Binnie, 1996; Dykes et al., 2001; Helgason et al., 2003). 
107 
One trial in the UK has shown that the dental team can be involved in delivering 
smoking cessation advice, with a resultant quit rate of 11 % at nine months (Smith et al., 
1998). However, this trial was not of an randomised controlled trial design. 
One US study utilised dental hygienists to give advice on quitting to two groups of 
patients, the first of whom smoked cigarettes, while the second used smokeless tobacco. 
It was found that the intervention was effective for smokeless tobacco, but not for 
cigarettes (Severson et al., 1998). However, an earlier study utilising dental hygienists 
to give advice to patients who smoked cigarettes, found a cessation rate at six months of 
14.6% (Seeker-Walker et al., 1988). Neither of these studies used any form of 
biochemical validation and relied on self-report only, nor did the latter study have a 
control group. 
Therefore, within the UK, there is the need to investigate more fully the potential 
effectiveness of dental hygienists in delivering smoking cessation advice, by running a 
trial with an ReT design, and with the primary outcome of smoking cessation, 
biochemically validated. 
3.2 Aim 
The aim of this trial was to examine the feasibility and efficacy of a smoking cessation 
intervention, delivered by dental hygienists, in a cohort of periodontal patients attending 
an outpatient dental hospital department. 
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The research question was: 
What is the efficacy of a smoking cessation programme, based on the 'brief 
intervention' and delivered by dental hygienists? 
- Success being measured both in terms of primary (absolute cessation) and secondary 
(reduction in smoking behaviours/change in psychological readiness for behaviour 
change) outcomes. 
3.3 Material and Method 
3.3.1 Trial Design 
A randomised controlled trial design was considered the most appropriate methodology. 
The setting for the intervention was the Periodontology Department of Glasgow Dental 
Hospital and School. With respect to the delivery of the intervention, the three staff 
dental hygienists, working within the Periodontology Department, participated in the 
trial and gave the patients smoking cessation advice. For the purposes of confidentiality, 
the hygienists were colour-coded Red, Green and Blue, with respect to the project 
administration and analysis. In addition, a research dental hygienist helped with patient 
follow-ups. 
3.3.2 Training of Dental Hygienists 
Prior to undertaking the delivery of smoking cessation advice, the hygienists attended 
training sessions in smoking cessation. Topics covered included basic smoking 
cessation training (2 sessions), nicotine replacement therapy training (I session) and 
smoking cessation trial methodology (1 session). Further information on the course 
content and personnel involved in delivering the training is to be found in Appendix 5. 
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3.3.3 Ethical Approval 
Ethical approval was sought from the local Area Dental Ethics Committee, and approval 
was gained in February 2001. A copy of the Letter of Approval is attached in Appendix 
6. 
3.3.4 Patient Recruitment 
Clinical activity figures indicated that, between April 1999 and March 2000, there were 
1554 newly referred patients examined by consultants within the Department of 
Periodontology at Glasgow Dental Hospital and School. Of this pool of patients, 
approximately 50% are referred to the staff dental hygienists for treatment. An audit 
carried out within the Department in the summer of 2000 found that around 37% of new 
patient referrals were smokers. Based on this information, it was estimated that there 
would be a pool of approximately 275 new patients annually, who smoked, and who 
were referred to the staff hygienists for treatment. 
Prior to the start of the smoking cessation study, as part of normal professional practice, 
all new patients who smoked, on attending the Consultant Periodontal Clinics, received 
information on the role that tobacco plays in periodontal disease and 'very brief advice 
to quit by one of the four consultants assessing their periodontal health. 
From the cohort of new patients who attended from April 2001, and who were to be 
referred to the dental hygienists for treatment, those who smoked more than ten 
cigarettes a day were offered the opportunity to participate in the smoking cessation 
trial. Exclusion criteria included patients aged below 18 years, those already in receipt 
of NR T or currently undergoing smoking cessation therapy, or patients with complex 
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medical histories. Recruitment was via the patient's consultant who explained the nature 
of the trial, and gave the patient the study information sheet and asked them to sign the 
consent forms. It was made explicit that the patient would not necessarily be allocated 
to receive further advice and help in smoking cessation. Copies of the patient consent 
and information forms are in Appendix 7. 
3.3.5 Sample Size Calculation 
The sample size calculation was based on the secondary outcome of reduction in 
cigarette consumption. Macgregor (1996) reported that just over 25% of subjects in the 
control group had some reduction in cigarette consumption. 
For this calculation, success was defined as being a reduction in smoking activity. It 
was deemed of interest to consider a projected success rate of 25% in the control group 
with a minimum projected success rate of 50% in the intervention group. The sample 
size calculation was therefore based on being able to detect such a minimum difference, 
using a chi-squared test with 80% power and a two-tailed significance level of 5%. 
This calculation resulted in the requirement of at least 60 individuals within each group 
to be followed-up at 3 months. 
3.3.6 Baseline Questionnaire Data Collection 
To obtain baseline information from the smokers, a questionnaire containing both open 
and closed questions was designed. Demographic information including name and 
address, hospital number, age, gender, occupation and information on postal code (to 
enable DEPCAT analysis) was requested from the participants. 
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3.3.6.1 Assessment of Nicotine Dependence 
A further section in the questionnaire assessed the patient's level of nicotine 
dependence, using standard scales (Heaviness of Smoking Index/Fagerstrom Test for 
Nicotine Dependence/Fagerstrom Tolerance). 
The Heaviness of Smoking Index is comprised of two questions which determine the 
number of cigarettes smoked per day, and the timeframe between waking in the 
morning and having the first cigarette of the day (Heatherton et al., 1991). 
The Fagerstrom Test for Nicotine Dependence (FTND) includes the above two 
questions and four additional questions covering the cigarette of the day the respondent 
would most hate to give up, whether smoking was more frequent during the first hours 
of the day, whether smoking took place when ill and whether there was difficulty 
refraining from smoking in public places (Heatherton et al., 1991). 
The Fagerstrom Tolerance Score includes all of the six questions detailed above and 
two further questions concerning the habit of inhalation of smoke, and the nicotine level 
of the cigarettes (Fagerstrom, 1978). 
3.3.6.2 Assessment of Motivation to Stop Smoking 
Readiness to quit is often measured using a version of 'Stage of Change', though the 
questions used are not so easily obtained via the literature, nor are they as standardised, 
as the FIND. Therefore, following a search of the literature, an adapted instrument 
containing elements of 'Stage of Change , (after Prochaska & DiClemente, 1983), was 
designed using the terms 'contented smoker', 'concerned smoker' and 'wanting to quit' 
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A 'contented smoker' is defined as someone who does not wish to stop smoking (a 
'precontemplator'), a 'concerned smoker' is defined as someone who wishes to stop 
smoking sometime in the next six months (but not in the next month) (a 
'contemplator'), and those in the category 'want to quit' would wish to do so at 
sometime in the next month (Le. are in the 'preparation' phase). 
Motivation to quit was also assessed using two standard scales measuring strength of 
motivation and desire to quit (Foulds, 1996). These were measured on a five-point 
Likert scale, ranging from very positive to very negative, encompassed by the terms 
'Yes, definitely' to 'Definitely not'. Questions on this scale were: 'Would you give up 
smoking altogether if you could do so, easily?' and 'How much do you want to stop 
altogether?' 
3.3.6.3 Reasons for Stopping Smoking and Quitting History 
Included in the questionnaire was a section on reasons for wanting to stop smoking. 
Options provided included health, expense, 'not fair on other people' and 'don't like 
being addicted'. Patients were also asked what they perceived to be their biggest 
problem in quitting. Recent quitting history was also elicited via questions on quit 
attempts in the last year, including specific questions on whether they had had two or 
more quit attempts or a quit attempt lasting longer than one week. Other environmental 
exposure to tobacco was determined by asking the respondents whether anyone at work 
or at home smoked. 
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The questionnaire was piloted with 15 smokers who attended the staff hygienists after 
which very minor modifications were made with regard to layout. The final 
questionnaire used in the study is to be found in Appendix 8. 
3.3.7 Baseline Biochemical Assessment of Exposure to Nicotine using Cotinine 
(COT) and Carbon Monoxide (CO) 
3.3.7.1 Cotinine 
To assess the patient's current exposure to nicotine, a baseline salivary sample of 
unstimulated saliva was collected for cotinine (COT) analysis. Samples were stored at 
-20°C, prior to being analysed by Mr Bill Borland, a specialist toxicologist biochemist 
at Gartnavel General Hospital in Glasgow. EIA (enzyme immunoassay) kits were used 
to determine the level of cotinine in the samples (Cozart UK). The detailed 
methodology with regard to the cotinine analysis is outlined in Chapter 2. 
3.3.7.2 Carbon Monoxide 
In addition to the sample of saliva taken for cotinine analysis, an exhaled air sample was 
collected via a carbon monoxide (CO) monitor. The monitors used were 
picoSmokelysers (Bedfont Scientific). The patient blew into the monitor using a 
disposable mouthpiece connected to aT-piece, which in tum was linked to the monitor 
and screen. A reading of CO, in ppm, was shown within seconds on the LED display. 
These monitors were provided on long-term loan by Smoking Concerns (Health 
Promotion, Greater Glasgow NHS Board). The monitors were calibrated regularly in 
accordance with the instructions supplied by the manufacturers. 
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3.3.8 Randomisation Process 
A two stage randomisation process was used, firstly to allocate randomly recruited 
patients to a staff hygienist, and then to allocate randomly the patient to a group 
(intervention or control). 
3.3.8.1 Randomisation of Patient to Hygienist 
The three staff hygienists were each allocated a colour (Red, Blue and Green) for 
identification purposes. 
Prior to the commencement of patient recruitment, a randomisation list was produced by 
the project statistician, using the random permuted blocks method, to ensure exactly 
equal numbers of patients were allocated to each hygienist after every 18 patients 
recruited. The randomisation list was then transcribed into a log book, which contained 
sequential patient log numbers and against each log number, the allocated hygienist. 
When a patient was recruited into the study, the patient was assigned the next available 
patient log number, from which the allocated hygienist was deduced. 
3.3.8.2 Randomisation of Patient to Group 
Recruited patients, having been randomly allocated to a hygienist, completed the 
baseline questionnaire at the first visit, from which information was extracted for use in 
randomising the patient to a group. 
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The infonnation used in the randomisation process was: -
• Age 
• Sex 
• DEPCAT 
• Level of Nicotine Dependence 
• 'Stage of Change' 
«34,35-44,45-54, >55 years) 
(Female, Male) 
(I - 2; 3 - 5; 6 - 7). 
(6 and below, above 6) 
(Stage I -'contented smoker') 
('precontemplator') 
(Stage 2 - 'concerned smoker') 
('contemplator') 
(Stage 3 - 'want to stop') 
('preparation') 
Patients were randomly allocated to either the intervention or control group using the 
minimisation method (Pocock, 1983), which is a fonn of stratified randomisation. The 
aim of this was to achieve balance in the numbers of participants in the two groups with 
regard to the above five factors. 
The minimisation method cannot be used to prepare a randomisation list in advance. 
Instead, a continually up-to-date record of group allocations by the five patient factors 
was kept, using sets of index cards (one set per hygienist), with one index card for each 
level of each of the five factors. To assign a newly recruited patient to a group, the 
infonnation from the baseline questionnaire was collated and the five relevant index 
cards were pulled out and the number of patients in each group, for this combination of 
patient factors, calculated. 
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Rather than strictly allocating the new patient to the group with the smallest number of 
patients to date, a random element was introduced, whereby a previously prepared 
randomisation list was used to allocate the patient to the group with fewest patients to 
date, with a given probability less than one. When, for the given combination of the 
five patient factors, there were equal numbers of patients in the two groups to date, a 
pre-prepared simple randomisation list was used to allocate the patient to a group. 
Following randomisation, the hygienist was informed of the outcome and subsequently 
passed on the information to the patient at the following visit. The control group was 
given no further smoking cessation advice. 
The intervention group within this study were given more advice and help as detailed 
below. 
3.3.9 Protocol for Intervention Group 
3.3.9.1 Structured Approach to Giving Smoking Cessation Advice -'5As' 
Patients were given advice on smoking cessation in a format based on the 5As - Ask 
your patient, Advise your patient, Assess your patient, Assist you patient, Arrange 
follow-up for you patient (Table 3.1). These 5As were to be reinforced at every visit. 
In order to standardise the smoking cessation advice delivered by the three staff 
hygienists, a protocol checklist based on the 5As, was customised for use in the study. 
This version is attached in Appendix 9. 
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Table 3.1 The 5As Protocol 
Stage Action 
Ask your Patient Ask about current smoking habits: 
(make comment about baseline infonnation) 
• number of cigarettes, time to first cigarette 
• smoking pattern 
• smoking history 
• number of years as a smoker 
• quitting history 
Advise Your Patient Advise quitting tobacco use 
• advice is to be clear, personalised and finn 
• emphasise not only the links with periodontal 
disease and oral cancer, but also to the general 
health risks 
Assess your Patient Assess willingness to quit 
• What are the important reasons for them to give up, 
is it fitness, smoking near children etc? 
• Where are they on the 'Stage of Change' and when 
are they thinking of giving up? 
• a contented smoker -'not at the moment' 
• a concerned smoker -'within the next 6 months' 
• preparing to stop - 'within the next 30 days' 
Assist your Patient Assist patients who agree to stop 
• set a timescale for action 
• give infonnation on the process of quitting, such as 
smoking cessation materials from Smoking 
Concerns, and Aspire (ASHIHEBS 2002) 
• review what helped and hindered from previous 
attempts 
• identify likely problems and appropriate strategies 
to overcome them, e.g. smoking and drinking etc, 
what to do about other smokers etc 
• enlist support of family and friends 
• plan how to cope with increase in food and drink 
• give advice, infonnation and an offer of Nicotine 
Replacement Therapy (see below) 
Arrange follow-up Arrange follow-up appointments 
• reinforcement of 5As as part of periodontology 
(oral hygiene phase and treatment) visits 
• monitoring of patients progress, use of CO 
monitors at each visit 
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On the first visit after the patient had been randomised to the intervention group, the 
hygienist delivered the advice as per the above protocol. The approximate time taken 
for the delivery of the advice was 15 min. For subsequent appointments, hygienists 
filled in another '5As' checklist, personalising and developing an individual approach 
with each patient. 
3.3.9.2 Nicotine Replacement Therapy (NRT) 
The use of Nicotine Replacement Therapy (NR T) as part of treatment, is known to 
increase cessation rates and is an important adjunct to the provision of 'brief advice'. It 
is a well-accepted means of dealing with nicotine withdrawal. 
The NRT used in the trial was the brand Nicorette (Pharmacia and Upjohn), and funding 
for this was provided by Smoking Concerns, Glasgow's Tobacco Control Project 
(Health Promotion Department, NHS Greater Glasgow). Patients in the intervention 
group who wished access to this form of support, were therefore offered NR T at no 
charge. 
Only two forms of NRT were offered; patches and gum. It was decided that to offer 
additional types of NR T such as inhalers or tablets would be overly complicated, and as 
fairly small numbers of patients were involved, would pose stock control difficulties. 
Nicorette patches are 16-hour patches and are designed to be used during waking hours 
and removed at night. Patches were available in 15, 10 and 5 mg doses of nicotine, and 
applied to the skin of the upper arm or thigh. Patients started at the high dosage patch, 
and stepped down to the medium dosage when they felt ready. Patches are not suitable 
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for those individuals who have widespread dennatological conditions, or an allergy to 
the adhesive. 
Nicorette gum is available in 2 and 4 mg strengths. If a patient smoked more that 20 
cigarettes per day, the 4 mg gum was recommended. The typical dosage is 10-15 pieces 
of gum per day. Gum is not suitable for patients with dentures. Patients were taught the 
correct technique for taking gum to ensure buccal absorption. 
For audit purposes, dental hygienists filled in an internal (Glasgow Dental Hospital) 
prescription pad which recorded patient details and the amount and type of NRT 
prescribed. The NRT prescribing was underwritten by a dental surgeon (Mrs V. 
Binnie). 
3.3.9.3 Patients who were Not Willing to Commit to Quitting 
For some patients who did not feel able or ready to quit at the time of the initial 
intervention, various options were available as described in Table 3.2 below. For those 
patients who wanted to make some changes, the approach used is listed in the upper part 
of the table. For 'contented smokers', the delivery of the 5Rs is recommended, as 
detailed in the lower half of Table 3.2. 
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Table 3.2 Protocol for Patients not Willing to Commit to Quitting 
Patients who agree to some change in 
smoking behaviour 
Patients who DO NOT want to quit 
(5Rs) 
3.3.10 Protocol for Control Group 
• explain that smoking is a cyclical 
process and some behaviour change 
such as reducing number of 
cigarettes, making at least one quit 
attempt is partial success 
• look at reducing consumption of 
cigarettes 
• encouraged to make at least one quit 
attempt of 24 hours or longer 
• emphasise the relevant benefits for 
the patient 
• emphasise the risks of continuing to 
smoke 
• list the rewards from stopping 
• discuss the roadblocks to quitting 
(withdrawal symptoms, lack of 
support etc) 
• emphasise that repeat attempts are 
more successful 
This group was given no further structured advice regarding smoking. However, if the 
patient raised the topic, this was dealt with using normal professional practice. Details 
of any such advice were recorded within the patients' notes. 
3.3.11 Questionnaire Follow-up for Intervention and Control Groups at 
3 and 6 Months 
Patients were followed-up at 3 and 6 months after recruitment in the Periodontology 
Department. This included a questionnaire-based assessment of smoking behaviour. 
The follow-up questionnaire asked about smoking behaviour during the previous three 
months, and patients were asked whether they considered themselves to be smokers or 
non-smokers. If they considered themselves to be quitters, they were asked about a quit 
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date, and whether they used phannaceutical support in the form of NRT or Zyban. 
Patients who still considered themselves to be smokers were asked about any changes in 
smoking behaviour, including the number and length of any quit attempts in the 
previous three months, any reduction in smoking either by smoking less or inhaling less, 
or whether they had changed cigarette brands. Some of the questions had previously 
been used in a smoking cessation study in general practice (Butler et al., 1999), whilst 
others were designed for this study (smoking less of a cigarette; inhaling less). 
Information was also collected on the participants current 'Stage of Change '. Full 
copies of these questions are in Appendix 10. 
3.3.12 Measures of Abstinence used to Determine Quitting 
In this trial, the measure of point prevalence was used, with prolonged abstinence 
measures also reported for 6-month outcomes. Smokers were not asked if they 'had 
smoked, not even a puff, in the last fortnight', but as cotinine sampling was used, 
contact with nicotine could be established and verified over the previous week. This 7-
day window is the suggested time frame for verifying smoking as suggested by Hughes 
et al. (2003). In the context of this study, participants were categorised as being 
prolonged abstainers if they were classified as definitive quitters at both 3 and 6 months. 
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3.3.13 Biochemical Follow-up of Intervention and Control Groups at 
3 and 6 Months 
As at baseline, a salivary sample was collected for cotinine (COT) analysis, and an 
exhaled air sample used for carbon monoxide (CO) analysis. Three and six-month saliva 
samples were collected in similar bottles to those used at baseline, but were labelled and 
colour-coded (red for 3 months and blue for 6 months) to aid identification during 
storage and anal ysi s. 
With respect to cotinine, a cut-off level of 20ng/ml was used in this study with a value 
below 20ng/ml generally indicating a non-smoker. With respect to the CO cut-off level 
used to determine smoker from non-smoker, a value of 9ppm or above indicated a 
smoker. 
However, if there was evidence that a patient had been using NR T, a higher COT could 
be expected, and thus the smoker's classification of cessation was verified by the CO 
value. Furthermore, if a self-reported quitter, in the absence of self-reported NRT use, 
had a cotinine level higher than the cut-off stated, but the CO indicated that the 
individual was a non-smoker, cognisance was taken of the baseline measurements of 
COT to determine how much the nicotine loading had reduced. 
3.3.14 Follow-up for Intervention and Control Groups at One Year 
Attempts were made to contact patients at one year after recruitment, initially by 
telephone, and for those for whom it proved impossible to establish contact this way, 
follow-up via a postal questionnaire was attempted. Patients were asked whether they 
had quit or not, and if so, the date on which they quit. The self-reported quitters were 
also asked to provide a sample of saliva, to be posted to the dental school for cotinine 
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analysis. If the patient described themself as a smoker, they were asked about the 
number of cigarettes they smoked, and the reasons for currently smoking. A copy of 
both telephone and postal questionnaires are to be found in Appendix 11. 
3.3.15 Statistical Analysis and Data Handling 
Information from the questionnaires and biochemical information regarding CO and 
COT levels was scribed onto a data entry form designed in Microsoft Access. Using 
these forms, data were then manually entered into separate Microsoft Access databases 
for the following time points in the trial (baseline, 3 and 6 months), and an Excel 
database for the 12 month results. Data were then exported for statistical analysis into 
Minitab (version 14) and StatXact (version 4). 
Statistical analyses consisted predominately of comparing the intervention and control 
groups in terms of baseline information (both questionnaire and biochemical data) and 
also the primary outcomes at 3, 6 and 12 months and secondary outcomes at 3 and 6 
months after recruitment. 
When comparing the two groups, continuous, normally-distributed data were 
summarised by means and standard deviations and analysed using two-sample t-tests 
and confidence intervals. Data which were numerical but not normally-distributed were 
summarised by medians and inter-quartile ranges and groups compared using Mann-
Whitney tests and confidence intervals. When comparing groups in terms of categorical 
variables, tables were produced to summarise the data, which were analysed using chi-
squared tests. The primary and secondary outcomes, which were binary variables, were 
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compared between groups using tests of equal proportions and confidence intervals for 
the difference between groups. 
All statistical tests were considered to be statistically significant if the p-value was less 
than 0.05 and correspondingly if the confidence interval for the difference did not 
bracket zero. 
3.3.16 Summary of Cessation Trial Methodology 
A diagrammatic summary of the stages of the smoking cessation trial is to be found in 
Figure 3.1 below. 
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Figure 3.1 
SUMMARY OF SMOKING CESSATION TRIAL 
Consultant Clinic 
Current Smoker 
> 10 cigarettes per day 
Recruitment to Trial 
Patient information 
Patient consent 
Randomisation to Hygienist 
Red 
Green 
Blue 
Visit 1 - All Patients 
Baseline Questionnaire 
Salivary Cotinine 
Carbon Monoxide 
Randomised to Intervention and Control 
based on: 
Age 
Sex 
DEPCAT 
Level of Dependence (FTNO) 
Motivation to Quit ("Stage of Change") 
126 
SUMMARY OF SMOKING CESSATION (cont). 
I 
1 , 
Visit 2 Intervention Visit 2 Control 
Informed of allocation Informed of allocation 
Periodontology treatment Periodontology treatment 
5As + Offer of N RT No further smoking cessation 
or 5 Rs 
CO monitoring 
-
• 
• 
• 
advice 
-
• 
• 
• 
Visit 3/4/5 Intervention 
5As reinforced 
CO monitoring 
Periodontology treatment 
Visit 3/4/5 Control 
Periodontology treatment 
No further advice 
I 
• 
3 month follow-up - all patients 
3 month questionnaire re quitting 
If smoker, secondary outcomes 
CO monitoring 
Salivary COT sample 
6 month follow-up - all patients 
6 month questionnaire re quitting 
If smoker, secondary outcomes 
CO monitoring 
Salivary COT sample 
1 year follow-up 
Telephone interview 
If no success, postal 
questionnaire 
Postal salivary COT if quitter 
127 
I 
3.4 Baseline Results 
3.4.1 Recruitment Phase 
The patient recruitment phase began in April 2001 and lasted for 16 months, with the 
last patient enrolled into the trial in July 2002. 
In total, 118 patients were recruited at baseline. Table 3.3 outlines the recruitment of 
patients by hygienist. 
Table 3.3 Allocation of Recruited Patients by Hygienist and Group 
Hygienist No. Sessions Intervention Control Total patients 
Per Week 
Blue 9 23 (39%) 24 (41%) 47 (40%) 
Red 8 21 (36%) 20 (34%) 41 (35%) 
Green 5 15 (25%) 15 (25%) 30 (25%) 
Total 59 (50%) 59 (50%) 118 (100o/~ 
There was an unequal distribution of participants among the three hygienists which 
broadly reflected the number of sessions each hygienist worked per week, and thus their 
patient caseload. The 0.9 wte hygienist had 40% of the participants, while the 0.5 wte 
hygienist was responsible for 25% of the total recruited. 
Following recruitment to the trial, one patient subsequently died, and one patient 
withdrew consent for follow-up visits; these two cases were therefore withdrawn from 
any further analysis. These participants had both been allocated to the control group. 
Patient data collection was completed in July 2003. Therefore, the duration of the trial 
was 28 months. 
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3.4.2 Patient Characteristics 
3.4.2.1 Gender of Participants 
As can be seen from Table 3.4, there was an excess of females (71 %) compared to 
males (29%) participating in the trial. There were slightly more males in the control 
group (35%) than intervention (24%). However, this difference was not statistically 
significant. 
Table 3.4 Gender of Participants 
Intervention Control All 
Male 14 (24%) 20 (35%) 34 (29%) 
Female 45 (76%) 37 (65%) 82 (71%) 
Total 59 57 116 
l = 1.805, df= 1, p = 0.179 
3.4.2.2 Deprivation Category of Participants 
All deprivation categories were represented among participants recruited into the trial 
(Table 3.5). The majority of participants were from DEPeAT 4 (26 participants), with 
the lowest proportion from DE peAT 1 (5 participants). 
When looking at the differences between intervention and control groups, it can be seen 
that there were approximately equivalent numbers in each deprivation category, with the 
exception of DEPeAT 7 (21% control, compared to 8% intervention). Overall, there 
were no statistically significant differences between the numbers of participants in the 
intervention and control groups. 
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Table 3.5 Deprivation Category of Intervention and Control Groups 
DEPCAT Intervention Control All 
1 3 (5%) 2 (3%) 5 (4%) 
2 6 (10%) 6 (10%) 12 (10%) 
3 7 (12%) 9 (16%) 16 (14%) 
4 15 (25%) 11 (19%) 26 (22%) 
5 10 (17%) 8 (14%) 18 (16%) 
6 13 (23%) 9 (16%) 22 (19%) 
7 5 (8%) 12 (21%) 17 (15%) 
Total 59 57 116 
,.l = 4.864, df= 6, p = 0.561 
3.4.2.3 Age of Participants 
As shown in Table 3.6, the youngest participant recruited was 22 years of age and the 
oldest 71. The mean age of the control group was statistically significantly higher than 
the intervention group by 3.6 years. 
Table 3.6 Age of Participants 
Age (Years) All Intervention Control p-value 95%CI 
n=116 n=59 n=57 (C-I) 
Mean (stdev) 41.2 (8.2) 39.9 (8.0) 43.5 (8.0) 0.019 (0.6,6.5) 
Range (22-71) (22-57) (30-71) 
3.4.2.4 Nicotine Dependence Measures 
A number of questions were asked about current tobacco usage to enable calculation of 
the Heaviness of Smoking Index, Fagerstrom Test for Nicotine Dependence and 
Fagerstrom Tolerance Test. 
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a) Daily Consumption of Cigarettes 
Overall, the majority of trial participants (57%) smoked between 11 and 20 cigarettes 
per day (Table 3.7). One in ten smoked 10 cigarettes, with just under one-third of 
participants smoking 21 or more cigarettes per day. There was no statistical difference 
between the intervention and control groups with respect to number of cigarettes 
smoked. 
Table 3.7 Participants' Reported Num ber of Cigarettes per Day, at Baseline 
No. of cigarettes Intervention Control All 
10 or less 9 (15%) 4 (7%) 13(11%) 
11 - 20 33 (56%) 33 (58%) 66 (57%) 
21 - 30 14 (24%) 17 (30%) 31 (27%) 
31+ 3 (5%) 3 (5%) 6 (5%) 
Total 59 57 116 
X2 = 2.18, df= 3, P = 0.536 
In response to the question about the exact amount smoked daily, Table 3.8 shows that 
the median number of daily cigarettes smoked was 20, i.e. a pack per day. This average 
level of smoking was the same for intervention and control groups. 
Table 3.8 Participants' Reported Exact Daily Number of Cigarettes, at Baseline 
All Intervention Control p-value 95%CI 
n=116 n=59 n=57 (C-I) 
Median 20 20 20 0.196 (-1, 5) 
IQ Ran2e 15-22 15-20 15-25 
Range 10-40 10-40 10-40 
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With regard to the distribution of reported exact daily number of cigarettes for all 
participants, as illustrated in Figure 3.2, there is clumping of the data at 10, 15, 20 and 
25 cigarettes per day. 
Figure 3.2 All Participants' Self-Reported Exact Number of Cigarettes 
Smoked per Day at Baseline 
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b) Self-Reported Time to First Cigarette of the Day 
Table 3.9 shows that few trial participants (7%) smoked within the first five minutes of 
waking, with the majority of participants smoking their first cigarette between 30 
minutes and one hour after waking (52%). There was no significant difference between 
the intervention and control groups with regard to time taken to light up in the morning. 
132 
Table 3.9 Participants' Self-Reported Time to First Cigarette of the Day, 
at Baseline 
Intervention Control All 
Less than 5 min 5 (9%) 3 (5%) 8 (7%) 
6-30 min 4 (7%) 8 (14%) 12 (10%) 
31--60 min 35 (59%) 25 (44%) 60 (52%) 
Above 60 min 15 (25%) 21 (37%) 36 (31%) 
Total 59 57 116 
X2 = 4.467, df= 3, p = 0.215 
c) Participants' Self-Reported Smoking more Frequently in the Morning 
As can be seen in Table 3.10, a larger proportion of participants recruited to the trial 
smoked more frequently in the morning (57%) than at other times of the day. A slightly 
higher percentage of patients in the control group reported smoking in the morning, but 
this difference was not statistically significant. 
Table 3.10 Participants' Self-Reported Smoking More Frequently in the Morning, 
at Baseline 
Intervention Control All 
Yes 30 (51%) 36 (63%) 66 (57%) 
No 29 (49%) 21 (37%) 50 (43%) 
Total 59 57 116 
"l = 1.792, df=l, P = 0.181 
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d) Difficulty in Refraining from Smoking in Public Places 
Most participants in the trial, as can be seen in Table 3.11, did not find it difficult to 
refrain from smoking in public places, with no significant differences found between 
allocated groups. 
Table 3.11 Participants' Self-Reported Difficulty in Refraining from Smoking in 
Public Places, at Baseline 
Intervention Control All 
Yes 17 (29%) 10 (18%) 27 (23%) 
No 42 (71%) 47 (82%) 89 (77%) 
Total 59 57 116 
X2 = 2.062, df=l, p = 0.151 
e) Participants' Self-Reported Difficulty in Giving up First Cigarette 
of the Day 
The majority (62%) of trial participants stated that they would find it difficult to give up 
their first cigarette of the day (Table 3.12). There was no significant difference between 
intervention and control groups. 
Table 3.12 Participants' Self-Reported Difficulty in Giving Up First Cigarette 
of the Day, at Baseline 
Intervention Control All 
Yes 38 (64%) 34 (60%) 72 (62%) 
No 21 (36%) 23 (40%) 44 (38%) 
Total 59 57 116 
X2 = 0.279, df=l, p = 0.598 
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f) Participants' Self-Reported Smoking Habits when III in Bed 
Most participants (75%) did not smoke in bed when ill (Table 3.13). There was no 
significant difference between intervention and control groups. 
Table 3.13 Participants' Self-Reported Smoking Habits when III in Bed, 
at Baseline 
Intervention Control All 
Yes 12 (20%) 17 (30%) 29 (25%) 
No 47 (80%) 40 (70%) 87 (75%) 
Total 59 57 116 
X2 = 1.391, df=l, P = 0.238 
g) Participants' Self-Reported Level of Nicotine in Cigarettes Smoked 
As shown in Table 3.14, the majority of participants (64%) smoked cigarettes 
containing a medium level of nicotine, while one in three reported smoking low nicotine 
cigarettes. There was no statistically significant difference between the two groups. 
Table 3.14 Participants' Self-Reported Level of Nicotine in Cigarettes Smoked, 
at Baseline 
Intervention Control All 
Low nicotine 16 (28%) 18 (32%) 34 (30%) 
Medium nicotine 38 (67%) 35 (61 %) 73 (64%) 
High nicotine 3 (5%) 4(7%) 7(6%) 
Total 57 57 114 
X2 - 0.384, df - 2, p = 0.825 
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h) Participants' Self-Reported Inhalational Smoking Habits 
Table 3.15 shows that the majority of trial participants always inhaled cigarette smoke 
(92%). None of the subjects did not inhale at all. There was no statistically significant 
difference between the intervention and control groups with regard to this habit. 
Table 3.15 Participants' Self-Reported Level of Inhalation of Cigarette Smoke, 
at Baseline 
Intervention Control All 
Don't inhale 0(0%) 0(0%) 0(0%) 
Sometimes inhale 5 (9%) 4 (7%) 9 (8%) 
Always inhale 52 (91 %) 53 (93%) 105 (92%) 
Total 57 57 114 
X2 = 0.121, df= 1, P = 0.728 
3.4.2.5 Composite Measures of Smoking Dependence 
a) Heaviness of Smoking Index (HSI) 
The HSI is a composite score based on two questions: the first with regard to number of 
cigarettes per day and the second alluding to 'time to first cigarette' of the day. The 
minimum achievable HSI is zero, and the maximum is six. 
Table 3.16 shows that overall the HSI ranged from zero to six, with a median value of 
three for the intervention group and four for the control group. There was no 
statistically significant difference between the two groups. 
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Table 3.16 Heaviness of Smoking Index for Pa rticipants, at Baseline 
All Intervention Control p-value 95% CI 
n=116 n=59 n=57 (C-I) 
Median 3.0 3.0 4.0 0.197 (0.0, 1.0) 
IQ 3.0- 4.0 3.0-4.0 3.0-4.0 
Range 0-6 0-6 0-6 
Figure 3.3 illustrates the similar distributions of the HSI in the intervention and control 
groups. 
Figure 3.3 Dotplot of Intervention and Control HSI scores, at Baseline 
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The Fagerstrom Test for Nicotine Dependence (FTND) comprises the two questions 
utilised in the Heaviness of Smoking Index, with an additional four questions relating to 
giving up the first cigarette of the day, smoking in public places, smoking when ill and 
smoking more in the morning. The minimum score in this index is zero, with a 
maximum score of 10. 
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Table 3.17 indicates that the median value across all participants was five, with scores 
ranging from zero to 10. When the FTND scores of the two groups were compared, 
there was no statistically significant difference. 
Table 3.17 Fagerstrom Test for Nicotine Dependence for Participants, 
at Baseline 
All Intervention Control p-value 
n=116 n=59 n=57 
Median 5.0 5.0 5.0 0.343 
IQ 3-6 3-6 3-7 
Range 0-10 0-10 0-9 
95%CI 
(C-I) 
(0.0, 1.0) 
Figure 3.4 illustrates the slightly wider interquartile range of the data in the control 
group. 
Figure 3.4 Fagerstrom Test for Nicotine Dependence: Boxplot of 
Intervention and Control Groups at Baseline 
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c) Fagerstrom Tolerance Score 
The Fagerstrom Tolerance Score includes data from the FTND and is supplemented by 
information relating to nicotine level in the cigarettes and inhalational habits. Almost 
the full range was used, with values ranging from two to 12 (the maximum value) being 
reported (Table 3.18). The median score was eight. There was no statistically 
significant diffe rence between intervention and control groups. 
Table 3.18 Fagerstrom Tolerance Score for Participants, at Baseline 
All Intervention Control p-value 95%CI 
n=11 5 n=58 n=57 JC ..... I) 
Median 8.0 8.0 8.0 0.418 (-1.0, 1.0) 
IQ 6.0-9.0 6.0-9.0 6.0-9.5 
Ran~e 2.0-1 2.0 2.0-1 2.0 2.0-12.0 
As can be seen from Figure 3.5, there was a slightly wider interquartile range in the 
control group as compared to the intervention group. 
Figure 3.5 Fagerstrom Tolerance Score: Boxplot of Intervention and 
Control Groups at Baseline 
12 
10 
~ 
f 
J! 8 
~ 
E 
f 
~ 6 
& 
I! 
4 
2 
Control 
139 
3.4.2.6 Environmental Exposure to Smoke 
a) Exposure to Smoke at Home 
Table 3.19 shows that the majority of trial participants were not exposed to smoke at 
home (61 %). There was no statistically significant difference between the intervention 
and control groups. 
Table 3.19 Exposure to Smoke at Home for Participants, at Baseline 
Intervention Control All 
Yes 20 (34%) 25 (44%) 45 (39%) 
No 38 (66%) 32 (56%) 70 (61%) 
Total 58 57 115 
X2 = 1.061, df=l, P = 0.303 
b) Exposure to Smoke at Work 
Just over half (52%) of the trial participants reported being exposed to smoke at work 
(Table 3.20). Overall, 12% were not in paid employment, and hence experienced no 
workplace exposure. There was no statistically significant difference between the 
intervention and control groups. 
Table 3.20 Exposure to Smoke at Work for Participants, at Baseline 
Intervention Control All 
Yes 32 (56%) 27 (47%) 59 (52%) 
No 19 (33%) 22 (39%) 41 (36%) 
Not applicable 6 (11%) 8 (14%) 14 (12%) 
Total 57 57 114 
X2 = 0.929, df = 2, p = 0.628 
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3.4.2.7 Lifetime Measures of Smoking Exposure 
a) Number of Years Smoked 
The trial participants were asked to recall the length of time they had been smokers. As 
shown in Table 3.21 , the mean number of years smoked was slightly higher in the 
control group. However, the difference between intervention and control groups was not 
statistically significant. The smallest number of years smoked by a trial participant was 
four years, with the maximum reported number of years of smoking exposure being 50 
years. It can be seen from Figure 3.6 that the range of the data for the control group was 
slightly wider. The boxplots also illustrate the slightly higher average number of years 
smoked for participants in the control group, compared to the intervention group. 
Table 3.21 Number of Years Smoked by Participants, at Baseline 
All In terven tio n Control p-value 
n=115 n=58 n=57 
I Mean (stdev) 23.8 (8.1) 22.5 (7.9) 25.2 (8.2) 0.08 
I Ran2e (4-50) (4-40) (6-50) 
Figure 3.6 Boxplot of Number of Years Smoked by Intervention 
and Control Groups, at Baseline 
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b) Pack-Years 
Whole life exposure was calculated by multiplying the number of years smoked by 
number of packs of cigarettes (estimated at 20 cigarettes in a pack) per day, to give a 
self-reported measure of exposure. 
There was a difference of 3.3 years in the mean number of pack-years between 
intervention and control, with the control group having the slightly higher exposure 
(Table 3.22). However, this difference was not statistically significant. The pack-years 
exposure of the participants ranged from 2 to 74 years. 
Table 3.22 Number of Pack-Years for Participants, at Baseline 
All Intervention Control p-value 95% CI 
n=l13 n=57 n=56 (C-I) 
Mean (stdev) 23.1 (12.5) 21.5(12.5) 24.8 (12.1) 0.16 (-1.3,8.0) 
Range (2-74 ) (2-74) (3-64) 
3.4.2.8 Measures of Motivation to Quit 
Two measures of motivation were used to determine the participants desire to quit. The 
first measure involved asking two questions regarding strength of desire to quit, and 
these are reported separately, and also as a composite total motivation score. For the 
second measure, participants were asked to categorise themselves with regard to their 
intention and readiness to quit ('Stage of Change'). 
I·n 
a) Participants Desire to Stop Altogether, if They Could Do So Easily 
Table 3.23 shows that the vast majority (90%) of trial participants would either 
definitely or probably quit if it was easy to do so. There was no difference between 
intervention and control groups. 
Table 3.23 Participants' Self-Reported Desire to Stop Smoking, if they Could Do 
So Easily, at Baseline 
Intervention Control All 
Yes, definitely 45 (78%) 46 (81 %) 91 (79%) 
Yes, probably 6 (10%) 7 (12%) 13(11%) 
Possibly 6 (10%) 3 (5%) 9 (8%) 
Probably not 0(0%) 1 (2%) 1 (1%) 
Definitely not 1 (2%) 0(0%) 1(1%) 
Total 58 57 115 
x? = 3.079, df= 4, p = 0.619 
b) Participants' Desire to Stop Altogether 
In response to the question about how much they wanted to stop altogether, 78% of 
participants said that they either strongly or quite strongly wanted to stop altogether 
(Table 3.24). There was evidence of an association between the group and the level of 
the desire to stop altogether. There were more control than intervention participants 
who responded that they very strongly wanted to stop altogether. There were more 
intervention than control participants who indicated that they moderately wanted to stop 
altogether. 
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Table 3.24 Participants' Self-Reported Desire to Stop Altogether, at Baseline 
Intervention Control All 
Very strongly 19 (33%) 24 (42%) 43 (37%) 
Quite strongly 22 (38%) 25 (44%) 47 (41%) 
Moderately 15 (27%) 4 (7%) 19 (17%) 
Slightly 2 (3%) 2 (4%) 4 (3%) 
Not at all 0(0%) 2 (4%) 2 (2%) 
Total 58 57 115 
X2 = 9.133, df= 4, p = 0.042 
c) Total Motivation Score 
It can be seen from Table 3.25, that the predominance of the measurements for the 
composite motivation scores are in the seven to eight range, with 71% of the 
participants having one of these scores. 
Table 3.25 Distribution of Total Motivation Score for Participants, at Baseline 
Intervention Control All 
2 0(0%) 2 (0%) 2 (2%) 
3 1 (2%) 1 (2%) 2(2%) 
4 6 (11 %) 2 (3%) 8 (7%) 
5 4 (7%) 2 (3%) 6(5%) 
6 11 (19%) 5 (9%) 16 (13%) 
7 17 (30%) 22 (38%) 39 (34%) 
8 19 (33%) 23 (40%) 42 (37%) 
Total 58 57 115 
The median motivation score for all participants was seven. There was no statistically 
significant difference between the intervention and control groups (Table 3.26). 
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Table 3.26 Total Motivation Score for Participants, at Baseline 
All Intervention Control p-value 95% CI 
n=115 n=58 n=57 (I-C) 
Median 7 7 7 0.156 (0.0, 1.0) 
IQ 6-8 6-8 6-8 
Ran2e 2-8 3-8 2-8 
d) Measurement of 'Stage of Change' 
Table 3.27 indicates that only 13% of the trial participants were not interested in 
stopping and thus could be considered 'contented smokers'. With regard to showing 
interest in stopping some time in the next six months, 45% of individuals reported to be 
in the category of 'concerned smoker', while 42% of participants reported wanting to 
stop within the next month. 
Slightly more participants in the intervention group (46%) wanted to stop, compared to 
38% in the control group, and there were more participants (16%) in the control group 
who were not interested in quitting compared to the intervention (10%). However, there 
was no statistically significance difference between the intervention and control groups 
with regard to the 'Stage of Change' of participants. 
Table 3.27 'Stage of Change' of All Participants, at Baseline 
Intervention Control All 
Not interested 6 (10%) 9 (16%) 15 (13%) 
(,precontemplators ') 
Concerned 26 (44%) 26 (46%) 52 (45%) 
('contemplators') 
Want to stop 27 (46%) 22 (38%) 49 (42%) 
('preparation') 
Total 59 57 116 
"I: =1.076, df= 2, p = 0.584 
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3.4.2.9 Participants' Self-Reported Reasons for Wanting to Quit, at Baseline 
Table 3.28 shows that the most popular reason for wanting to quit was a concern for 
health (95%), followed by the expense (80%). Only 50% had concerns about other 
people's exposure to smoke. 
Table 3.28 Self-Reported Reasons for Wanting to Quit: All Participants, 
at Baseline 
Heal th reasons 104 (95%} 
Expense 92 (80%) 
Don't like being addicted 66 (57%) 
Not fair on other peogle 57 (50o/~ 
Other reasons 25 (22%) 
Number replying = 115 
3.4.2.10 Participants' Self-Reported Biggest Problem in Trying to Quit 
Of the 116 participants, 104 (90%) gave information on what they perceived to be their 
biggest problem in attempting to give up smoking. 
Comments were analysed and a number of key themes emerged from the data. 
Problems concerning withdrawal caused by nicotine dependence were mentioned by 30 
of the participants, while non-nicotine dependence issues such as habit and enjoyment 
were thought to be the major problem by 31 of the individuals recruited to the trial. 
Issues relating to weight control and body image emerged as problems for 9 of the 
participants, with social issues regarding the use of alcohol being cited as the key 
problem for 9 of the respondents. Lack of self-efficacy or fear of failure was reported 
by 9 of the trial participants. 
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Environmental exposure to tobacco from those around the smokers, either at work or in 
the home was cited as a problem by six respondents. 
Only one respondent cited 'No problem!' 
3.4.2.11 Biochemical Assessment of Exposure to Nicotine, at Baseline 
Two biochemical measures were used to assess exposure to nicotine at baseline, a 
salivary sample for cotinine analysis and an exhaled air sample for carbon monoxide 
analysis. 
a) Measurement of Cotinine (COT) 
As shown in Table 3.29, no statistically significant difference was seen between the 
intervention and control groups in terms of mean cotinine levels, with values of 232 and 
243ng/ml respectively. However, there was a wide range in the levels of cotinine 
determined in the baseline samples. As can be seen from Figure 3.7, there was 
substantial overlap of the data for intervention and control groups, with the interquartile 
range of the control data being slightly wider. 
Table 3.29 Levels of Salivary Cotinine (measured in nglml) of Participants, 
at Baseline 
All Intervention Control p-value 95%CI 
n=116 n=59 n=57 (C-I) 
Mean 237.5 231.9 243.3 0.539 (-25.3, 48.2) 
(stdev) (99.4) (95.0) (104.3) 
Range (14-491) (14-479) (18-491) 
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Figure 3.7 Boxplot of Cotinine Levels in Intervention and Control Groups, 
at Baseline 
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b) Measurement of Carbon Monoxide (CO) 
The mean carbon monoxide measurement (CO) in the intervention group was 22.0ppm 
compared to 20.8ppm in the control group (Table 3.30). This difference was not 
statistically significant. There was considerable variation in the baseline carbon 
monoxide measurements. 
As can be seen from Figure 3.8, there was substantial overlap of the data, with an outlier 
in both the intervention and control groups. The CO level of S2ppm from a control 
participant would seem to be quite atypical. 
Table 3.30 Levels of Carbon Monoxide (measured in parts per million) of 
Participants, at Baseline 
All Intervention Control p-value 95%CI 
n=112 n=58 n=54 (I-C) 
Mean (stdev) 21.4 (8.9) 22.0 (8.8) 20.8 (9.1) 0.483 (-2.2, 4.S) 
Ran2e (S.0-52.0) (S.0-44.0) (5.0-S2.0) 
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Figure 3.8 Boxplot of Carbon Monoxide levels in Intervention and Control 
Groups, at Baseline 
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3.4.2.12 Summary of Comparison of Control and Intervention Groups 
with respect to Randomisation Factors 
The aim of the randomisation (as detailed in Section 3.3.8) was to provide balance 
between the intervention and control groups with respect to age, sex, DEPCAT, level of 
nicotine dependence and intention to quit as measured by 'Stage of Change'. 
There was no statistically significant difference between intervention and control groups 
with respect to sex and DEPCAT. Similarly, there was no difference between the 
intervention and control groups with respect to level of nicotine dependence, as 
measured by FTND and HSJ, nor with regard to motivation to quit, as measured by 
'Stage of Change' and Motivation Scores. 
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There was a difference with regards to age, with a statistically significantly higher mean 
age of 3.6 years in the control group. The 95% confidence interval suggests that the 
mean difference in age could be as little as 0.6 years or as high as 6.5 years. 
As regards the biochemical measures of tobacco exposure, namely carbon monoxide 
(CO) and cotinine (COT), there were no statistically significant differences between 
intervention and control groups. 
Therefore, the intervention and control groups participating within this randomised 
controlled trial were similar with respect to all baseline factors randomised on, with the 
one exception of age. 
3.5 Three Month Outcomes 
3.5.1 Patient Follow-ups 
Three-month data were obtained from 102 of the 116 participants (88%) registered at 
baseline. 
Table 3.31 shows the distribution of participants lost to the study in both the 
intervention and control groups. There were equal numbers of participants (seven) in 
each group for which it proved impossible to obtain follow-up data. 
Table 3.31 Follow-up of Participants at 3 Months 
Number of Participants 
Intervention (%) Control (%) 
At baseline 59(51O/~ 57 (49%) 
At 3 months 52 (88%) 50 (88%) 
'Lost' to study at 3 months 7 (12%) 7 (12%) 
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Analysis of the 14 individuals lost to the trial indicated that, with regard to age, the 
mean for the intervention group was 41.9 (SD 5.6) years compared to 41.4 (SD 5.7) 
years in the control group. The median number of cigarettes smoked in the intervention 
and control groups at baseline were 20 (range 10-20) and 15 (range 10-20) per day, 
respectively. With regards to pack-years, the intervention group had a slightly higher 
mean exposure of 23.4 (SD 7.7) years compared to 18.0 (SD 7.5) years in the control 
group. 
3.5.2 N urn ber of Treatment Visits of Participants between Baseline and 3 Months 
Information was collected on the number of visits to the hygienists by the participants 
for the time period between baseline and three months. The median number of visits for 
both groups was four, with ranges of one to six and two to seven for the intervention 
and control groups respectively. 
3.5.3 Primary Outcome at 3 Months 
3.5.3.1 Self-Reported Smoking Status at 3 Months 
At three months, each participant was asked whether they considered themself to be 
smoker. A summary of the responses is displayed in Table 3.32. It can be seen that 
nine (17%) of the participants in the intervention group described themselves as 
quitters, compared to five (10%) in the control group. However, the difference between 
intervention and control in terms of the proportion of participants reporting as having 
quit did not reach statistical significance (p=0.484, 95% CI (I-C)=( -9,28)%). 
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Table 3.32 Participants ' Self Reported Smoking at 3 Months 
Are you a smoker? Intervention Control All 
No 9 (1 7%) 5 (10%) 14 
Yes 43 ( 83%) 45 (90%) 88 
Total 52 50 102 
3.5.3.2 Summary of Self-Reported Quitters at 3 Months including 
Biochemical Measures of Cotinine (COT) and Carbon Monoxide (CO) 
In addition to the measure of self-report, two further measures of smoking cessation, 
both biochemical, were collected from patients. Additionally, information on exposure 
to NRT medication at the three month time period was collected. In Table 3.33, 
information regarding the 14 participants who claimed to have quit, including log 
number, allocated group, treating hygienist, level of COT and CO, and NRT use at time 
of sampling are displayed. 
Table 3.33 Three Month Summary Table of Biochemical Measures (COT, CO) 
and use of NRT at Time of Sampling, for Self-Reported Quitters 
Log Allocated Hygienist COT CO NRT Use at time of 
Group (ng/rnJ) (ppm) sampling 
1 I Blue <2 1 no 
2 I Green <2 2 no 
36 I Red 28 2 no 
50 I Red 16 3 no 
58 I Red 71 20 no 
81 I Blue 111 5 Gum 
83 I Green <2 1 no 
86 I Blue <2 2 no 
103 I Blue <2 1 no 
21 C Red <2 2 no 
43 C Red 140 3 Patches 
61 C Green 33 3 no 
82 C Blue 17.5 - Lozenges 
118 C Blue 106 8 Patches 
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The participants' log number gives an approximate timescale of when participants were 
recruited to the study. It can be seen there were two successful quitters early on in the 
trial, i.e. cases 1 and 2, and a clustering of participants emolled in the 80' s, i.e. 81, 82, 
83 and 86. 
All hygienists had participants who claimed to have quit, both in intervention and 
control groups. The Blue hygienist had four intervention and two control quitters. The 
Green hygienist had two intervention and one control, the Red hygienist had two 
intervention and two control participants who claimed to have stopped tobacco use. 
With respect to CO measurements, 12 trial participants, (eight intervention, four 
control) had values of 8ppm or below. There was no measurement of CO for one 
individual (participant 82), and one person (participant 58) had a value of 20ppm, well 
above the cut-off. 
With respect to cotinine levels, eight individuals (six intervention and two control) had 
values below the cut-off of 20nglml. Six individuals had levels above this, and these 
are detailed on a case-by-case basis below. 
A number of the trial participants reported using NRT at the 3-month point (participants 
43, 81, 82, 118). In the intervention group, one reported its usage and in the control 
group there were three participants who were taking this medication at the time cotinine 
sampling was undertaken. All had CO levels below the cut-off value of 9ppm. 
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Additionally, two cases had slightly higher cotinine levels than the previously stated 
cut-off point. Participant 36 had a cotinine of 28ng/ml and participant 61 had a cotinine 
of 33ng/ml. Both had low CO values below the cut-off level, 2 and 3ppm respectively. 
When notice is taken of the baseline measurements, participant 36 then had a cotinine 
level of 232ng/ml and CO of 15ppm. The level of COT at 3 months constituted an 88% 
drop in cotinine levels. F or participant 61, the baseline measurements were COT 
185ng/ml and CO 13ppm. The 3-month value constituted an 82% drop in cotinine 
levels. 
One individual (participant 58) claimed to have quit, though cotinine and carbon 
monoxide levels were substantially above the cut-off (71ng/ml and 20ppm 
respectively). This subject reported no exposure to nicotine replacement therapy. The 
classification of a patient who reports non-smoking which is not corroborated by the 
biochemistry is a 'deceiver'. 
In addition to those individuals who claimed to have quit, one trial participant (113) 
allocated to the intervention group (Blue hygienist) described themself as a smoker, but 
had biochemistry more appropriate for a quitter. With a COT level of 18nglml and a 
CO of 2ppm, these values would indicate that this individual was more suitably 
categorised as a non-smoker. Such an individual can be classified as a 'closet quitter'. 
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3.5.3.3 Definitive Quitters as measured by Self-report, Cotinine and 
CO Analysis at 3 Months 
Table 3.34 shows the definitive categorisation of smoking status, taking into account all 
available evidence. This resulted in 14 participants being classified as quitters. 
Table 3.34 Definitive Quitters as measured by Self-Report, Cotinine 
and CO Analysis at 3 Months 
Log Allocated Self Report Cotinine CO 
Number Group 
1 I ./ ./ ./ 
2 J ./ ./ ./ 
36 I ./ X ./ 
50 J ./ ./ ./ 
81 I ./ X ./ 
83 I ./ ./ ./ 
86 J ./ ./ ./ 
103 I ./ ./ ./ 
113 I X ./ ./ 
21 C ./ ./ ./ 
43 C ./ X ./ 
61 C ./ X ./ 
82 C ./ ./ 
-
118 C ./ X ./ 
Blue- InterventIon Purple= Control 
ISS 
Category 
quitter 
quitter 
quitter 
quitter 
quitter 
quitter 
quitter 
quitter 
closet 
quitter 
quitter 
quitter 
quitter 
quitter 
quitter 
Therefore, in summary, with respect to all patients followed-up, there were mne 
participants (17.3%) who were classified as quitters in the intervention group, compared 
to five (10.0%) in the control group. There was no statistically significant difference 
between intervention and control groups in terms of the proportion of participants 
classified as quitters (p=0.484, 95% CI (I-C)=(-9.3, 27.9)%). However, the 95% CI for 
the difference does indicate that the difference could be as much as 28% in favour of 
intervention over control. 
However, assuming all patients lost to follow-up were still smoking, the nine and five 
definitive quitters represented quit rates of 15.3% and 8.8% of the intervention and 
control patients recruited respectively. However, the difference between intervention 
and control groups, in terms of the proportion of participants defined as having quit, did 
not reach statistical significance (p=0.449, 95% CI (I-C)=(-8.4, 25.6)%). 
3.5.3.4 Self-Reported Pharmacological Use in 3-Month Quitters 
Although four of the quitters were using NRT at the 3-month time point, several others 
had employed this aid to smoking cessation during the preceding three months. Table 
3.35 details the different types of nicotine replacement therapies used by the quitters in 
the trial during the previous three months. 
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Table 3.35 Use of Nicotine Replacement Therapy by Quitters during Initial 
3 Month Period 
Log Allocation Hygienist NRT or Zyban 
use 
1 I Blue Patches(N ic) 
2 I Green Patches(N ic) 
36 I Red Patches(N ic) 
50 I Red nil 
81 I Blue Gum(Nic) 
83 I Green Lozenges(NQ) 
86 I Blue nil 
103 I Blue Patches(Nic) 
113 J Blue nil 
21 C Red Zyban 
43 C Red Patches(N/elle) 
61 C Green nil 
82 C Blue LozengesiNQ) 
118 C Blue Patches(NQ) 
Nic = Nicorette (brand ofNRT in patches or gum form, provided free in trial) 
N/elle = Nicotinelle 
NQ = Niquitin 
Most of the 3-month quitters reported using some form ofNRT: five of the intervention 
group reported using Nicorette patches provided by the study, one used Nicorette gum 
(also provided) and one participant purchased NiQuitin lozenges. With regard to the 
control group, one patient used Zyban, one used Nicotinelle patches, one Niquitin 
patches and one used Niquitin lozenges. Three participants from the intervention group 
and one from the control group reported no use of pharmacological aids in quitting. 
3.5.4 Secondary Outcomes at 3 Months 
Those participants who classified themselves as smokers three months after recruitment, 
were asked a number of questions about possible changes in their smoking behaviour. 
Questions covered included details about attempts at quitting, as well as reduction in 
smoking and changing to a low tar brand. Excluded from the analysis below is the one 
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intervention participant who was classified as a quitter on the basis of biochemical 
measurements. In addition, data were not collected from the 'deceiver'. 
3.5.4.1 Self-Reported Attempts at Quitting 
Participants were asked about whether they had had a quit attempt in the previous three 
months, and if so, how many. As can be seen from Table 3.36, 56% of the intervention 
group reported a quit attempt, compared to 43% of the control group. With respect to 
two or more quit attempts, one third (33%) of the intervention participants and 30% of 
the control group reported that they had tried to give up tobacco. Neither of these 
differences was statistically significant. 
With regard to length of quit attempt, 55% of the intervention group and 39% of the 
control group had attempted to quit for 24 hours or more. This difference was not 
statistically significant. When asking participants about a longer and more sustained 
quit attempt of at least one week, 37% of the intervention group and 18% of the control 
group reported a quit attempt of this duration. This difference was statistically 
significant. 
Table 3.36 Self Reported Quit Attempts (number and duration) of Participants 
at3 Months 
Number (%) of Participants Reporting Quit Attempts 
Quit attempts: All Intervention Control p-value 95% CI 
n=87 n=43 n=44 (I-C) 
In last 3 months 43 (49%) 24 (56%) 19 (43%) 0.235 (-8,34)% 
2 or more 27 (31%) 14 (33%) 13 (30%) 0.761 (-16,23)% 
24 hours or 40 (47%) 23 (55%) 17 (39%) 0.129 (-5,37)% 
more * 
1 week or more 24 (28%) 16 (37%) 8 (18%) 0.043 (1,37)% 
*This question was answered by 86 participants (42 Intervention, 44 Control) 
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3.5.4.2 Use of Nicotine Replacement Therapy in Participants Categorised 
as Non-Quitters at 3 Months 
With respect to the use of NR T in trial participants in the intervention group who were 
not categorised as quitters at 3 months, 15 tried patches and 9 used gum. 
No data were available on NRT use in the control group who did not report quitting at 3 
months. 
3.5.4.3 Changes in Smoking Behaviours 
Information was elicited relating to a number of other areas of behaviour related to 
smoking. 
Table 3.37 shows that a high number of intervention (93%) and control (86%) patients 
delayed smoking for greater than 5 minutes after waking. Few participants reported 
trying to modify their smoking behaviour by inhaling less of the cigarette smoke, with 
only 28% of the intervention group and 18% of the control group adopting this 
behaviour. With regard to smoking less of a cigarette, 56% of the intervention group 
took this action, compared to 45% of the control group. When asked about brand 
changing and switching to a low tar cigarette, 28% of the intervention group self-
reportedly did this, compared to 16% of the control group. 
There were no statistically significant differences with respect to any of the above 
changes in smoking behaviour, although the 95% confidence intervals are wide, and 
there is some evidence of the intervention groups performing better than those in the 
control group. 
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With respect to number of cigarettes smoked, 81 % of the intervention group reported 
they had reduced their intake, compared to 45% of the controls. This difference was of 
statistical significance (p<0.00 1). 
Table 3.37 Self-reported Changes in Smoking Behaviour at 3 Months 
Number (%) of Participants 
All Intervention Control p-value 95%CI 
n=87 n=43 n=44 (I-C) 
Delay Smoking 78 (90%) 40 (93%) 38 (86%) 0.303 (-6, 19)% 
for >5 min 
Inhale Less of a 21 (24%) 12 (28%) 9 (18%) 0.415 (-11,25)% 
Cigarette 
Smoke Less of a 44 (51%) 24 (56%) 20 (45%) 0.331 (-11,31)% 
Cigarette 
Changed to Low 19 (22%) 12 (28%) 7 (16%) 0.172 (-5,29)% 
Tar Cigarettes 
Reduced Number 55 (63%) 35 (81 %) 20 (45%) <0.001 (17,55)% 
of Cigarettes per 
Day 
When examining the self-reported percentage reduction in daily number of cigarettes 
(Table 3.38), the median reduction was 33% for the intervention group and 0% for the 
control group. This difference was statistically significant. 
Table 3.38 Percentage Self-Reported Reduction in Cigarette Intake at 3 Months 
All Intervention Control p-value 95%CI 
n=85 n=41 n=44 (I-C) 
Median 25 33 0 0.015 (0,25) 
IQ Range 0-49 20-50 0-38 
Ran2e 0-90 0-90 0-75 
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3.5.4.4 Relationship of Self-Reported Smoking Reduction in Cigarettes and 
Cotinine Levels at Baseline and 3 Months for Individual Participants 
Changes in cotinine measurements between baseline and 3 months were studied III 
relation to corresponding self-reported reductions in smoking levels. 
Levels of cotinine at baseline and 3 months were plotted for those participants who 
reported either a reduction or no reduction in smoking (Figure 3.9). Those participants 
who reported having reduced, did not always have a concomitant reduction in cotinine 
levels. 
Figure 3.9 Relationship of Self-Reported Reduction in Cigarettes and 
Cotinine levels at Baseline and 3 Months for Individual 
Participants 
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3.5.4.5 Relationship of Reduction in Cotinine Levels between Baseline and 
3 Months and Self-Reported Reduction in Cigarettes 
Figure 3.10 uses a boxplot to illustrate the relationship of change in cotinine (baseline 
level minus 3 month level) and self-reported reduction in cigarettes. There was a 
slightly higher mean reduction in cotinine, 39 (SO lOO)ng/ml in the group who did NOT 
report reducing their smoking (coded in blue), compared to a mean value of 18 (SD 
115)ng/ml in the group who reported reducing (coded in pink) (p=0.404, 95% CI 
(C-I)=(-29,70)nglml). 
Figure 3.10 Boxplot of Change in Cotinine Levels and Self-Reported 
Reduction in Cigarettes at 3 Months 
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3.5.4.6 3-Month Change in Cotinine Levels by Allocated Group 
Figure 3.11 illustrates the change in levels of cotinine between baseline and 3 months 
(baseline level minus 3 month level) in the two groups. A slightly higher mean 
reduction was seen in the control group (coded in green) (38 (SD I07)nglml), compared 
to the mean value of 29 (SD III )nglml in the intervention group (coded in red). There 
was no statistically significant difference in the reduction of cotinine between the 
intervention and control groups (p=O.713, 95% CI (C-I)=(-38, 55)ng/ml). 
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Figure 3.11 Boxplot of Change in Cotinine Levels by Allocated Group 
at 3 Months 
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3.5.5 Changes in Intention to Stop Smoking at 3 Months 
All participants were asked at baseline and at 3 months about whether they considered 
themselves to be 'contented smokers' , 'concerned smokers' or 'wanting to stop' . 
3.5.5.1 Shift in 'Stage of Change' for all Participants Between Baseline and 
3 Months 
Table 3.39 details the base line data for all the trial participants and the ' stages ' those 
participants self-reportedly held at three months. Those participants who made positive 
behaviour change and moved forward in the ' Cycle of Change' are coded in pink. Those 
participants for whom there was no change between baseline and 3 months are coded in 
blue. Some participants moved backwards in the cycle, i.e. reported being less likely to 
quit, and these are coded in green. 
Table 3.39 shows that 29 trial participants moved forward, with 14 quitting and 15 
reporting being more likely to quit at 3 months than at baseline. The majority of the 
trial participants (51 ) reported being in the same ' Stage of Change' at 3 months as they 
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had been at baseline. With regard to those who moved backwards in the cycle and 
reported being less likely to quit at 3 months, 20 individuals fitted this category. 
Table 3.39 Shift in 'Stage of Change' for All Participants at 3 Months 
Status at Status at 3 Months 
Baseline Contented Concerned Want to stop Quitter 
Contented 6 6 - 1 
Concerned 1 31 9 4 
Want to stop I 18 14 9 
No Change: blue Positive Change: pink Negative Change: green 
3.5.5.2 Shift in 'Stage of Change' for Intervention Group at 3 Months 
In Table 3.40, the position in the 'Cycle of Change' of the intervention participants at 3 
months, relative to baseline, is shown. Fourteen individuals moved forward, and were 
more likely to quit at 3 months (coded in pink), while seven individuals moved 
backwards in the cycle (coded in green). Twenty eight of the participants were in the 
same 'Stage of Change' at 3 months as at baseline (coded in blue). 
Table 3.40 Shift in 'Stage of Change' for Intervention Group at 3 Months 
Status at Status at 3 Months 
Baseline Contented Concerned Want to stop Quitter 
Contented 2 3 - -
Concerned 0 17 3 2 
Want to stop 0 7 9 6 
No Change: blue Positive Change: pink Negative Change: green 
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3.5.5.3 Shift in 'Stage of Change' for Control Group at 3 Months 
In the control group, there were 12 participants who made negative changes in the cycle, 
23 participants who stayed in the same place and 15 who moved forward in the 'Cycle 
of Change' (Table 3.41). 
Table 3.41 Shift in 'Stage of Change' for Control Group at 3 Months 
Status at Status at 3 Months 
Baseline Contented Concerned Want to stop Quitter 
Contented 4 " 1 
-' -
Concerned 1 14 6 2 
Want to stop 1 10 5 3 
No Change: blue Positive Change: pink Negative Change: green 
3.5.6 Number of Treatment Visits for Quitters and Non-Quitters at 3 Months 
The median number of visits between baseline and three months for quitters was 4.5 
(range 1-6), with the median number of visits for trial participants categorised as 
smokers at 3 months being 4.0 (range 2-7). 
3.6 Six Month Outcomes 
3.6.1 Patient Follow-ups 
Six-month data were obtained from 71 (61%) of the 116 participants registered at 
baseline. 
Table 3.42 shows the distribution of participants lost to the study ill both the 
intervention and control groups. 
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Table 3.42 Follow-up of Participants at 6 Months 
Intervention Control Total 
At baseline 59(51%) 57 (49%) 100% 
At 3 months 52 (88%) 50 (88%) 88% 
At 6 months 36(61%) 35 (61 %) 61% 
'Lost' to study at 23 (39%) 22 (39%) 39% 
6months 
Forty-five (39%) of the participants recruited at baseline were lost to follow-up at the 6 
month time period. The fall out rates for the intervention and control groups were very 
similar, with 23 (39%) and 22 (39%) of the participants lost to the two groups 
respecti vel y. 
Of the 45 individuals for whom it proved impossible to obtain 6 month data, the mean 
age was 40.3 years (SD 6.3) in the intervention group, compared to 42.0 (SD 8.0) in the 
control group. The median number of cigarettes smoked in the intervention and control 
groups was 20 (range 10-35) and 20 (range 10-40) respectively. With regard to pack-
years, the exposure in the control group was slightly higher with a mean value of 26.5 
(SD 14.2) compared to 22.4 (SD 10.5) in the intervention group. 
3.6.2 Number of Treatment Visits Between Baseline and 6 Months 
for All Participants 
The number of visits to the hygienist was collected for both intervention and control 
groups. For the intervention group, the median number of visits, between 3 and 6 
months, and baseline and 6 months, was 2 (range 0-5) and 6 (range 4-8) respectively. 
With regard to the control group, over the same time periods, the median number of 
visits was 2 (range 0-5) and 6 (range 3-8) respectively. 
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3.6.3 Primary Outcome at 6 Months 
3.6.3.1 Self-Reported Smoking Status 
At the six-month time point, participants were asked whether they considered 
themselves to be smokers. Table 3.43 shows that six participants (17%) in the 
intervention group and three (9%) in the control group described themselves as quitters. 
Table 3.43 Participants' Self Reported Smoking at 6 Months 
Are you a smoker? Intervention Control All 
No 6 (17%) 3 (9%) 9 (l3o/~ 
Yes 30 (83%) 32 (91 %) 62_(87%) 
Total 36 35 71 
There was no statistically significant difference between intervention and control group 
in terms of the proportion of participants self-reported as having quit (p-value=0.485, 
95% CI (I-C)=(-12, 34)%). It should be noted that the confidence interval is wide, and 
this interval may indicate a benefit in favour of the intervention group. 
3.6.3.2 Summary of Self-Reported Quitters at 6 Months including 
Biochemical Measures of Cotinine (COT) and Carbon Monoxide (CO) 
The information collected at the 6-month time point, was similar to that collected at 3 
months. Thus, in addition to self-reported measures recorded via questionnaires, 
samples of exhaled air and saliva were collected for CO and cotinine analysis 
respectively. 
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Table 3.44 summarises information from the trial participants who self-reported quitting 
and includes information on log number, allocated group, treating hygienist and 
biochemical measures of COT and CO, in addition to reported NRT use at time of 
sample collection. 
Table 3.44 Six Month Summary Table of Biochemical Measures (COT, CO) and 
Use of NRT at Time of Sampling for Self-Reported Quitters 
Log Allocation Hygienist COT CO NRT Use at time 
(ng/ml) (ppm) of sall!l!linA 
1 I Blue <2 1 no 
2 I Green <2 2 no 
39 I Red <2 2 no 
60 I Green 87 2 Patches (Nic) 
83 I Green 5.2 2 no 
103 I Blue <2 2 no 
21 C Red <2 1 no 
43 C Red <2 - no 
118 C Blue 38 1 Patches (NQ) 
Nic= Nicorette (brand ofNRT in patches or gum form, provided free in trial) 
N/eHe = NicotineHe 
NQ = Niquitin 
All hygienists had participants who claimed to have quit, both in the intervention and 
control groups. The Blue hygienist had two intervention and one control patient, the 
Green hygienist had three intervention patients and the Red hygienist had one 
intervention and two control patients who stopped smoking. 
One participant in each group claimed to be using NRT at the time of cotinine sampling 
(participants 60 and 118). Both had cotinine levels above the 20ng/ml cut-off, but low 
CO values. 
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3.6.3.3 Definitive Quitters as measured by Self-Report, Cotinine and CO Analysis 
at 6 Months 
Table 3.45 shows the categorisation of smoking status, taking into account all available 
evidence. The self-reporting quitters were all definitely classified as non-smokers, six 
intervention (16.7%) and three controls (8.6%). The use of biochemical validation did 
not change the classification of any of the participants' smoking status compared to the 
self-report. 
Table 3.45 Definitive Quitters as measured by Self-Report, Cotinine and 
CO analysis at 6 Months 
Log Number Self Report Cotinine CO Category 
1 ./ ./ ./ quitter 
2 ./ ./ ./ quitter 
39 ./ ./ ./ quitter 
60 ./ X ./ quitter 
83 ./ ./ ./ quitter 
103 ./ ./ ./ quitter 
21 ./ ./ ./ quitter 
43 ./ ./ 
-
quitter 
118 ./ X ./ quitter 
Blue=InterventlOn Purplc- Control 
Of the patients recruited at baseline, 6 (10.2%) in the intervention group were definitive 
quitters, compared to 3 (5.3%) in the control group. However, there was no significant 
difference between intervention and control group in terms of the proportion of 
participants self-reported as having quit (p-value=0.530, 95% CI (I-C)=(-8.5, 23 .6)%). 
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3.6.3.4 Prolonged Abstinence Measures at 6 Months 
With respect to prolonged abstinence measures, four of the intervention and three of the 
control were biochemically validated as quitters at 3 months (participant numbers 1, 2, 
83, 103, '; ,; ,,). 
Of patients followed-up, prolonged abstinence measures would indicate that 11.1 % in 
the intervention group had quit compared to 8.6% in the control group. 
When prolonged abstinence is considered in terms of all patients recruited to the study, 
the corresponding figures are 6.8% for the intervention group and 5.3% for the control 
group. 
3.6.3.5 Characteristics of Six Month Quitters 
As can be seen from Table 3.46 below, all of the quitters at 6 months were female. With 
respect to age, in the intervention group, five (out of six) were aged 37 or younger, with 
one quitter aged 53. In the control group, there was one participant in each of the mid-
life decades (32, 49, 54). 
With respect to DEPeAT, in the intervention group, five (out of six) were in the more 
affiuent DEPeAT 1-4, with one participant (103), from DEPeAT 5. In the control 
group, two out of three participants were from more affiuent DEPeAT 1-4, with one 
participant in DEPCA T 6. 
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Table 3.46 Demographic Descriptors of 6 Month Quitters 
Log Allocation Hygienist Sex DEPCAT Age 
1 I Blue F 3 53 
2 I Green F 4 28 
39 I Red F 3 33 
60 I Green F 4 37 
83 I Green F 1 35 
103 I Blue F 5 38 
21 C Red F 6 32 
43 C Red F 4 54 
I 18 C Blue F I 49 
With respect to tobacco exposure at baseline as measured by cigarettes per day, in the 
intervention group, quitters were more likely to be moderate or light smokers, with four 
out of six smoking 15 or less, one smoking 25 and one smoking 40 per day (Table 
3.47). When looking at the intervention group's nicotine dependence as measured by 
the FTND, two quitters scored 4 or below indicating low dependence, and four scored 6 
or above, indicating high or very high dependence. 
With regards to the three control group quitters, the numbers of cigarettes smoked per 
day at baseline were 18, 20 and 30. This resulted in heterogeneity amongst their 
nicotine categorisation as measured by FTND, with one participant each of low, 
medium and high dependence. 
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Table 3.47 Smoking History, Physiological Dependency & Intention to Quit 
at Baseline of6 Month Quitters 
Log Allocation Cigs per Years Pack- FTND Motivation Stage of 
day Smoked Years to Quit ChanAe 
1 I 40 37 74 8 8 3 
2 I 15 10 7.5 6 8 2 
39 I 10 16 8 0 7 2 
60 I 25 17 21 6 8 3 
83 I 15 20 15 6 8 3 
103 I 10 22 11 4 6 3 
21 ( 30 18 27 7 5 1 
43 ( 20 38 38 4 6 2 
118 ( 18 33 30 5 7 3 
Concerning years smoked, in the intervention group, five out of six had smoked 
previously for between 10 and 22 years, with one smoking for 37 years. With respect to 
pack-years, five out of six had baseline levels between 7.5 and 21 pack-years, with one 
participant having an exposure of74 pack-years. 
The control group quitters had a higher baseline smoking exposure than those from the 
intervention group, with the former participants having smoked for 18, 30 and 33 years, 
which translates into 27, 30 and 38 pack-years. 
With regards to 'Stage of Change' at baseline, four out of the six intervention group 
quitters were category 3 (want to stop) with four also scoring 8 on the Motivation Scale 
at baseline. There was more heterogeneity amongst the control group, with one in each 
stage and the three scores on the Motivation Scale being 5, 6 and 7. 
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3.6.3.6 Self-Reported Pharmacological Use in Quitters at 6 Months 
Table 3.48 shows reported use of pharmacological support, including NRT and Zyban, 
by those participants biochemically validated as quitters at 6 months. 
Table 3.48 Use of Nicotine Replacement Therapy by Quitters (6 Months) 
Log Allocation Hygienist NRTor Zyban 
use 
1 I Blue Patches(Nic) 
2 I Green Patches(Nic) 
39 I Red Patches(Nic) 
60 I Green Patches(Nic) 
83 I Green Patches(Nic) 
103 I Blue Patches(Nic) 
21 C Red Zyban 
43 C Red Patches(N/elle) 
118 C Blue Patches(NQ) 
N ic= Nicorette (brand ofNRT in patches or gum form, provided free in trial) 
N/e lle = Nicotinelle 
NQ = N iquitin 
All reported using some form of pharmacological support in quitting. Eight of the nine 
quitters used patches of some kind and one participant used Zyban. All intervention 
quitters reported using Nicorette patches which were given free of charge by the 
hygienists working on the trial. Of the patients in the control group, one reported Zyban 
use, one reported use of Nicotinelle patches and one reported use ofNiquitin patches. 
One participant (83) had changed their method of nicotine replacement therapy: at the 
3-month mark this individual reported using lozenges (Niquitin), whereas at the 6-
month point, Nicorette patches were being used. 
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3.6.3.7 Trial Participants who Relapsed Back to Smoking 
Table 3.49 summarises the data obtained from the six participants who self-reported and 
were biochemically validated as having quit at 3 months, and who reported relapsing at 
6 months. Most subjects who reported smoking again had cotinine levels above the cut-
off point. None of the subjects reported NRT use. One subject had a low level of 
cotinine (around 20ng/ml) with a CO value of9ppm, both borderline values in assessing 
smoking status. Another had low cotinine, 21 ng/mJ, with a higher CO of 13. 
Information was also collected on the participants' number of cigarettes, and a number 
report smoking at low levels (below 10 per day). 
Table 3.49 Relapsers at 6 Months (participants who at 3 months had quit, 
and now report smoking again) 
Log Allocation Hygienist Self COT CO NRT Use at 
report (ng/mt) (ppm) time of 
sampling 
36 I Red S 95 6 no 
81 I Blue S 143 19 no 
82 C Blue S 170 3 no 
86 I Blue S 20 9 no 
50 I Red S 74 3 no 
113 I Blue S 21 13 no 
3.6.4 Secondary Outcomes at 6 Months 
Those participants who classified themselves as smokers six months after recruitment, 
were asked a number of questions about possible changes in their smoking behaviour. 
Questions covered included details about attempts at quitting, as well as reduction in 
smoking and changing to a low tar brand. 
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3.6.4.1 Self-Reported Attempts at Quitting 
When looking at quit attempts between 3 and 6 months, Table 3.50 shows that 83% of 
the intervention group reported at least one attempt, compared to 56% of the control 
group. This result was of statistical significance. Forty three percent of the intervention 
participants and 28% of the control group reported two or more quit attempts. The 
difference was not statistically significant. 
With regard to the duration of quit attempt, 60% and 47% of the intervention and 
controls respectively had abstained for 24 hours or more. This difference was not 
statistically significant. However, when asking participants about a longer and more 
sustained quit attempt of one week or more, a significant difference was seen, with 47% 
and 16% of the intervention and control groups respectively, reporting a quit attempt of 
this duration. 
Table 3.50 Self Reported Quit Attempts - Number and Duration at 6 Months 
Number (%) ofPartic!pants R~porting Quit Attempts 
Quit attempts: All Intervention Control p-value 95%CI 
n=62 n=30 n=32 JI-C) 
In last 3 months 43 (69%) 25 (830/01 18 (56%) 0.033 J3,53)% 
2 or more 22 (35%) 131430/01 9 (28%) 0.260 i-ll,41)% 
24 hours or more 33 (53%) 18 (60%) 15 -<47%) 0.330 i-13, 40)% 
1 week or more 19 (31%) 14 (47%) 5 (16%) 0.018 16,56)% 
3.6.4.2 Changes in Smoking Behaviour 
Table 3.51 indicates that a high number of intervention (93%) and control (81%) 
participants delayed smoking for greater than 5 minutes. A relatively small number of 
participants reported inhaling less (23% of the intervention group and 16% of the 
control group). With regard to smoking less of a cigarette, 47% of the intervention 
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group took this action, compared to 41 % of the control group. When asked about brand 
changing and using a low tar cigarette, 40% of the intervention group self-reported 
taking this action, compared to 28% of the control group. 
There were no statistically significant differences with respect to any of the above 
changes in smoking behaviour. The 95% confidence intervals are wide, and there is 
some evidence of the intervention group faring better than control. 
With respect to asking participants whether they reduced their number of cigarettes, 
67% of the intervention group reported they had reduced their intake, compared to 56% 
of the control group. This difference was not statistically significant. 
Table 3.51 Changes in Smoking Behaviour for Participants at 6 Months 
Number (%) of Participants 
All Intervention Control p-value 95% CI 
n=61 n=30 n=32 (I-CJ 
Delay Smoking 54 (87%) 28 (93%) 26 (81 %) 0.380 (-10,38)% 
for >5 min 
Inhale Less of a 12 (19%) 7 (23%) 5 (16%) 0.546 (-17,35)% 
Cigarette 
Smoke Less of a 27 (44%) 14 (47%) 
Cigarette 
13 (41 %) 0.688 (-20,34)% 
Changed to Low 21 (34%) 12 (40%) 
Tar Cigarettes 
9 (28%) 0.386 (-14,38)% 
Reduced Number 38 (61%) 20 (67%) 
of Cigarettes per 
18 (56%) 0.430 (-14,38)% 
Day 
However, the median self-reported percentage reduction in cigarette intake was 45% for 
the intervention group and 22.5% for the control group. This was statistically 
significant (Table 3.52). 
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Table 3.52 Percentage Reduction in Cigarette Intake for Participants at 6 Months 
All Intervention Control p-value 95%CI 
n=50 n=26 n=24 (I-C) 
Median 27.0 45.0 22.5 0.005 (4,33)% 
IQ Range 0.0-50.0 18.8-61.5 0.0-32.0 
Range 0-90 0-90 0-50 
3.6.4.3 Relationship of Self-Reported Smoking Reduction in Cigarettes and 
Cotinine Levels at Baseline and 6 Months for Individual Participants 
Figure 3.12 shows levels of cotinine at baseline and at 6 months, plotted for those who 
did and did not report having reduced smoking. As was previously seen at the 3-month 
time point, not all of those who reported reducing smoking showed a concomitant 
reduction in cotinine levels. 
Figure 3.12 Relationship of Self-Reported Reduction in Cigarettes and 
Cotinine Levels for Individual Participants at Baseline 
and 6 Months 
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3.6.4.4 Relationship of Change in Cotinine Levels between Baseline and 6 Months 
and Self-Reported Reduction in Cigarettes 
Figure 3.1 3 illustrates the average reduction in cotinine levels for those who reported 
reducing smoking (coded in blue) and those who did not (coded in pink). A significantly 
higher mean reduction, 61 (SD 90)ng/ml, was seen in the group who reported reducing 
their number of cigarettes smoked, compared to the group who did not report reducing 
their smoking (2 (SD 11 4 )ng/ml); (p=O.040, 95% CI (I-C)=(3 , 1 14)ng/rnJ). 
Figure 3.13 Boxplot of Cotinine Levels and Self-Reported Reduction in 
Cigarettes at 6 Months 
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3.6.4.5 Six Month Reduction in Cotinine Levels by Allocated Group 
When looking at the mean reduction in cotinine levels for both intervention and control 
groups (Figure 3.14), a slightly higher mean reduction was seen in the control group 
(coded in green: 48 (SD 111 )ng/rnI), than in the intervention group (coded in red: 28 
(SD 95)ng/rnI). There was no statistically significant difference between intervention 
and control groups (p=0.454, 95% CI (C-I)=(-33,72)ng/rnI). 
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Figure 3.14 Boxplot of Change in Cotinine Levels by Allocated Group 
at 6 Months 
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3.6.5 Changes of Intention to Stop and Stay Stopped at 6 Months 
All participants, i.e. quitters and non-quitters, were asked at baseline, 3 and 6 months 
about whether they considered themselves to be ' contented smokers', ' concerned 
smokers' or 'wanting to stop' . 
3.6.5.1 'Stage of Change'- All Participants at 6 Months 
Table 3.53 details the baseline measurements of all trial participants and the 'stages' 
these participants held at 6-months. In addition to the categories of 'contented smoker', 
'concerned smoker' (want to quit in the next 6 months) 'want to stop' and 'quitter', 
additional categories are shown relating to 'maintainers' (those smokers who were 
quitters at both 3 and 6 months) and ' relapsers' (those smokers who were quitters at 3 
months but had returned to smoking by 6 months). 
Those participants who made positive behaviour change and moved forward in the 
'Cycle of Change' are coded in pink. Those participants for whom there was no change 
between baseline and six months are coded in blue. Some participants moved 
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backwards in the cycle and reported being less likely to quit and these are coded in 
green. 
Table 3.53 Shift in 'Stage of Change' for All Participants between Baseline 
and 6 Months 
Status at Status at 6 months 
Baseline Contented Concerned Want to Quitter Maintenance Relapse 
Stop 
Contented 5 4 - - 1 
Concerned 19 7 1 2 , -. 
Want to 6 1 4 -I 
Stop 
As can be seen from Table 3.53 for all trial participants, 20 individuals moved forwards 
in the 'Cycle of Change' (coded in pink), either by reporting being more likely to quit, 
or quitting and maintaining their quit attempt. With regards to moving backwards in the 
'Cycle of Change' (coded in green), there were 21 individuals who either reported being 
less likely to quit or relapsed. Thirty individuals made no change between baseline and 
6 months. 
3.6.5.2 Shift in 'Stage of Change' for Intervention Group at 6 Months 
Table 3.54 shows changes in position of the 'Cycle of Change' for those participants in 
the intervention group. There were 13 participants who moved forward (coded in pink) 
and either reported being more likely to quit, or quit and maintained their quit attempt. 
Twelve individuals moved backwards in the 'Cycle of Change', either by reporting 
being less ready to quit at 6 months, than at baseline or by relapsing. With respect to 
making no changes between baseline and 6 months, there were 11 individuals in this 
category (coded in blue). 
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Table 3.54 Shift in 'Stage of Change' for Intervention Group at 6 Months 
Status at Status at 6 months 
Baseline Contented Concerned Want to Quitter Maintenance Relapse 
Stop (action) 
Contented 1 3 - - - 0 
Concerned .., 7 4 I I I 
-' 
Want to 0 5 3 I 3 3 
Stop 
3.6.5.3 Shift in 'Stage of Change' for Control Group at 6 Months 
Table 3.55 shows the changes for the control group. Seven individuals reported moving 
forwards in the cycle, nine moved backwards and 19 participants made no change. 
Table 3.55 Shift in 'Stage of Change' for Control Group at 6 Months 
Status at Status at 6 months 
Baseline Contented Concerned Want to Quitter Maintenance Relapse 
Stop (action) 
Contented 4 1 - - I 
Concerned 0 12 3 - 1 1 
Want to 1 6 3 - 1 1 
Stop 
3.6.6 Number of Treatment Visits for Quitters and Non-Quitters at 6 Months 
The median number of visits for quitters at 6 months was 7 (range 6-8), while the 
median number of visits for trial participants categorised as smokers at 6 months was 6 
(range 1-8). 
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3.7 One Year Outcomes 
Trial participants were followed-up at the one-year mark, by telephone interviews in the 
first instance. If contact was unsuccessful, a short postal questionnaire was sent to their 
home address. 
If the individual claimed to have stopped smoking, a request was sent out by post for a 
sample of the patient's saliva for cotinine analysis. 
3.7.1 Follow-up of Participants at all Time Periods 
Table 3.56 details the number of participants followed up at the different time periods. 
Table 3.56 Comparison of Follow-up of Participants at all Time Periods 
Intervention Control Total 
At baseline 59 (51%) 57 (49%) 116 (100%) 
At 3 months 52 (88%) 50 (88%) 102 (88%) 
At 6 months 36 (61 %) 35 (61 %) 71 (61%) 
At 1 year 33 (56%) 23 (400/01 56 (48%) 
As the time period increased from baseline, the response rate diminished. At the one 
year point, contact was established with 56 (48%) of the original trial participants. At 
this time, information was collected from more individuals in the intervention group 
(56%) than in the control group (40%). 
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3.7.2 Details of Patient Contacts 
Information on the type of contact established and any barriers to follow-up, are detailed 
in Table 3.57. 
Table 3.57 Follow-ups of Participants at 1 Year 
Telephone contact with patient 36 (31%) 
Postal contact established with patient 20 (18%) 
Patient details incorrect 10 (8%) 
Patient wants no contact 7 (6%) 
No contact established 42 (36%) 
Telephone contact was established with 36 of the original trial participants, and postal 
contact was made with a further 20 individuals. Incorrect patient details and patients 
wanting no further contact accounted for a further 17 individuals. Attempts were made 
to obtain postal information from the remaining 42 trial participants, and no information 
was returned from the individuals concerned. 
3.7.3 Primary Outcomes at One Year 
Participants were asked whether they considered themselves to be smokers or not. In 
Table 3.58, the results of the self-reported quitters are displayed. 
Table 3.58 Participants' Self Reported Smoking at 1 Year 
Are you a smoker? Intervention Control All 
No 7 (21%) 3 (13%) 10 (18%) 
Yes 26 (79%) 20 (87%) 46 (82%) 
Total 33 23 56 
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The self-reported seven and three quitters represented quit rates of ] 2% and 5% of the 
intervention and control patients recruited respectively. However, the difference 
between intervention and control in terms of the proportion of participants reporting as 
having quit did not reach statistical significance (p=0.411, 95% CI (I-C)=(-7, 25)%). 
As discussed there was no collection of CO values, but those respondents who claimed 
to have quit were asked for postal cotinine. The results of this can be seen in Table 3.59. 
Table 3.59 One Year Summary Table of Biochemical Measure (COT) and 
Use of NRT at time of sampling for Self-Reported Quitters 
Log Allocation Hygienist Self COT NRT Use at 
report (ng/ml) time of 
sampling 
1 I Blue NS <2 no 
13 I Green NS <2 no 
15 I Blue NS none no 
38 I Green NS 373 no 
39 I Red NS <2 no 
52 I Green NS <2 no 
103 I Blue NS none no 
20 C Green NS 385 no 
21 C Red NS <2 no 
43 C Red NS <2 no 
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Trial participants 1, 103, 21 and 43 were quitters at 3 and 6 months also, with 
participant 39 being a quitter by 6 months. Participant 38 was a ' recent' quitter, i.e. 
within the last 6 months. Patients who did not provide samples for biochemical 
verification were deemed to be smoking again. 
Cotinine salivary samples were received from eight out of the ten self-reported quitters. 
Cotinine measurements confirmed that six of these individuals were non-smokers 
(Table 3.59). Participant 20 during the telephone interview described themself as a 
quitter, but by the time the postal cotinine had arrived, this individual was smoking 
again. Participant 38 would appear to be a 'deceiver'. None of the trial participants 
reported on NRT use at the one-year time point. 
Table 3.60 Definitive Quitters as measured by Self-Report and Cotinine 
at 1 Year 
Log Number Allocated Self Report Cotinine Category 
Group 
1 I ./ ./ quitter 
13 I ./ ./ quitter 
39 I ./ ./ quitter 
52 I ./ ./ quitter 
21 C ./ ./ quitter 
43 C ./ ./ quitter 
Blue- Intervention Purple= Control 
In summary, on the basis of biochemical verification, data were available for 8 
individuals, which confirmed 4 intervention and 2 control participants to have quit 
smoking (Table 3.60). 
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Therefore, of the patients followed-up, this results in a quit rate of 12.1 %, compared to 
8.7% in the control group. The difference between intervention and control groups was 
not statistically significant (p=0.798, 9S%CI (I-C)=(-21.0, 32.0)%). 
Of the patients recruited at baseline, the four and two definitive quitters represented quit 
rates of 6.8% and 3.S% of the intervention and control patients recruited respectively. 
However, the difference between intervention and control groups, in terms of the 
proportion of participants defined as having quit, did not reach statistical significance 
(p=0.669, 9S% CI (I-C)=(-9.0, 21.S)%). 
3.7.4 Information from Smokers 
Participants were asked, if they smoked, whether they considered themselves to be 
occasional or regular smokers. All 46 smokers who replied consider themselves to be 
regular smokers. When asked if they had tried any further quit attempts or felt more 
able to try again, 24 smokers (1S intervention and 9 control) replied in the affirmative. 
When asked about why they smoked at least as much as they did a year ago a number of 
explanations were given. The results are listed in Table 3.61. 
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Table 3.61 Reasons for Not Quitting by Participants Still Smoking at 1 Year 
Wasn't ready to give up 2 
Related to stress 9 
Patches didn't work 0 
Too hard to give up 12 
Changed my mind 0 
Individual problems Icircumstances 21 
• habit 11 
• enjoyment 3 
• boredom 2 
• addiction 1 
• lack of willpower 1 
• don't want to 1 
• stressful domestic situation l' 
• routine 1 
Number of responses = 44 
187 
Chapter 4 Discussion 
4.1 Introduction 
The discussion of the body of work concerning the use of cotinine is to be found in 
Chapter 2. In this chapter, the main findings relating to the smoking cessation trial 
detailed in Chapter 3 are discussed. 
In the initial section below, the theme of smoking cessation has been placed in the 
overall context of tobacco control measures. In the second section, methodological 
issues relating to the trial design are discussed. The findings of the study are then 
examined and compared with previous work. In the last sections, the implications of this 
body of work, including its limitations will be discussed. 
4.2 Background 
As previously mentioned, smoking cessation is but one small part, albeit an important 
one, of the whole tobacco control agenda. Other measures include reducing the demand 
for tobacco products through prevention, and addressing the issues of environmental 
tobacco smoke, through enabling the legislative and public health agenda. 
Comprehensive bans and restrictions on advertising, together with legislation relating to 
the packaging and labelling of cigarettes, are also important in controlling tobacco use 
(Jamrozik, 2004). Currently in Scotland, the focus is very much on environmental 
smoke issues, with the Scottish Parliament currently conSUlting on a widespread, or 
more restricted, smoking ban in public places (Scottish Executive, 2004b). 
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Smoking cessation is, however, still seen as an important area within this overall agenda 
and, in Scotland, there is to be increased funding and expansion of such services 
(Scottish Executive, 2004a). 
Smoking cessation and its delivery is a complex issue. With the rise in the number of 
specialist smoking cessation services in both England and Scotland, this presents a 
number of service delivery possibilities with respect to smoking cessation. Issues 
relating to the role of dental team members, and the various options of how matters can 
be taken forward, are discussed in Section 4.5. 
4.3 Methodological Issues 
4.3.1 Design of Trial and Sample Size calculation 
There has been limited research in the UK regarding smoking cessation in the dental 
setting, especially utilising a randomised controlled trial design (RCT). This was the 
methodology of choice for the study reported here. Typically, RCTs seek to measure 
and compare different events that are present or absent after the participants receive the 
interventions (Jadad, 1998). 
Usually, one of the interventions is regarded as a standard of comparison or control. The 
control can be conventional practice, a placebo, or no intervention at all. In the case of 
this trial, all participants received at their first visit both verbal information about the 
role smoking plays in periodontal disease, and 'very brief advice' to quit from the 
consultants as part of standard clinical care. In addition, all patients registered on the 
trial received an information sheet. Therefore, the control group were subject to some 
advice, albeit 'very brief, from the consultants at their first appointment. In summary, 
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the intervention group received advice and help in the form of the SAs and the offer of 
free NRT, whereas the control group received 'usual care', as detailed above. 
With regards to the other previously reported dental smoking cessation studies, in the 
Macgregor trial (1996) participants were systematically allocated to either the 
intervention or control group (Le. using alternate allocation). The trial of Smith et al. 
(1998) did not use an RCT design and all participants were given the same intervention. 
The largest RCT of dental hygienists and smoking cessation was by Severson et al. 
(1998) in which, after stratification by size of practice (as defined by number of hygiene 
visits/week) and number of years the dentist was in practice, the dental practices were 
then randomly allocated to one of three groups, 'usual care', 'minimal' or 'extended' 
intervention. The trial of Cohen et al. (1989) randomly allocated private dental 
practices to one of four groups 'control', 'reminder', 'gum' or 'reminder and gum'. 
There was no uniformity in the studies outlined above, with regard to the definition of 
control group. In the trial by Severson and co-workers (1998), the control leg meant 
'usual care', where dentists and hygienists were free to use their clinical judgement, and 
some of the patients may have received some smoking information. In contrast, in the 
trial by Macgregor (1996), the participants in the control phase received no smoking 
cessation advice at all. 
With respect to sample size calculation, this was based on secondary outcomes as 
outlined in Chapter 3. In terms of the primary outcome, to detect, for example, a 10% 
difference between groups with 80% power, would have required the follow-up of at 
least 160 patients in each group. Audit figures for the Periodontology Department in 
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2000 suggested that there would have been approximately 275 suitable patients per 
year. Therefore to recruit approximately 350 patients, would have required a 
recruitment period of at least 30 months, which was not considered feasible within the 
time constraints of this PhD. Therefore, the sample size calculation was based on the 
secondary outcome of reduction in number of cigarettes. Again, assuming that half of 
the suitable patients were recruited, a recruitment period of approximately one year was 
envisaged. The recruitment period for this trial actually lasted 16 months. 
None of the other reported smoking cessation trials within the dental setting reported 
sample size calculations. 
4.3.2 Choice of Intervention - 5As 
The 5As approach to smoking cessation was selected as the intervention of choice for a 
number of reasons. Firstly, when this trial was planned in 2000/2001, the methodology 
recommended for delivering smoking cessation advice in primary care in Scotland was 
the 5As (Health Education Board for Scotland and ASH Scotland, 2001). This guidance 
had, in turn, been influenced by the American Guidelines for health professionals (Fiore 
et al., 2000). This latter body of work was subsequently reflected in the approach 
adopted in the delivery of smoking cessation in a number of settings in the USA and 
Australia (Litt, 2002; Solberg et al., 2002). There is also recent evidence of the 5As 
being used with patients in various settings, including primary and secondary care (Litt, 
2002; Solberg et al., 2002) and with several groups, including pregnant women and 
asthmatic patients. In addition, the only smoking cessation trial in the UK in general 
dental practice had used a precursor approach, known as the 4As (Smith et a/., 1998). 
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An advantage of the SAs approach to the delivery of smoking cessation advice is that 
there is a structure to the methodology which makes it relatively easy to teach to health 
professionals, such as dentists and hygienists, for whom it is now recognised that 
smoking cessation is one of their responsibilities, in addition to their standard clinical 
care. 
Other methodologies are available for delivering smoking cessation advice, such as 
motivational interviewing or the use of a 'stage-matched' intervention such as 'Pro-
change' (University of Rhode Island, 1997). In this latter programme, information is 
given to the trial participant depending on an assessment of the individual's 'Stage of 
Change'. This programme has been designed for use in primary care, and has proved 
very popular for use in UK pharmacies (Anderson and Mair, 2000). 
Both of the above methodologies were briefly considered, but discounted for use in this 
trial. The motivational interviewing was thought to be too time-consuming to undertake 
in this setting, and the 'Pro-change' programme was considered to be untried for use by 
dental staff. 
Therefore, the SAs was selected as the most appropriate methodology, for use by dental 
hygienists in this particular setting, for reasons relating to time and ease of use. 
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4.3.3 Choice of Baseline Data Collection 
4.3.3.1 Choice of Biographical Data 
Patient data collected included age, occupation and postcode (to enable categorisation of 
DEPCAT). As the sample was overwhelmingly female (71%) and the patients' 
description of their job title did not easily translate into a category for use by the 
Registrar General's Classification, it was decided to use the Carstairs DEPCAT Index as 
the reported socio-economic indicator. A DEPCAT Score was obtained for all patients 
from postcode sector data. Patients' telephone numbers and addresses were also 
recorded to allow follow-up contacts to be made. 
4.3.3.2 Choice of Nicotine Dependence Measures 
In attempting to determine a patient's nicotine dependence, three composite measures 
were collected; Heaviness o/Smoking Index (2 questions), Fagerstrom Test/or Nicotine 
Dependence (6 questions) and Fagerstrom Tolerance Questionnaire (8 questions). 
The most commonly used index is the FTND, and the briefest one the Heaviness 0/ 
Smoking Index (Heatherton et al., 1991). With respect to the Fagerstrom Tolerance 
Questionnaire, the present study found there was little advantage obtained from asking 
the two additional questions concerning the brand and type of cigarette, and level of 
inhalation. Although patients were able to detail their brand of cigarette, often 
insufficient information was given to allow determination of the level of nicotine of 
their chosen cigarette. In addition, as all participants recruited at baseline inhaled 
smoke, there was very little variation accounted for by this question. 
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The indices of choice with regards to research and evaluation of smoking cessation 
programmes would appear to be the Heaviness of Smoking Index for brevity, and the 
FTND for more detailed information (Heatherton et a/., 1991). In Scotland, the 
specialist smoking cessation services are presently collecting information based on the 
Heaviness of Smoking Index (PATH, 2003). 
4.3.3.3 Choice of Motivation to Quit Measures 
Two motivation to quit measures were used, the Motivation Index by Foulds (1996) and 
a modified form of' Stage of Change', which was influenced by the work of Prochaska 
and DiClemente (1983, 1993). 
While there is much uniformity amongst researchers when using the FTND (Hetherton 
et al., 1991), there is some variation in the questionnaires used relating to the' Stage of 
Change', particularly when categorising trial participants to the various stages. 
Additionally, researchers sometimes use different terms for the same stages, for 
example, 'precontemplators' can be known as 'not interested in quitting', 
'contemplators' can be known as 'interested in quitting (within the next 6 months)', and 
those in the 'preparation' stage can be known as 'want to stop (within the next month)'. 
In addition to the differing terminology, the definition of the stages can vary, 
particularly with the 'preparation' stage. A number of researchers define those 
individuals as being in the 'preparation' stage if they want to quit within one month and 
have had a quit attempt in the last year (prochaska and DiClemente, 1983; Prochaska 
and Velicer, 1997; Etter et a/., 2003). Others, however, define the 'preparation' stage 
solely as wanting to quit within the next month (Foulds, 1996; Butler et a/., 1999; 
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Hughes et al., 2000; Etter and Pemeger, 2001). This latter interpretation is the version 
that was used in this trial. Utilising only the time frame for intention to quit enables a 
more standardised approach to be taken when categorising intention to quit at 3 and 6 
months, therefore enabling movement in the 'Stage of Change' to be monitored. 
Other researchers have changed the timeframe associated with the definitions of 
'contemplator' and 'preparation' stages. Rohren and co-workers (1994) shortened the 
timeframe for classification of 'contemplator' from 6 months to one month, and 
produced their own definition of the various stages. Donovan et al. (1998) changed the 
timeframe for 'preparation' to a fortnight, rather than a month. Thus, when making 
comparisons between different studies involving 'Stage of Change', the degree of 
variation that may exist between the measures used has to be borne in mind. 
4.3.3.4 Choice of Nicotine Exposure Measurements 
With respect to lifetime exposure to nicotine, patients were asked how many years that 
they had smoked, and together with the information obtained relating to the number of 
cigarettes per day, lifetime exposure in the form of pack-years was calculated. 
Pack-years, in addition to other questionnaire-derived data, can be subject to bias due to 
the nature of its collection, i.e. self-report (Scott et al., 2001). Additionally, the pack-
years measure gives an estimate of lifetime exposure based on current tobacco use and 
does not take into account the fact that individuals may have varied their smoking 
behaviour over time. However, pack-years is the only measure that is currently used as 
an indicator of lifetime exposure, and as such, is used in respiratory (Patel et al., 2004) 
coronary (Chambless et al., 2003) and periodontal research (Chen et al., 2001). 
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4.3.3.5 Use of Biochemical Monitoring including Cotinine and Carbon Monoxide 
It was decided to use both carbon monoxide and cotinine as a means of biochemical 
validation. It is known that cotinine measurement is more accurate with respect to 
detecting exposure to tobacco smoke over a longer time frame than carbon monoxide 
(SRNT Subcommittee on Biochemical Verification, 2002). In relation to this former 
indicator, previous work (as detailed in Chapter 2) had refined the method of sample 
collection and validated the analysis using the EIA kits, as there had been very little 
previous research carried out in the UK using this cotinine assay. Smith et al. (1998) did 
use salivary cotinine samples for validating the tobacco exposure of the dental patients 
recruited to their trial, but the method of analysis was gas chromatography. 
In Chapter 2, differentiation between smokers and non-smokers was straightforward, 
with patients being recruited either as a smoker and non-smoker, and cotinine being 
used to determine their daily exposure to nicotine. When cotinine is being used with 
smokers as a means of biochemical verification, particularly during or after a quit 
attempt, the picture was more complex. It was part of the recruitment criteria, that 
participants had to smoke at least 10 a day, and all recruits reported at least this 
exposure. At 3 months, it was in some cases difficult to categorise individuals into 
quitters or non-quitters, firstly due to some participants being 'light smokers' and 
secondly due to the use ofNRT at this time point. 
With respect to the CO monitoring, two carbon monoxide monitors were lent to the 
project, free-of-charge by Smoking Concerns (NHS Greater Glasgow). CO readings 
were taken at every visit for participants in the intervention group, as a motivational 
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tool, to encourage those smokers who had not quit, as well as a means of reinforcement 
for those individuals in the process of quitting. 
In addition, CO was also measured at the time points used for cotinine sampling. This 
enabled a comparison of the two measures of determining smoking exposure, and the 
preliminary findings of this accessory body of work was the subject of a research 
abstract and is included in Appendix 13. As this strand of research was not included in 
Chapter 3, which focuses on the efficacy of the smoking cessation trial with respect to 
primary and secondary outcomes, it will not be discussed further. 
Most of smoking cessation work, including the national evaluations of specialist 
smoking cessation services, is validated by the use of CO, rather than cotinine, because 
of resource implications. Additionally, CO being non-nicotinic, is of use in validating 
smoking cessation in the presence ofNRT, and was used in this way, within this trial. 
Some researchers dismiss the use of biochemical monitoring, and rely purely on self-
report (Sinclair et aI., 1998; Butler el al., 1999). The reasoning behind this is that they 
feel the 'deceivers' obtained using this methodology are few in number and the 
economic costs, particularly in relation to staff time, do not justify its use. 
However, it can be argued that use of biochemical validation provides a more complete 
picture, and it is firmly recommended in the position paper by the Society for Research 
on Nicotine and Tobacco (SRNT Subcommittee on Biochemical Verification, 2002). As 
detailed in Chapter 2, the half-life of cotinine is around 20 hours, and can detect an 
individual who has smoked within the past week. Therefore there is a recommendation 
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that a period of seven days is used to assess compliance with non-smoking in most 
studies, and to ensure that there are no false positives (SRNT Subcommittee on 
Biochemical Verification, 2002). 
It could be postulated that the explicit use of biochemical monitoring helps reduce the 
number who attempt to give false information. In this project, one 'deceiver' was 
detected at three months. Additionally, at one year, two individuals were identified who 
described themselves as non-smokers, but cotinine levels verified that this was not the 
case. The Smith trial also detected two deceivers (Smith et al., 1998). 
One study where there was a noticeable difference between self-report and 
biochemically validated status was the Scottish Health Survey in 1998 (Shaw et al., 
2000). According to the information sheet issued to trial participants, these individuals 
did not know that their salivary samples were to be used to measure tobacco exposure. 
There was an under-reporting of prevalence of smoking, especially by males, and this 
was most marked in the younger age-group (9% under-reporting in the 16-24 year age 
group). 
Additionally, Velicer et al., (1992) reported that in medical settings, such as those 
involving patients with heart disease or pregnant women, the difference between self-
reported quitting and biochemical verification of quitting could be as high as 13%. 
These results clearly show the importance of biochemical validation. Therefore, to 
evaluate smoking cessation more accurately, it is essential that some form of 
biochemical validation is used. Of the two methodologies, cotinine is the validator of 
198 
choice because of its long half-life (Jarvis et al., 1987). However, if patients are using 
NRT, CO monitoring can be useful. One newer means of biochemical verification 
involving cotinine is the use of the near-patient test (Cope et ai., 2000). Further work 
using this technique is required to fully develop its potential. 
4.3.3.6 Choice of Measures of Abstinence in Smoking Cessation Trials 
There are a number of measures that can be used to detennine smoking cessation rates 
at follow-up including point prevalence, prolonged abstinence and continuous 
abstinence. Several papers have discussed the uses of these measures in detail (Velicer 
et al., 1992; Hughes et al., 2002; Hughes et ai., 2003; Velicer and Prochaska, 2004). 
In this trial, the measure of point prevalence was used, with prolonged abstinence 
measures also reported for 6-month outcomes. 
Within the dental literature, there is little use of continuous abstinence measures, with 
most studies reporting point prevalence measures (Secker-Walker et al., 1988; 
Macgregor, 1996; Smith et ai., 1998). One trial reported that they used sustained 
abstinence, with smokers reporting that they 'had not smoked at all, not even a puff' 
during the last seven days before assessment at 3 and 12 months (Severson et al., 1998). 
This methodology is similar to the follow-ups in this present trial, with cotinine testing 
substituted for the question detailed above. 
Hughes et al. (2003), in a position paper for the Society for Research on Nicotine and 
Tobacco, discuss issues relating to measures of abstinence in smoking cessation clinical 
trials. They describe one type of trial which they call a 'cessation induction' trial, an 
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example of which would be physicians giving advice to all smokers. In a trial of this 
design, smokers may not be currently trying to quit, and with respect to patient follow-
up, they recommend this should be related to the initiation of the intervention, with 
point prevalence measures being reported at 6 and 12 months and a prolonged 
abstinence of ~ 6 months duration. 
The second type of trial described in this paper is an 'aid-to-cessation' trial, an example 
of which would be group behaviour therapy or a medication trial. This type of trial tests 
a treatment among smokers currently willing to quit. In this case, the experimenter, not 
the subject, sets the quit date. It is suggested that, in this type of trial, follow-up of 
smokers willing to try stopping on the set quit date should relate follow-ups to the quit 
date and report 6 and 12 month abstinence rates. 
In the trial described in this thesis, there are more parallels with the 'cessation 
induction', rather than the 'aid-to-cessation' trial. One of the main differences focuses 
on patients' intentions. Patients, per se, do not come in the first instance for smoking 
cessation treatment to the Periodontal Department at Glasgow Dental Hospital, they 
attend initially for periodontal treatment. Therefore, there are differences between this 
group, and the group of 'clients' who turn up for treatment at a specialist smoking 
cessation service. 
4.3.3.7 Choice of Monitoring Time Points 
There is debate over the timeframes used to measure 'success' in smoking cessation 
trials (Hughes et ai., 2003). A number of time frames are available: 24 hours, 1 week, 1 
month, 3 months, 6 months, and one year, or longer (2 to 3 years). 
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Researchers are in agreement that one-year outcomes are desirable, whether self-
reported or biochemically validated (Hughes et aI., 2003). However, there is a direct 
relationship between length of follow-up and patients lost to follow-up, with a higher 
number lost at the one-year mark, than at the six-month time frame (Velicer et at., 
1992). Where there is some debate, is over what other timeframes can be used to 
determine efficacy. One month is the time frame used by UK specialist smoking 
cessation services and this often coincides with the end of a course of group treatment. 
Quit rates are higher at this time point compared with longer time frames, with the 
English Specialist Smoking Cessation Services reporting a quit rate of 57% (of those 
setting a quit date) abstinent at one month, self-reported (Department of Health, 2004). 
One month outcomes include a grace period of two weeks, in which the smoker may 
lapse, but require the smoker not to have smoked, even a puff, in the two weeks 
preceding the collection of one month data. In Scotland, one-month outcomes are to be 
collected, but are to be biochemically validated with CO (PATH, 2003). The Specialist 
Smoking Cessation Services in Scotland intend also to collect self-reported three-
months outcomes. 
Follow-up at three months provides a longer term view of quitting, though a number 
who had quit at one month will have relapsed. At six months, some participants who 
had quit at three months will continue to be abstinent, and some of those participants 
who had quit using NRT, may have stopped taking the medication. In addition, some 
may have relapsed. At one year, the quitters will be more akin to a non-smoker, though 
relapse will still be possible. 
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With respect to dental smoking cessation interventions, follow-ups vary: from 3 months 
and 12 months (Severson et ai., 1998),9 months (Smith et ai., 1998), between 3 and 12 
months (Macgregor 1996), 6 months (Seeker-Walker et al., 1988), 6 and 12 months 
(Cohen et ai., 1989). A contemporaneous smoking cessation trial running in Newcastle 
Dental School in the Periodontology Department used similar time frames to this 
project, i.e. 3 and 6 months and one year (Heasman et ai., 2004). 
Given unlimited resources, there could be an argument for taking measurements at 1, 3, 
6, and 12 months. However, this would require a great deal of statT input, as patient 
follow-ups can be time-consuming and frustrating, and the possibility would arise that 
the process of obtaining outcome data could consume more resources than was required 
to deliver the intervention in the first place. There would also be a considerable and 
unsustainable commitment required from the patients for multiple assessments. Most 
interventions, be they service-orientated or research, often do not have the luxury of 
multiple follow-ups, and therefore decisions have to be made about what timeframes to 
use, to give maximum comparability with work already completed. 
4.3.3.8 Reporting of Patient Follow-ups 
With regard to success rates, there are two ways in which the data can be presented. 
Success rates can be calculated for those from whom data were collected at a particular 
time point, and a number of researchers use this methodology (Seeker-Walker et al., 
1988; Macgregor, 1996, Butler et al., 1999). Others estimate success rates with all 
participants lost to follow-up being deemed to be smokers (Smith et ai., 1998; Silagy 
and Stead, 2004; Rice and Stead, 2004). One study reports both (Cohen et al., 1989), 
and one bases outcomes on patients followed-up for secondary outcomes, but calculates 
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success of quitting at 3 and 12 months using all patients registered to the trial, assuming 
all patients lost to follow-up are still smokers (Severson et al., 1998). Within this trial, it 
was decided to report both outcomes, to enable comparison with work already carried 
out in the dental smoking cessation field. 
4.3.4 Choice of Pharmacological Support 
With regard to the provision of pharmaceutical support for the trial, it was decided, in 
association with advice from Smoking Concerns (NHS Greater Glasgow), to use only 
nicotine patches and gum, and not include other forms of NRT such as lozenges and 
inhalers. This was considered most practical from a stock control perspective. Access 
to NRT is now considered standard practice for patients in smoking cessation trials 
(Silagy et al., 2004). 
The use of Zyban was discussed and discounted, as at the time this trial was being 
planned, there was some controversy over the use of Zyban. In addition, the funding 
and prescribing mechanisms for delivering this drug to the patients would have been 
complex, and would have required referral back to the general medical practitioner. 
4.3.5 Primary Outcomes 
As discussed previously, it was decided to report outcomes at 3 and 6 months and one 
year. The three smoking cessation outcome measures used were self-report, and the two 
biochemical measures of salivary cotinine measurement and CO levels in an exhaled air 
sample. Measurement of follow-up was in association with the patient's registration 
date into the study and not with the patient's quit date. Other dental and medical studies 
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have used this methodology (Seeker-Walker et at., 1988; Severson et at., 1998; Smith et 
at., 1998; Butler et ai., 1999). 
The main measure used was point prevalence, biochemically validated by salivary 
cotinine, which confirms the absence of nicotine over the previous seven days. In the 
presence ofNRT, smoking cession was validated by the use of CO, and this is in line 
with the recommendations of Hughes et at. (2003). The other measure used was that of 
prolonged abstinence. This was reported for 6-month outcomes for this current study. 
4.3.6 Secondary Outcomes 
The secondary outcomes used within this study were reported quit attempts of varying 
duration and reduction in smoking, for example, by lowering the daily number of 
cigarettes smoked. 
Researchers differ in their opinions as to whether there is merit in looking at secondary 
outcomes in smoking cessation programmes. One school of thought is that smokers 
have to 'prepare' to quit and that making changes to smoking behaviour such as short-
term quit attempts, or cutting the number of cigarettes, should help to increase the 
smokers self-efficacy and make them more ready to quit (Hughes, 2000; Carpenter et 
at., 2003). However, others feel that giving smokers the soft: option is a delaying tactic, 
rather than helping them tackle the ultimate goal of full cessation (Fiore et at., 2000). 
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4.4 Discussion of Results 
4.4.1 Introduction 
The amount of literature available in the smoking cessation field in both primary and 
secondary care is vast, especially with respect to particular target groups such as 
pregnant women, adolescents, patients with a pre-existing condition such as asthma, 
COPD (chronic obstructive pulmonary disease) and heart disease. Many of these 
groups are not directly comparable with the group under study in this thesis. Thus, the 
results of the present study have been discussed mainly in relation to the dental 
literature in this field. The one exception to this is to compare findings with those of the 
trial by Butler and co-workers (1999), which was set in a general medical practice, and 
utilised two methodologies, one 'very brief advice and a more intensive intervention 
using motivational interviewing. Aspects of its data collection, especially with respect 
to secondary outcomes and 'Stage of Change', influenced the development of the 
present body of work. The trial by Butler and co-workers has been included in two 
recent reviews of the use of 'Stage of Change' and in both was highly rated (Riemsma 
et al., 2003; van Sluijs et al., 2004). 
4.4.2 Number of Patients Recruited 
There were 118 patients, 59 intervention and 59 control subjects, recruited to the trial 
over a 16-month period. It had been hoped to follow-up 120 patients at 3 months, but 
numbers fell short of this figure. A number of factors contributed to this. A previous 
audit carried out in the Periodontology Department, monitoring throughput of patients 
who smoked, gave higher numbers than the throughput of patients during the 
recruitment period. This was in part due to the loss of one of the consultants in 
Periodontology a number of months into the trial, resulting in a lower number of clinics 
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available from which to recruit patients. In addition, this particular consultant had been 
the most active in recruiting patients for the study. Due to time constraints, it was not 
possible to lengthen further the time period of recruitment. 
With regards to patients recruited, one patient subsequently withdrew consent and one 
patient died, and both of these had been allocated to the control group, so final analysis 
was carried out on 116 patients (59 intervention, 57 control). This constitutes almost 
balanced numbers of participants in the intervention and control groups, which is 
desirable for a randomised controlled trial (Jadad, 1998). Each hygienist also had almost 
equivalent numbers of intervention and control patients, and the case-load of smoking 
cessation trial participants for each hygienist reflected the number of sessions worked 
per week. 
4.4.3 Characteristics of Patients Recruited to Smoking Cessation Trial at Baseline 
4.4.3.1 Comparability of Groups with respect to Randomisation factors 
As described in the methodology, the aim of the randomisation procedure was to ensure 
that the intervention and control groups were similar with respect to the characteristics 
of age, sex, DEPeAT, level of nicotine dependence and intention to quit. This was 
achieved, with the exception of age, where a statistically significant difference was 
found. It should, however, be stressed that the difference in the mean age of 3.6 years 
between the two groups can be considered acceptable, as often within trials, subjects are 
matched within an age banding of five years. 
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4.4.3.2 Sex and Gender Issues regarding Participants recruited to the Trial 
A high proportion of the trial recruits were female, with 71% of the total being women. 
Other trials have exhibited a similar level of females (Seeker-Walker et al., 1988; Butler 
et al., 1999), though some have been evenly balanced (Smith et al., 1998), and some 
have had more males (57%) (Macgregor, 1996). In some trials the gender of participants 
has not been reported at baseline (Severson et al., 1998). 
With respect to the higher number of females in the present study, this reflected the 
patient cohort attending the Periodontal Department at Glasgow Dental Hospital for 
treatment, i.e. the centre used for recruitment. 
In the UK, the prevalence of periodontal disease is higher in men. On average, they 
have greater pocket depths and more plaque (Kelly et al., 2000). However, it is known 
that women present more readily for regular dental care, including periodontal treatment 
(Bullock et al., 2001). 
In Scotland, smoking rates in men and women are almost equivalent (Shaw et al., 
2000). With respect to smoking cessation, it has been suggested that women may find it 
more difficult to quit than men (perkins et ai., 1999; Wetter et al., 1999). The reasons 
are not well understood, but are likely to be due to a combination of biological, 
psychological and social factors (Mackay and Amos, 2003). 
When looking at health issues, Greaves and Barr (2000) have stated that it is important 
to differentiate between the impact of sex (the biological differences between men and 
women) and gender (the social and cultural differences experienced by women and 
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men). Most issues to do with smoking are gender-based. Women, especially those from 
a low income background, can face barriers when they try to quit smoking. There are 
issues related to stress, self-esteem and body image, and tobacco can be seen as a means 
of helping with weight control (Greaves and Barr, 2000). Physiologically, when both 
men and women quit, it is likely that they will put on weight in the region of 6-12 lb. 
This weight gain can be a negative reinforcer for many females (USDHHS, 200 1 b). 
4.4.3.3 Deprivation Category of Participants 
Approximately 50% of the trial participants were recruited from the more affluent areas 
of the West of Scotland, i.e. DEPCATS 1-4, with the others recruited from the more 
economically disadvantaged DEPCATS 5-7. 
This pattern does not reflect the distribution of smokers within the population. It is 
known that there is a direct relationship between increasing deprivation category and 
smoking prevalence. Once again, the recruitment setting, i.e. a hospital periodontal 
department, will have influenced this finding, with a higher proportion of the smokers 
from the more affluent areas seeking treatment for smoking-related periodontal 
problems. There is a similar relationship with deprivation and dental attendance, with 
patients from a higher socio-economic group more likely to seek regular dental 
attendance (Kelly et al., 2000). 
With respect to the dental smoking cessation literature and deprivation, previous studies 
have not reported this descriptor of their patients' socio-economic background 
(Macgregor, 1996; Severson et al., 1998; Smith et al., 1998). The Butler trial (1999), 
conducted in a general medical practice setting, reported manual/non-manual 
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occupation as a means of describing the patients' occupational background. The more 
recent research, i.e. published in the 2000's, will be more likely to report deprivation 
descriptors (Bauld et al., 2003). 
Smokers from deprived backgrounds continue to be seen as a special target group. It is 
known that smoking prevalence is much higher in this group, and there are issues 
around the individual's efficacy and low self-confidence which can be barriers to 
quitting. Smoking is seen as a means of coping with the stresses of living in a 
disadvantaged community (Stead et al., 2001). Low-income smokers tend to be more 
heavily dependent on tobacco, and may be more sceptical about the success of NR T 
(Wiltshire et al., 2003). Smokers from deprived areas are also less likely to try to quit 
and are more likely to be unsuccessful when they do try to quit (Bauld et al., 2003). 
As such, attempts are being made to try to develop services that are more locally 
sensitive to the needs of the low-income smoker in the relevant areas in Scotland. 
Partnership in Action in Tobacco and Health (PATH) has recently funded a number of 
projects aiming to deal with the issues of smoking and low income. One innovative 
idea is the use of 'Buddies', defined as former smokers who have sucesssfully quit, and 
who could be used as counsellors (May and West, 2000). This use of peer counselling 
helps to strengthening the smoker's self-efficacy at this vulnerable time. 
In summary, from a DEPeAT perspective, participants in this trial were typical of those 
individuals attending the dental hospital Periodontology Department, and not typical of 
the West of Scotland population of smokers. 
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4.4.3.4 Age of Participants 
With respect to this trial, the mean age of the participants was 41.2 years, i.e. middle 
age and this is reflected by the setting and the fact that patients attending this clinic had 
some evidence of periodontal disease. Often participants in smoking cessation trials are 
middle-aged, and may exhibit some smoking-related symptoms (Secker-Walker et al., 
1988; Cohen et ai., 1989; Smith et al., 1998; Butler et al., 1999). 
At national level, there is much focus on tackling the problem of young smokers, 20 
years and under (NHS Health Scotland and ASH Scotland, 2004). Much research effort 
has been put into attempting to make services appropriate and accessible for this age 
group, as well as preventing young people from taking up this deadly habit. 
However, increasing cessation rates amongst all groups of smokers is still seen as very 
much a priority in Scotland, with the current planned expansion of specialist smoking 
cessation services (Health Scotland and ASH Scotland, 2004). 
4.4.3.5 Nicotine Dependence Measures 
The median Heaviness of Smoking Index for trial participants was three, with 
participants scoring from zero to six. The median FTND was five, with participants 
scoring from zero to 10. With reference to FTND and level of addiction, a score of 0-2 
is considered very low, 3-4 is low, 5 would indicate medium addiction, 6-7 is 
considered high, with 8-10 very high addiction. Therefore, with respect to nicotine 
dependence of the trial participants, the median score of five would indicate medium 
addiction. However, as the scores ranged from zero to 10, it would appear that 
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individuals exhibited a range of nicotine dependence from very low to very high 
addiction. 
One US dental trial reported a mean FTND score of 5.5 (Cohen et al., 1989). Severson 
and co-workers implied that they collected such data, but indicated that as there was no 
difference in these measures between their three study groups, the information was not 
reported (Severson et al., 1998). With respect to the UK dental smoking cessation 
studies, they did not report tobacco dependence using the FTND or Heaviness of 
Smoking Index, but tended instead, to report individual components of these indices, 
often in the form of number of cigarettes per day (Secker-Walker et al., 1989; Smith et 
a/. , 1998) or smoking within the first half-hour of waking (Smith et al., 1998). These 
findings, in relation to the present study, are reported below. 
With regards to number of cigarettes smoked, the median number for trial participants 
was 20 (a pack a day). Only 5% of trial participants smoked 31 + per day, with 27% 
smoking between 21 and 30 per day. With respect to the Smith trial, 64% smoked ~ 20 
cigarettes per day (Smith et al., 1998). Of the recruits to the Secker-Walker trial, the 
mean number of cigarettes was 22.2 cigarettes per day (Secker-Walker et al., 1989). 
These figures are both higher than the smoking levels in this trial. Macgregor (1996) did 
not report mean cigarette consumption from his cohort, only that they had to smoke at 
least five cigarettes to be included in the trial. 
The Scottish Health Survey 1998 reported mean numbers of cigarettes smoked per day 
of 17.5 for men, and 15 for women (Shaw et al., 2000). Thus, generally, trial 
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participants smoked at the same or slightly higher levels than those surveyed in the SHS 
1998. 
Of the trial participants, only 17% smoked within the first 30 minutes of waking. In 
contrast, in the Smith trial, 76% smoked within the first half hour of waking (Smith et 
ai., 1998). Therefore, for this element of the FTND, the Glasgow group exhibited less 
addiction than the participants in the Smith trial. 
4.4.3.6 Environmental Exposure to Smoke at Home and Work 
Over one third (39%) of the study participants were exposed to smoke at home. It is 
known that trying to quit when there are others smoking in the vicinity can be difficult, 
and individuals are less likely to succeed in these circumstances (Health Scotland and 
ASH Scotland, 2004). 
Half of all trial recruits (52%) were exposed to smoke at work. Once again, such 
exposure will tend to make quitting more difficult. 
Environmental tobacco smoke, especially in the workplace, is a topical issue in 
Scotland, with a public consultation currently underway, relating to banning smoking in 
public places. The Scottish Executive is seeking the public's views with regard to 
restriction or prohibition of smoke in enclosed public places. This could take the form 
of a total ban (as in force in Ireland from 2004) or a targeted ban on smoking in specific 
places such as hospitals and schools, or where food is served (Scottish Executive, 
2004b). Other options would be to give powers to local authorities to regulate smoking 
in public places, or a combination of statutory controls and voluntary action. 
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4.4.3.7 Lifetime Exposure to Cigarette Smoke 
With regards to lifetime exposure, patients were asked how many years they had 
smoked, and with information accrued from the number of cigarettes smoked, pack-
years were calculated. The mean number of pack-years was 23.1, with a range of two to 
74. There was a difference of 3.3 in mean number of pack-years between intervention 
and control, with the control group having a slightly higher exposure. This difference 
was within acceptable limits, and related to the slightly higher mean age of the control 
group. 
Only one of the previous dental smoking cessation studies reported pack-years (Secker-
Walker et al., 1988), with an average of 29.5 pack-years for the 51 participants in that 
trial. Therefore, the participants in the Glasgow trial exhibited a slightly lower mean 
level of lifetime exposure than the participants in the US study. 
The lack of use of the measure of pack-years in the dental smoking cessation literature 
is surprising, considering there is widespread use of pack-years in periodontal research 
(Grossi et al., 1995; Mullally et al., 1999; Haffajee and Socransky, 2001). 
4.4.3.8 Measures of Motivation to Quit at Baseline 
Two measures of motivation to quit were obtained: Motivation Score (Foulds, 1996) 
and an adapted form of the 'Stage of Change' (Prochaska and DiClemente, 1983, 1993). 
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a) Motivation Score (Foulds) 
With respect to the Motivation Score (Foulds, 1996), two questions contributed to this, 
both measuring strength of desire to quit ('How much do you want to give up 
altogether', and 'Would you give up smoking, if you could do so easily'). Both scales 
were added together to give a total score. The use of this Motivation Score by Foulds 
proved to be of limited use, as most participants (71 %) had a score of seven or eight and 
professed interest in quitting. The scale was not sensitive in teasing out who would 
quit, and who would not. None of the previous dental trials used this Motivation Score 
in their data collection forms. 
b) 'Stage of Change' 
At baseline, 13% of the sample recruited to this trial were not interested in quitting 
('precontemplators'), 45% were thinking about quitting sometime in the next six 
months (,contemplators') and 42% wanted to stop sometime within the next month 
('preparation' stage). This reflects a lower percentage of 'precontemplators', and a 
higher percentage of smokers in the 'preparation' phase, than in other studies (Butler et 
al., 1999). 
Regarding the high level of individuals in the 'preparation' stage, as already discussed 
in Section 4.3.3.3, the definition of the stages can vary, particularly in relation to the 
'preparation' stage. A number of researchers define those individuals as being in the 
'preparation' stage if they want to quit within one month, and have had a quit attempt in 
the last year (Prochaska and DiClemente, 1983; Prochaska and Velicer, 1997; Etter et 
al., 2003). Others, however, define the 'preparation' stage solely as wanting to quit 
within the next month (Foulds, 1996; Butler et al., 1999; Hughes et 01., 2000; Etter and 
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Pemeger, 2001). With respect to this current study, the definition of wanting to quit 
within the next month was used alone, i.e. it did not include whether a quit attempt of at 
least 24 hours had been made in the last year. This would have led to a higher number 
of participants being allocated to the 'contemplation' phase, rather than the 
'preparation' stage. 
Population surveys of smokers would indicate that 40% of smokers are In the 
'precontemplation' phase, 40% in the 'contemplation' stage and 20% in the 
'preparation' stage (Velicer et ai., 1995). None of the dental studies reported using 
'Stage of Change' as a measure at baseline. However, many asked about intention to 
quit, with one asking as a 12-month outcome, about intention to quit within the next 30 
days and whether a quit attempt in the last year had been made (Severson et ai., 1998). 
With respect to other smoking cessation studies, in a UK general medical practice, 53% 
and 49% of the 'brief advice' and 'motivational consulting' groups were 
'precontemplators', 23% and 28% were 'contemplators', with 9% and 10% respectively 
being in the 'preparation' stage (Butler et ai., 1999). This is a much higher level of 
'precontemplators' than in the Glasgow study, with a much lower number of 
participants in the 'preparation' stage. The same definition of 'preparation' was used in 
the two studies, so the differences between these two studies are not due to variation in 
definition of the different stages. It may be that the popUlations were not similar enough 
for comparison, i.e. a group attending general medical practice in a primary care setting 
and a group attending a Periodontology clinic in a dental secondary care setting. 
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One study, looking at assessing 'Stage of Change' in smokers, found that including 
previous quit attempts in the classification of smokers in the 'preparation' stage had 
quite an impact, in that 18-24% of smokers were downgraded to 'contemplation stage' 
as they had not made a quit attempt in the last year (Etter and Sutton, 2002). When 
looking at the present study, if this method of analysis had been used, 30% of the 
participants categorised as 'preparation', would be downgraded into the 'contemplator' 
category. 
Etter and Sutton (2002) criticised the definition of including quit attempts within the 
categorisation of the 'preparation' stage, and concluded that with such an inclusion, the 
'contemplation' stage becomes a heterogeneous category that encompassed smokers 
wanting to quit in the next 6 months, and who may/may not have had a quit attempt, and 
smokers who want to quit within the next month but have not made a quit attempt. 
Etter and Pemeger (1999) compared two measures of 'Stage of Change', using a 
conventional questionnaire and a shortened, easier to interpret version, and found that 
only 62% of participants were classified in the same stage through use of the two 
questionnaires. Thus, variations in questionnaire design can make comparing results 
from different studies difficult and in some cases, not valid. 
Researchers have also looked at 'Stage of Change' test-retest reliability, and found that 
over a 7-day interval, 16% of 'precontemplators' and 6% of contemplators progressed 
to the next stage, and 33% of those in the 'preparation' stage regressed to 
'contemplation' (Hughes, 2001). Etter and Sutton (2002) found a similar, if less 
marked change, in their study with 15% of participants changing category over an 8-day 
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period. Therefore, it is postulated that there is a certain fluidity in this model, and this 
must be acknowledged. 
As mentioned previously, the 'Stage of Change' is only one element in Prochaska's 
Transtheoretical Model of Change. Other elements include processes of change, 
decisional balance, and self-efficacy (Prochaska and DiClemente, 1983). Use of these 
elements would have required additional data collection, and as such, was outwith the 
scope of this thesis. 
4.4.3.9 Cotinine and Carbon Monoxide Levels at Baseline 
Recruitment into the trial was by self-reported daily smoking of at least 10 cigarettes 
per day. No individual was recruited into the trial who was currently trying to quit, or 
was taking NRT. 
When the results of cotinine analysis became available a number of months after patient 
recruitment, it was found that two individuals had cotinine levels below the cut-off, one 
intervention and one control. Both cases had, however, CO concentrations well above 
the cut-off level. One individual (intervention) was lost to follow-up at 3 months. The 
other participant (control) had biochemistry indicative of more regular smoking at this 
time point. 
While it could perhaps be argued that the low cotinine levels measured at baseline for 
these two individuals, should have resulted in them having being excluded from the 
study, given their relatively high CO levels, the decision was made to include these 
individuals in the analysis. 
217 
4.4.4 Patient Follow-ups at 3, 6 and 12 Months 
With respect to follow-ups, data were collected from 88% of participants (both 
intervention and control) at 3 months. This very acceptable rate was due to the patients 
still largely being under periodontal treatment by the dental hygienists, and this 
considerably aiding the collection of follow-up information. Severson et al. (1998) 
reported a follow-up rate of 75.7% at this time point, with Macgregor (1996) reporting a 
3-6 month follow-up rate of 88%. 
With respect to the 6-month follow-ups, the rate reduced to 61 % for both intervention 
and control groups. Obtaining patient data at this time point proved to be more 
challenging, especially for those patients who had finished attending the Periodontal 
Department. Some patients had been referred internally for further treatment, and it was 
possible to obtain follow-up data within the specified timeframe during their attendance 
at other departments within the hospital. Other patients who were not returning within 
the specified timeframe were contacted, and it was requested that they attended the 
research hygienist solely for collection of data. 
Cohen et al. (1989) had a follow-up rate of 42% at this time point, with Seeker-Walker 
and co-workers (1988) obtaining data from 94% of their original sample. In this latter 
study, telephone interviews were used to collect data and patients did not have to attend 
in person for any biochemical verification. 
With respect to one-year follow-ups in this study, there were much-reduced rates of 
56% in the intervention group and 40% in the control group, with the overall rate being 
48%. The data collection methodology was different at this time point, utilising 
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telephone and postal follow-ups. Whereas telephone data collection had yielded a very 
respectable rate of 94% follow-up at six months in the trial described by Seeker-Walker 
and colleagues (1998), this means of data collection was not so successful in this trial, 
albeit at the much longer time-frame of one year. By this time, a large proportion of 
subjects had completed their treatment and were no longer current patients of Glasgow 
Dental Hospital. 
At one-year, Severson et al. (1998) had a follow-up rate of 75.7% (same as at 3 
months). This was a large well-funded trial with dedicated staff to help with patient 
follow-ups, and this is reflected in the impressive follow-up rate at one year. 
Other trials have reported similar problems to the present study, concerning attempts to 
obtain follow-up data. Cohen et al. (1989) had 36% of the original participants return at 
the one-year time point. Smith et al. (1998) reported data at the 9-month time frame on 
48% of the original recruits to the trial. Therefore, the 48% follow-up rate achieved in 
the present study compares favourably with most other dental smoking cessation trials. 
4.4.4.1 Primary Outcomes of Smoking Cessation 
Primary outcomes of smoking cessation were determined at 3, 6 and 12 months, 
biochemically validated. As previously discussed, the date of the follow-up was related 
to the date of the collection of the patients' baseline data, rather than the date of any quit 
attempt. Previous dental smoking cessation interventions have looked at outcomes at 3 
and 6 months, and it was decided to use these time points, as well as the longer-term 
outcome of one year. 
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4.4.4.2 Three Month Outcomes 
Point prevalence outcomes indicted that, of those individuals followed up at three 
months, 17.3% (9) of participants were classified as quitters in the intervention group, 
compared to 10.0% (5) in the control group. Assuming all patients lost to follow-up 
were still smoking, of the patients recruited at baseline, 15.3% (9) in the intervention 
group quit, compared to 8.8% (5) in the control group. 
The situation at 3 months is complex, as described in Table 3.33, with a number of 
quitters still using NRT and this being reflected in the cotinine levels. One 'deceiver' 
was identified, and one individual whose biochemistry was more indicative of a non-
smoker, was also identified. 
Of interest is the number of control participants who, at the time of data collection, were 
in the process of quitting. Two of the control group were disappointed at being 
allocated to the arm of the trial where no help was given, and as such, wrote comments 
on the three-month data collection forms. 
Patients recruited to such trials have to show informed consent, and as such, receive 
information as part of the recruitment process. In this study, the information sheet 
included not only details of the trial, but also information about periodontal disease and 
the role that smoking can play in exacerbating the condition. This, in itself, would 
almost constitute a 'brief intervention', even in the absence of any further advice and 
help. This, together with the 'usual care' advice that all smoking patients newly referred 
to the Periodontology Department receive, encouraged at least some of the control 
group to help themselves or to seek further support, as evidenced by the use of the NRT. 
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Severson and co-authors (1998), in their large study of both smokers and individuals 
using smokeless tobacco, linked the date of follow-up to the date of enrolment (as in the 
present study). The sample sizes in each of the treatment groups were approximately 20 
times the sample sizes in the present study: 'usual care' had 1,350 patients enrolled, 
with 1,305 and 1,374 in 'minimum' and 'extended' interventions respectively. At 3 
months, it was found that in the 'usual' care group, 63 (4.7%) had quit, compared with 
66 (5.1 %) in the 'minimal' intervention and 77 (5.6%) in the 'extended' intervention 
group. This study relied on self-report and did not use any form of biochemical 
validation. 
Macgregor (1996) followed up his patients at variable timeframes between 3 and 12 
months. Of the 38 patients who were given dental health advice only, 5.4% had quit, 
while 13.3% of the 98 patients who were also give advice to stop smoking had quit. 
At the three-month time point, with a quit rate of 15.2% in the intervention group, 
compared to 8.8% in the control group, the success of the present trial with respect to 
the intervention group is similar to that of Macgregor and in excess of that reported by 
Severson et al. (1998). The results are not statistically significant, but indicate a modest, 
positive effect in the right direction. 
It has to be borne in mind that both this trial and the one run by Macgregor (1996), were 
much smaller with regards to number of participants than the very large trial run by 
Severson and colleagues. 
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It should also be noted that the type of intervention may have influenced quit rates. In 
some studies it was difficult to determine the exact nature of the intervention. 
Additionally, compared with some other types ofrandomised controlled trials, e.g. drug 
trials, smoking cessation studies will have more variation in relation to the specific 
content of the intervention and the individual delivering the intervention is also likely to 
have a larger impact. 
4.4.4.3 Six Month Outcomes 
Point prevalence outcomes of those followed up at 6 months, indicated that 16.7% (6) 
of participants were classified as quitters in the intervention group, compared to 8.6% 
(3) in the control group. Assuming all patients lost to follow-up were still smoking, of 
the patients recruited at baseline, 10.2% (6) in the intervention group quit, compared to 
5.3% (3) in the control group. Prolonged abstinence figures (based on patients 
followed-up / total patients recruited) would indicate that 11.1 % / 6.8% of the 
intervention group had quit, compared to 8.6% / 5.3% of the control group. In this 
study, prolonged abstinence was defined as those quitters at 6 months, who had also 
been classified as quitters at 3 months. 
Two patients were still using NRT at the 6 month time point, and this was reflected in 
their cotinine levels. With many studies, the longer the period of follow-up, the lower 
the success rate, as individuals relapse. This occurred in this study, with a lower quit 
rate being found at 6 months, compared to 3 months. 
Secker-Walker and co-workers (1988) included six-month outcomes (point prevalence) 
in their trial of 51 smokers and data are reported on the 48 individuals who provided 
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infonnation at this time point. It was reported that seven (14.6%) trial participants 
stated that they had quit. Infonnation was collected by telephone interview. The 
comparable figures for this study (i.e. reported on the basis of those followed-up), 
reports a success rate of 16.7%, so the Glasgow study exhibits similar results to those of 
Secker-Walker and colleagues. It has to be stressed that this latter trial used no 
biochemical validation and therefore, results may be slightly inflated. 
In a trial by Cohen et al. (1989) using 'gum', 'gum and reminders', 'reminders' and a 
control group, findings were reported on both individuals followed-up and numbers 
recruited at baseline. The authors do not state what measure they use, but it would 
appear to be point prevalence. The ann of the trial most closely resembling the SAs and 
NR T intervention group in the Glasgow study would be the 'gum and reminders' group. 
The success rates for patients quitting (reported as patients followed-up / total patients 
recruited) in Cohen and co-workers trial were 9% / 3%, compared to 16.7% I 10.2% in 
the Glasgow trial. Therefore the findings of the present study would indicate a higher 
level of success. 
The one UK trial in general dental practice collected 9-month outcome data (measured 
from the patients' registration), and the findings were biochemically validated by 
cotinine (Smith et al., 1998). Of the patients recruited at baseline, 11% (17 patients) 
had quit at the 9-month point. This trial was not of an ReT design, so there are no 
control findings to report. Using the six-month figures from this PhD study, and with 
the findings calculated from all patients recruited at baseline, 10.2% of the intervention 
group quit, a finding similar to that of Smith and co-workers. 
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Evidence from smoking trials in general, (i.e. not restricted to the dental setting) would 
indicate that an intervention utilising various fonns of NRT with limited or intensive 
behavioural support, nonnally yields a success rate of between 5% and 12% at 6 months 
(Appendix 12). This table reports results as the difference between the intervention and 
control groups, with the control group being defined as willpower or placebo, or as no 
intervention. With a success rate of 10.2% (of all patients followed-up) in the 
intervention group, compared to 5.3% in control group (usual care), this project is 
within the expected limits of success. 
With regards to the prolonged abstinence results of this study, it was not possible to find 
comparable dental literature to make valid comparisons, due to differences in the way 
the results have been collected. It was also not possible to compare the findings with 
results from specialist smoking cessation services as neither England nor Scotland 
collects data at this time point. 
Therefore, the reporting of success in smoking cessation trials can be subject to 
variances not only in methodology regarding the different interventions, but also to how 
the results are reported at the varying time points and whether biochemical validation 
was used. 
4.4.4.4 Characteristics of 6 Month Quitters 
Descriptors of the 6-month quitters (Tables 3.46 and 3.47) would indicate that all were 
women. As the trial participants were predominately women (71%), this finding is not 
entirely unexpected. It is known that women attend for regular dental treatment more 
224 
readily than men, and are more likely to see the benefit of preventive treatment. and 
within this setting, these more positive health beliefs may have played a role. 
With respect to all quitters, seven out of nine came from DEPCA Ts I -4. As with many 
smoking cessation trials, individuals who are from the less deprived areas, tend to be 
more successful at quitting (Bauld et al., 2003; Jefferis et aI., 2004). 
When looking at the data and translating the age of the participants and the number of 
years smoked into the age of starting smoking, one issue becomes clear. All the quitters 
started smoking between the ages of 14 and 20. Individuals rarely start smoking after 
their early twenties (Dobson, 2004). Picking up the tobacco habit very often occurs 
during the teenage years, and this is why, over the last decade, much effort in both 
research and development has been expended in trying to provide services for young 
people, in an attempt to enable them to quit before they are truly addicted. 
4.4.4.5 Relapse Rates at 6 Months 
With respect to the relapse rate at 6 months, six of the 3-month quitters had relapsed 
back to smoking. Relapse can be defined as a return to regular smoking on seven 
consecutive days, as opposed to a lapse whereby an individual may have a single 
cigarette (Hughes et al., 2003). Some researchers feel that a lapse back to smoking 
within the first week of quitting can be indicative of failure to quit in the longer tenn 
(Kenford et al., 1994), while others feel that many smokers do have lapses very early on 
in the first few days, but may become abstinent between the 3 and 6 month mark 
(Hughes et al., 1992). 
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Patients in this study may have found it relatively easy to have a quit attempt (Section 
4.4.4.2), but sustaining that quit is challenging for individuals. 
Relapse prevention is an important factor in smoking cessation. The topic of relapse 
prevention interventions for smoking cessation is currently the subject of a Cochrane 
protocol (Hajek et ai., 2004). In this protocol, Hajek and co-authors state that 
multi session behavioural programmes should include relapse prevention components 
which aim to help smokers identify triggers or high risk situations for relapse, and give 
them advice and strategies for coping and avoidance. 
Self-help manuals and patient information often include tips about how to avoid relapse, 
and the information given to the patients in the current trial included these strategies 
(Smoking Concerns, 2004). Future studies may be required to evaluate what help or 
support recent quitters need to sustain their quit attempt. 
4.4.5 Pharmacological Support during the Trial 
Of the participants who were successful at quitting at 6 months, all made use of 
pharmaceutical support. Most made use of NRT (eight participants), with one 
individual using Zyban. These results indicate that use of NRT in a smoking cessation 
project in a dental setting is a key issue. The evidence for the effectiveness of NRT is 
now substantial (Silagy et ai., 2004), and access to its use is considered a key strand of 
smoking cessation therapy (Health Scotland and ASH Scotland, 2004). While there 
may be no doubt as to its efficacy, there is controversy over where it may be given out 
and who pays for it. 
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Within this trial, NRT was freely available for those participants allocated to the 
intervention group who wished to use it. The costs, as previously discussed, were borne 
by Smoking Concerns. This is not the situation that is currently available in other dental 
settings, or indeed the nonnal practice in the dental hospital in which this study was 
located. 
At the moment, dentists are not able to prescribe NRT or Zyban. However, this will 
change with the imminent abolition of the Dental Practice Formulary guidelines, 
allowing dentists to prescribe anything in the British National Formulary, including 
NRT. Guidance exists for the use of NRT both in Scotland and England (HTBS, 2002; 
NICE, 2002). As smoking is finnly implicated as a risk factor in periodontal disease and 
oral cancer, it would not seem unreasonable to allow dentists to prescribe effective 
medication in the fonn of NRT regarding tobacco dependence treatment. This, 
however, would involve the presumption that dentists have the appropriate knowledge 
and confidence to do so. There are no plans to allow dental hygienists to have the right 
of prescribing. Therefore, if they wish their patients to have NRT in the near future. it 
would need to be in conjunction with dentist prescribing. 
Another mechanism exists for prescribing and this is known as a Patient Group 
Direction. It was originally set up for use by phannacists to allow them to supply NRT 
as part of their smoking cessation interventions, as well as enabling distribution via 
NHS smoking cessation advisors, who cannot prescribe under normal circumstances. 
The aim was to prevent unnecessary visits to the family medical practitioner, to obtain 
supplies of the NRT product. However, in practice, it is a cumbersome system to set up 
and administer, and would probably be of limited value to the dental profession. 
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One further option exists for patients to gain access to NRT, and that is they purchase it 
over-the-counter, bearing the costs themselves. Dental team members could raise 
awareness of the differing types ofNRT, and suggest that they seek further infonnation 
from the pharmacist. 
4.4.6 Primary Outcomes at One Year 
Point prevalence outcomes of those followed-up at one year, indicated that 12.1 % (6) of 
participants were classified as quitters in the intervention group who were followed-up, 
compared to 8.7% (3) in the control group. Assuming all patients lost to follow-up were 
still smoking, of the patients recruited at baseline, 6.8% (6) of the intervention group 
quit, compared to 3.5% (3) in the control group. 
For the intervention group, this was slightly better than the results reported (for all 
patients recruited at baseline) by Severson et al. (1998), who found a quit rate of 2.4%, 
2.6% and 2.5% for 'usual care' 'minimal', and 'extended' interventions respectively. at 
12 months. 
The trial by Cohen et al. (1989), already discussed in relation to the six-month findings. 
also reported at one year. At this time point, Cohen reported the findings on both 
individuals followed-up and numbers recruited at baseline. As already specified. the 
arm of the trial most closely resembling the SAs and NRT intervention group would be 
the 'gum and reminders' group. The success rates for patients quitting (reported as 
patients followed-up / total patients recruited) for Cohen's trial were 16.<)0/0 / 4.7%, 
compared to 12.1 % / 6.8% in the Glasgow trial. Therefore, the findings for the Glasgow 
trial would indicate a slightly lower level of success. 
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Neither of the previously described trials (Cohen et al.. 1989; Severson el al.. 1998) 
used biochemical validation, so results quoted are purely self-report and may be subject 
to inflation. The Glasgow trial, used not only self-report, but also cotinine biochemical 
verification, so very stringent measures were used to define success. At the 3 and 12 
months time points, 'deceivers' were detected in this trial, and Smith and co-workers 
(1998) also found two deceivers, as verified by cotinine. Therefore, it would not be 
unreasonable to assume that the other trials would exhibit some degree of over-
reporting of success. 
4.4.7 Secondary Outcomes - Changes in Smoking Behaviour at 3 and 6 Months 
4.4.7.1 Quit Attempts 
At 3 and 6 months, trial participants who still smoked were asked whether there had 
been any changes in their smoking behaviour, including quit attempts of varying 
duration. At both time points, there was a statistically significant higher percentage of 
individuals in the intervention group than control who reported that they had made a 
quit attempt of one week or more in the preceding 3 months: 37% and 47% at 3 and 6 
months respectively for the intervention group, compared to 18% and 16% respectively 
for the control group. This would indicate that the intervention was successful in 
encouraging relatively high numbers of smokers to try to have a quit attempt of at least 
a week. 
Severson et al. (1998) collected secondary outcomes at I year, and found that 41 % of 
the 'extended' intervention had made a quit attempt during the period of the trial. None 
of the other dental interventions collected this information. 
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It has been reported that having successful quit attempts, albeit if the patient relapses, 
helps increase patient self-efficacy, increasing the likelihood that the patient will be 
successful in the future (Borland et al., 1991; West et al., 2001). 
In this study, secondary outcomes were not collected at the one year mark, due to the 
differing data collection methodology used, i.e. telephone and postal collection. It was 
decided to focus on primary outcome measures at this time point, to make the 
information collected brief, in an attempt to aid the response rate. 
4.4.7.2 Smoking Reduction 
At 3 months, 81 % (35) of the intervention group reported they had reduced their 
cigarette intake in the past 3 months, compared to 45% (20) of the control group, and 
this was statistically significant. At 6 months, however, the difference between the 
groups was not statistically significant, with 67% (20) of the intervention group having 
reduced their cigarette intake in the previous 3 months, compared to 56% (18) of the 
control group. 
Most dental trials undertaken to date, have not collected information on smoking 
reduction (Cohen et al., 1989; Severson et al., 1998; Smith et aI., 1998). The Macgregor 
trial did, and found that 67% of those given smoking cessation advice claimed to have 
reduced their smoking in some way. 
There are two aspects to smoking reduction, the first behavioural and the second. 
physiological. Some researchers feel that advocating smoking reduction is swaying 
smokers away from the real task of quitting (Fiore et al., 2000). whereas others feel 
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from a behavioural point of view, smoking reduction may be a stepwise approach to 
quitting (Carpenter et ai., 2003). 
Most public health strategies do not recommend promoting or reporting on reduced 
smoking among smokers who are trying to quit (Fiore el al., 2000). There is some 
evidence that smokers are able to titrate as much nicotine from a reduced number of 
cigarettes by altering their smoking patterns and inhaling more deeply (Hughes el a/.. 
1981 ). 
In contrast, Hughes (2000), in his review of reduced smoking, found that there were 
reductions in CO exposure ranging from 19% to 35% in participants who claimed to 
have reduced their percentage cigarette intake. 
More recent work by Carpenter and co-workers (2003) in a cohort of smokers not 
interested in quitting but willing to reduce, found that of smokers who were encouraged 
to reduce their number of cigarettes to 50% of their usual intake by week four. 71 % 
were able to reduce their intake by at least 33% and were able to maintain their 
reduction 6 months into the trial. The authors concluded that reducing smoking neither 
prompted nor undermined smoking cessation. In addition, they postulated that for some 
hardened smokers, smoking reduction may be an intermediate step, as it would help 
decrease withdrawal severity, urges for cigarettes and increase patient self efficacy. 
which should, in theory, help the future likelihood of a successful quit attempt. It has to 
be stressed that this work utilised CO with its short life, and it is postulated that using 
cotinine would have given more detailed results. 
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In the study reported in this thesis, infonnation was elicited from the individuals 
regarding whether they had reduced their smoking or not, and this was related to their 
cotinine levels at baseline, and at 3 and 6 months. The results showed that not all 
individuals who claimed to have reduced the number of cigarettes smoked reduced their 
nicotine loading, and in some instances, a reported reduction in number of cigarettes 
smoked was associated with an increased level of cotinine at 3 and 6 months compared 
to baseline. However, at 6 months, a significantly higher mean cotinine reduction 61 
(SD 90)ng/ml was seen in the group who reported reducing their smoking. 
As there is a dose-response seen regarding number of cigarettes smoked and the severity 
of periodontal disease, if smokers manage to reduce smoking and maintain it at low 
levels, there may be some benefit from a 'harm reduction' point of view. Tomar and 
Asma (2000) found that smokers who reduced the number of cigarettes from over 30 a 
day to less that 10, subsequently reduced their likelihood of developing periodontitis 
(OR = 5.8 to 2.79). Other health professionals are reluctant to countenance any safe 
level of smoking (Fiore et al., 2000). 
In summary, there is debate at present, as to the benefits of smoking reduction. either 
from a 'harm reduction' perspective, or as the first step on the road to quitting for 
heavily addicted smokers. 
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4.4.7.3 Changing to a Low Tar Brand 
At the 3-month mark, 22% (28% intervention and 16% control) of trial respondents 
self-reported moving to low tar cigarettes. At the 6-month time point, 34% (40% of 
intervention and 28% of control) claimed to have changed within the last 3 months to 
low tar cigarettes. No advice was given to the participants to change to lower tar 
cigarettes. 
This question was included in the questionnaire as this behaviour is often cited by lay 
individuals as a means of changing or reducing smoking behaviour. It is postulated that 
its inclusion in the questionnaire may have 'legitimised' this behaviour, and therefore 
prompted a higher than expected number of trial participants to take this course of 
action. 
Current theory is that there is no benefit from using light or low tar cigarettes. The 
marketing of such cigarettes as being 'the healthier option' has recently been banned in 
the UK and cigarettes have had to have 'light' and 'low' removed from their titles. 
Smokers are able to titrate just as much nicotine from 'light' cigarettes, and indeed 
smoking in such a way is thought to contribute to an increased risk of lung 
adenocarcinoma (Etter et al., 2003). Previous research showed that branding cigarettes 
as light, appealed to smokers who were younger, female and smokers with a lower 
nicotine addiction score (Etter et al .• 2003). 
Hyland and co-workers (2003) looked at the concept of whether switching to a low tar 
cigarette increased or decreased cessation behaviour. In a retrospective study, looking 
at participants in a Community Intervention Trial for Smoking Cessation (COMMIT), it 
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was found that 19% of regular smokers switched to a lower yield product over a two-
year period. In this sub-group, despite a greater desire to quit than amongst those 
smoker who did not change, switching to a low tar cigarette did not appear to increase 
or decrease the likelihood of future cessation, though motivation to stop smoking may 
be associated with switching. 
4.4.8 Movement in Stage of Change at 3 and 6 Months 
'Stage of Change' data can be used in two ways. Firstly, it can be used as a 'predictor' 
of outcome and the outcome in this case would be smoking cessation. Secondly. it can 
be used directly as an 'outcome measure', where the participants' self-reported 
movement through the cycle is enumerated, in relation to whether they received the 
intervention (5As and NRT) or control (usual care). 
With respect to the former use, i.e. as a predictor of outcome, data collected on the 
participants' self-assessment of readiness to change at baseline, was used to examine 
whether those who said they were in the most ready state, i.e. wanting to stop smoking 
within the next month ('preparation') actually took action and went on and quit. 
Of the 14 biochemically validated quitters at 3 months, at baseline nine (64%) had 
classified themselves as wanting to stop ('preparation'), four were 'contemplators' and 
one was not interested in quitting (a 'precontemplator') (Table 3.39). In contrast, of the 
88 participants who were still smoking at 3 months, only 33 (38%) had described 
themselves as being in the 'preparation' stage and 12 (14%) were not interested in 
quitting. However, with such small numbers, all results have to be interpreted with 
caution. 
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At six months, a number of quitters (seven) had moved on to the 'maintenance' phase 
(i.e. quit for at least six months) and six had relapsed (Table 3.53). There would not 
appear to be any direct relationship between the 'Stage of Change' at baseline and 
outcomes at six months. 
With respect to looking at 'Stage of Change' as an outcome measure, where 'success' 
would be considered as positive movement through the model itself, it was expected 
that those in the intervention group would perhaps have shown an increased rate of 
forward movement. It was hoped that the smoking cessation advice given to the 
intervention group would enable them to think more positively about stopping smoking, 
even if they did not quit. 
At 3 months, there was little difference between intervention (14) and control (15) for 
those who moved forwards (Tables 3.40 and 3.41). There were slightly more who 
moved backwards in the control group (12) than for the intervention group (7). With 
respect to the 6-month results, there were slightly more participants in the intervention 
group who moved forward (13), compared to the control group (7), suggesting a 
potential slight benefit from being allocated to this group. However, once again, with 
relatively small numbers, it is difficult to form any firm conclusions. 
None of the dental trials used 'Stage of Change' as a predictor in their study. One study, 
however, used it as a secondary outcome measure at 12 months (Severson et al., 1998). 
The authors reported that there was a statistically significant difference between the 
number of participants in the 'extended' intervention group, who claimed that they 
wanted to quit in the next month, compared to the 'usual care' group. 
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Butler and co-workers (1999) used 'Stage of Change' in a trial in general medical 
practice, reporting patients' self-reported intention to quit at both baseline and 6 
months. No analysis of any movement of the 'Stage of Change' was undertaken 
although the numbers of participants in each 'Stage', at both baseline and 6 months, 
were reported. There was a greater reduction between baseline and 6 months in the 
percentage of participants who claimed to be not interested in quitting in the 
'motivational consulting' group compared to the 'brief advice' group. Between baseline 
and six months there was little change in the proportion of participants claiming they 
wanted to quit within the next month, with similar proportions in the two groups. 
Butler and co-workers also used the baseline 'Stage of Change' to examine whether 
there was the same benefit of 'motivational consulting' over 'brief advice' for 
participants who were not interested in quitting at baseline ('precontemplators') 
compared to participants who showed some interest in quitting ('contemplation', 
'preparation' and 'action'). The analysis showed that the additional effect of 
'motivational consulting' over 'brief advice' was significantly greater for participants 
who were classed as 'precontemplators' at baseline, in terms of self-reporting a quit 
attempt and reducing smoking. There were similar results, although not statistically 
significant, with regard to not smoking in the previous month, not smoking in the 
previous 24 hours, two or more quit attempts and a quit attempt of at least one week's 
duration (all self-reported). 
It is emphasised that the present study was experimental pilot usage of 'Stage of 
Change' in a dental setting. This had not been attempted before. Future work should 
include validating the questionnaire or finding another validated instrument, and further 
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developing meaningful analysis of the data collected. Options could include reanalysing 
the data, using a different definition for 'preparation stage', and analysing the results in 
the manner described above by Butler et ai. (1999). 
4.5 Smoking Cessation and the Dental Team - the way forward 
4.5.1 Secondary Care 
The work of this thesis has shown that, given training in smoking cessation and access 
to NR T for their patients, dental hygienists, working in a secondary care setting, can 
have a modest effect, with regards to the provision of smoking cessation, at least in line 
with success rates reported by other health professionals (NHS Health Scotland and 
ASH Scotland, 2004). 
Research has shown that hygienists tend to be more favourably disposed to the topic of 
smoking cessation than dentists (Fried and Rubenstein, 1990, Halling et ai., 1995; 
Gussy et ai., 1996; Syme et ai., 2001). Dental hygienists are also more likely than 
dentists to routinely advise their patients to quit smoking (Fried and Rubinstein, 1990; 
Chambers and Corbin, 1996; Nicotera et ai., 2004), and are more likely to be proactive 
in assisting their patients (Chambers and Corbin, 1996; Helgason et ai., 2003). 
Therefore, of the dental team members, it would appear that dental hygienists may be 
the most appropriate group to take this topic forward. 
Given the results of the present study, consideration should be given to developing 
smoking cessation services provided by trained dental hygienists, within a dental 
secondary care setting. This would be particularly relevant within Periodontal clinics, 
where patients attend for multiple treatment sessions. During hygiene phase therapy, 
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smoking advice can be integrated into the patient's relevant clinical care. In the present 
study, dental hygienists also discussed NR T with the patients and gave those who 
requested it, supplies of nicotine patches and gum. A contemporaneous trial running in 
a hospital periodontal department, in addition to using NRT, successfully utilised Zyban 
for patient support (Heasman et al., 2004). This trial found a quit rate of 40.5% among 
all participants at 3 months. As this work is very recent, it has yet to be reported in the 
form of a full peer-reviewed pUblication. 
Therefore, potential developments within this field would include investigation of 
methods available for the provision of appropriate pharmacological support, including 
NRT and Zyban. 
Within the restorative discipline, dental implant patients constitute another group who 
could benefit from smoking cessation advice. It is known that the implant failure rate is 
much higher in those who smoke (Bain, 2003). This author has been successful in 
promoting smoking cessation with this group. When looking at smoking cessation 
outcomes at 3 months, 6 months and 1 year, the success rates were 70.2%, 43.9% and 
40.4% respectively (Bain, 2003). However, these outcomes were not biochemically 
validated by cotinine. 
These high cessation rates, no doubt, reflect the motivated individuals who were 
carefully counselled as to the potential higher success rate if they quit smoking. 
Counselling included details about the patient's responsibilities for achieving the best 
prognosis, coupled with the information to cover the clinician in the event of implant 
failure in the non-compliant patient. It would seem unrealistic to translate these high 
238 
cessation rates into any other dental setting except, perhaps, for oral cancer/pre-cancer 
patients and success of smoking cessation programmes with this group is currently 
unevaluated. 
Thus other settings where advice and help regarding smoking cessation should be 
considered, are outpatient Oral Medicine/Oral Surgery clinics. In such settings, patients 
are referred with potentially malignant lesions, with tobacco as a key risk-factor. 
Patients may not attend such clinics as frequently as those in Periodontal departments, 
with treatment planning influenced by their diagnosis. Therefore, patient treatment and 
follow-up may present more of a challenge, compared to the more structured and 
regular-attending periodontal patients. 
Patients who are diagnosed with oral cancer and who smoke, constitute a specialised 
target group for whom a sensitive, individualised approach will be required. Further 
research is required to determine which methodology, with respect to smoking 
cessation, is the most appropriate to be used with this group. 
The dental hygienists who undertook this study were trained in various aspects of 
smoking cessation and were highly motivated. The outcome of future work carried out 
within dental secondary care settings will be dependent on the intervention used and the 
training and level of motivation of those delivering the smoking cessation intervention. 
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4.5.2 Primary Dental Care 
With respect to smoking cessation policy in Scotland, two recently released documents 
both acknowledge the role that dentistry, within the primary care system, can play in 
smoking cessation (NHS Health Scotland and ASH Scotland, 2004; Scottish Executive, 
2004a). However, it is perhaps disappointing that neither of these recent publications 
mentions dental hygienists or other professionals complementary to dentistry, with the 
only reference to dental team members being to the 'dentist', or 'general dental 
practitioner'. Guidance from the Scottish Executive (2004a), states that.. . .'GPs, 
practice nurses, midwifes, dentists, pharmacists, health visitors, and other health 
professionals, all potentially have a role to play in giving smoking cessation advice. 
Such advice need not take long, but the messages need to be consistent.' (Scottish 
Executive,2004a). 
It would appear from recent policy documents that there has been a move away from the 
previously-cited 'stepped care' approach, the focus of earlier recommendations (ASH 
Scotland & Health Education Board for Scotland, 2000). In this previous approach, 
patients were targeted with the least intensive intervention necessary to enable that 
person to stop smoking. There is now also added emphasis on referral pathways to 
specialist services (NHS Health Scotland and ASH Scotland, 2004). It acknowledges 
that there is a .. ' ... vital role in smoking cessation played by GPs and other primary care 
staff, general dental practitioners, community pharmacists ... either in referring 
patients to appropriated services or, if suitably trained and resourced, providing 
smoking support themselves' . 
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This recent recommended approach to smoking cessation, i.e. increased emphasis on 
referral to specialist services, raises two main issues, the first regarding the referral 
process itself, and the second point with respect to training and resources. Both of these 
points will be discussed below. 
The move to greater emphasis being placed on a referral system is not restricted to 
patients from the dental setting, but this mechanism is also recommended for other 
primary care patients, such as those from general medical practice (NHS Health 
Scotland and ASH Scotland, 2004). This approach makes the presumption that there are 
enough places available in the local smoking cessation services to accommodate those 
clients who wish to seek help. Scotland has 1.4 million smokers, with area prevalence 
rates influenced by levels of deprivation. 
Scotland is not the only country to place additional emphasis on referral to the specialist 
services as a means of delivering smoking cessation advice. In the US, the American 
Dental Hygienists Association has launched a tobacco cessation initiative entitled 'Ask, 
Advise and Refer'. This program has a target to increase to 50%, the percentage of 
dental hygienists that screen their patients/clients regarding tobacco use (including rate, 
type and amount) by 2006, from a baseline figure of 25% (Syme et al., 2001). The 
protocol involves asking the patient, advising the patient, and referring the patient for 
specialist help and advice, depending on what is available in the local US area. 
In addition, England have recently (July 2004) released 'Smoking Cessation Guidelines 
for the Dental Team', outlining a revised form of the '4As', where in addition to ask 
and advise, the arrange includes arranging referral to the specialist services, and in the 
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absence of patients wanting to take this course of action, an assist can be used where the 
dental personnel can help the patient set a quit date and provide the patient with more 
detailed help and assistance (Beaglehole and Watt, 2004). 
The second point raised by the NHS Health Scotland and ASH Scotland document, with 
respect to the delivery of smoking cessation services, is in relation to training and 
resources. Currently in Scotland, training in all aspects of dentistry for dental team 
members takes place via the postgraduate/post-qualification course system, 
administered by NHS Education for Scotland. CPD (Continuing professional 
development) courses are aimed at dentists, and PCD (Professionals complementary to 
dentistry) courses are designed to address the training needs of dental hygienists and 
dental nurses. Both types of course have covered 'Smoking Cessation' as one of their 
topics on offer, often as part of a day on 'Oral Cancer Prevention', at various locations 
around Scotland over the last few years. Smoking cessation infonnation also fonns part 
of a distance learning initiative distributed to all dental practitioners (and medical 
practices) in Scotland as part of an oral cancer prevention and detection initiative 
(Macpherson et al., 2003). 
Training standards for smoking cessation in both England and Scotland have been 
released (Health Development Agency, 2003; PATH, 2004). English training standards 
encompass three levels of training, 'brief advice', intensive one-to-one support and 
group interventions. Scottish training standards outline two levels of input; brief advice 
and specialist training support. All training developed in the future, including that for all 
dental team members, will need to encompass the relevant training standards, at 
whatever level is considered appropriate for each professional. 
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As previously stated, the current research was undertaken in a secondary care setting, 
and conclusions can be drawn about its relevance in this context. However, in primary 
care, with particular reference to primary dental care, other factors including the system 
of remuneration will influence the applicability of this work. 
Currently, in the UK there is no specific system of remuneration for dental health 
professionals in primary care to provide smoking cessation advice, in any fonn, to their 
patients. Thus, even 'brief advice' is considered by most dentists to be outwith the 
remit of current practice (Watt et a/., 2004). This lack of remuneration constitutes a 
specific barrier to the widespread adoption of smoking cessation advice within a 
primary care dental setting. Currently the system of remuneration for dental primary 
care in England is under review, and it is unclear what developments may be 
forthcoming, with regards to this area, north of the border. 
In addition, there would appear to be a lack of clarity at present as to the particular 
nature and level of the advice, that it would be appropriate for dental team members to 
deliver, be it 'brief advice', 'brief advice and refer', or more intensive one-to-one 
support, in appropriate situations. Further research into this area, including a health 
economics assessment would have to be undertaken. 
One study has attempted to look at the feasibility of using a fee for referral to the 
specialist smoking cessation services. In this pilot project in Sheffield, the equivalent of 
a check-up fee was given to dentists for referring patients to such specialist services. A 
successful referral was defined as a patient turning up to a smoking cessation clinic and 
setting a quit date. Initial evaluation suggested that, compared to other health 
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professionals such as nurses and phannacists, dentists were not as successful as 
identifying patients who could benefit from support (Beaglehole and Watt, 2004). The 
results would suggest that even at this level of input, further training of dental health 
professionals is required. There would appear to be no similar pilot projects taking 
place in Scotland. 
As workforce problems deepen with respect to numbers of dentists, both north and 
south of the border, in some quarters there will be an argument for dentists to restrict 
their sphere of practice to a more conventional model of delivering dental services, 
rather than more innovative work such smoking cessation. However, over the next few 
years in Scotland, there will be an expansion in the numbers of professionals 
complementary to dentistry, especially dental therapists (NHS Education for Scotland, 
2004). With the links so firmly established between tobacco use and both oral cancer 
and periodontal disease, it would seem a natural progression and extension of the 
hygienists' and therapists' duties, to give smoking cessation advice to their patients. 
However, as previously discussed, a number of issues would need to be addressed, both 
in terms of level of input, training and particularly with regard to funding. These 
professionals complementary to dentistry are likely to be the most cost-effective clinical 
members of the dental team staff to give smoking advice to patients, though as 
discussed previously, further economic costing would need to be undertaken to confirm 
this. 
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4.5.3 Summary 
In conclusion, this project has produced evidence of the potential effectiveness of dental 
hygienists contributing to the field of smoking cessation in a dental hospital periodontal 
department setting. The contribution that dental hygienists can make in other settings, 
such as dental primary care, is at present largely undetermined. However, this will be 
dependent to a large extent on the recommended direction of primary care smoking 
cessation work in Scotland and workforce and remuneration issues. 
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Chapter 5 Conclusions and Recommendations 
5.1 Conclusions 
The aim of this project was to examine the feasibility and efficacy of a smoking 
cessation intervention, delivered by dental hygienists, in a cohort of periodontal patients 
attending an outpatient dental hospital department. 
This work has shown that it was feasible to recruit patients into a smoking cessation 
trial of a ReT design, and deliver smoking cessation advice. 
With respect to the efficacy, this thesis has shown that, given training in smoking 
cessation and access to NR T for their patients, dental hygienists can have a modest 
effect, with regards to smoking cessation, at least in line with success rates reported by 
other health professionals (NHS Health Scotland and ASH Scotland, 2004). Results in 
this study were biochemically verified by carbon monoxide and cotinine. 
At 3 months, of the patients followed-up, 17.3% of the intervention group had quit, 
compared to 10.0% of the controls. Of patients recruited at baseline, 15.3% of the 
intervention group quit compared to 8.8% of controls. 
At the 6-month time point, of the patients followed-up, 16.7% of the intervention group 
had quit, compared to 8.6% of the controls. Of the patients recruited at baseline, 10.2% 
of the intervention group had quit, compared to 5.3% of the controls. Prolonged 
abstinence figures would indicate that of the patients followed-up at 6 months, 11.1 % of 
the intervention group had quit, compared to 8.6% of the control group. When 
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prolonged abstinence is considered in tenus of all recruited patients, the corresponding 
figures were 6.8% of the intervention group and 5.3% of the control group. 
At the l2-month time point, of the patients followed-up, 12.1% of the intervention 
group had quit, compared to 8.7% of the controls. Of the patients recruited at baseline, 
6.8% of the intervention group had quit, compared to 3.5% of the controls. 
With regards to changes in smoking behaviours, at both 3 and 6 months, for those 
patients who were not successful in quitting, a significantly higher number of patients in 
the intervention group self-reported that they had made a quit attempt of one week or 
more in the preceding 3 months: 37% and 47% at 3 and 6 months for the intervention 
group, compared to 18% and 16% respectively for the control group. With regards to 
self-reported reduction in daily cigarettes at 3 months, there was a statistically 
significant difference between intervention and control groups (33% v 0%). By 6 
months, this self-reported difference was not statistically significant. 
When self-reported reduction in smoking was associated with reduction in cotinine 
levels (reduction of smoking between baseline and 6 months), there was a statistically 
significant higher mean reduction in cotinine in the group who reported reducing 
smoking, compared to the group who reported that they had not reduced. 
With regards to using the patients' self-reported 'Stage of Change' at baseline as a 
predictor of likelihood of quitting, at 3 months, of the 14 biochemically validated 
quitters at this point, nine classified themselves as being in the most ready state i.e. 
'preparation' stage. Considering 'Stage of Change' as an outcome measure, where 
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'success' is considered positive movement through the model itself, at 3 months, there 
was no difference between intervention and control groups regarding numbers who 
moved forward. At six months, there were slightly more individuals in the intervention 
group who moved forward compared to the control group. However, this was pilot use 
of this model, and it had never been used in a dental setting previously. With the 
relatively small sample size involved, it is difficult to draw any firm conclusions about 
its use. Further work is required to investigate its potential application within this field. 
5.2 Limitations of the Project 
This project took place in a secondary care dental setting in the West of Scotland, and 
was delivered by three trained and highly motivated dental hygienists. Using different 
hygienists both in similar and different settings, such as general dental practice, may 
have yielded different results. Even within the secondary care dental setting, differing 
results may occur, depending on the exact content of the intervention and the skills and 
motivation of the clinician delivering the intervention. 
This project was designed from a public health perspective and looked at both the 
feasibility and effectiveness of smoking cessation within a secondary care dental setting. 
Although conducted within a Periodontal Department, it was not designed with a 
periodontal perspective as the first order priority. A prospective study, focussing on 
periodontal outcomes and how the smoking cessation process potentially benefits 
patients' periodontal health, would have been an important and interesting project. 
However, a smoking cessation intervention designed to collect meaningful data with 
respect to periodontal outcomes would have required a larger number of patients to be 
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recruited, to ensure enough quitters at follow-up, and as such, was outwith the resources 
available for this project. 
The number of participants recruited was relatively small, though of a similar size to 
some other smoking cessation trials (Macgregor, 1996; Smith et a/., 1998). There was 
some difficulty experienced in attempting to achieve the target of 120 participants at 3-
months follow-up, as only 118 were recruited, and it was not possible to extend the 
recruitment due to time constraints. In addition, it is not known how many patients 
were approached and refused, as this information was not collected. This would have 
been difficult to do, as the consultants who recruited the patients are under various time 
pressures. However, in any future studies, details of the numbers of patients approached 
should be collected by the researcher, if at all possible. 
No health economic analysis of this project has been undertaken to date. This was 
considered outwith the scope of this PhD. However, information concerning the 
hygienists' time involvement, success rate of the trial, costs of NRT and biochemical 
monitoring, including CO and cotinine testing has been collected, thus allowing 
economic analysis to be conducted in the future. Comparison of the approach used in 
this study with referral to the specialist services could also be made. 
In the US, dental hygienists have been involved previously in the promotion of smoking 
cessation with patients who use smokeless tobacco (Severson et a/., 1998). As stated 
previously, the target group used in this study was cigarette smokers, with those using 
other forms of tobacco excluded. Smokeless tobacco, including the forms used by 
ethnic minorities, is an important public health problem, but addressing the issues 
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around promoting smoking cessation with this group was outwith the scope of this 
thesis. Ethnicity was not an element collected as a patient descriptor, but any future 
smoking cessation work undertaken would collect such information. 
5.3 Recommendations and Future Work 
5.3.1 Cotinine and Carbon Monoxide Monitoring 
It is known that cotinine (COT), with its longer half-life than carbon monoxide (CO), 
can measure nicotine exposure in both smokers and non-smokers over a longer period 
of time. Cotinine (COT) is used mainly in research, whereas CO is used routinely in 
smoking cessation services. An advantage of the use of CO is that values can be fed 
back to the patients when smoking cessation advice is being given, and hence used as a 
motivational aid. Other means of using cotinine, with more instant feedback 
mechanisms, such as the near-patient test, should be evaluated for use within a dental 
setting. 
The relationship of both biochemical measures, i.e. COT and CO, and nicotine 
dependence, as measured by both Heaviness of Smoking Index and Fagerstrom Testfor 
Nicotine Dependence, should be evaluated, using the available dataset. 
In addition, the specificity and sensitivity of CO and COT should be investigated, with 
reference to self-report. 
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5.3.2 Smoking Cessation 
5.3.2.1 Further Analysis of Data collected 
Further work to identify the significant factors m predicting change in smoking 
behaviours of participants, for example using classification trees, could be undertaken. 
Potential predictors would be baseline demographics, smoking habits, level of 
physiological dependence as measured by the FTND, and motivation to quit. Both 
primary and secondary outcomes could be examined. 
Further analysis with respect to 'Stage of Change' should be undertaken. One aspect 
would be to carry out analysis using a different definition of the 'preparation' stage, as 
previously discussed. A further option would be to run an analysis of 'Stage of 
Change' similar to the methodology of Butler et al., (1999). 
5.3.2.2 Development of Smoking Cessation Services 
Given the results of the present study, staff within Periodontal Clinics should consider 
the feasibility of developing smoking cessation services delivered by dental hygienists. 
A protocol for smoking cessation based on 'brief advice' and utilising a simplified 
version of patient assessment could be developed. 
Other departments such as Oral Surgery/Oral Medicine departments may benefit from 
the availability of such services, for patient groups such as those with potentially 
malignant lesions. In addition, other patients such as those undergoing dental implant 
treatment, may also be a suitable target group. Such developments should include an 
economic analysis of the cost-effectiveness of such work, involving different models of 
delivery. 
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5.3.2.3 Qualitative Research involving Smoking Cessation in a Dental Setting 
Qualitative work, using focus group methodology, was undertaken, with the staff dental 
hygienists who participated in this project. The aim was to detennine their perceptions 
of the delivery of smoking cessation to their patients. Further analysis of this data 
should be carried out, to elicit the various strengths and barriers they encountered in 
their work. 
There is much questionnaire data available on the perceived roles of dentists and dental 
hygienists with respect to smoking cessation. However, very little qualitative research 
has been conducted regarding dental team members' attitudes to this activity. 
Qualitative work would enable some of the issues associated with remuneration and 
training to be explored in more depth, and the feasibility of the implementation of 
different models, be they 'very brief advice and refer' or 'brief advice', to be discussed. 
Dentists and dental hygienists from both primary and secondary care should be 
interviewed in depth. 
In addition, it would be useful for patients within a dental setting to give their opinions 
and perceptions on smoking cessation, as delivered by dental team members. 
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5.3 Dissemination of Results 
The results of this project should be disseminated to those developing smoking 
cessation policy at national and local levels. Dental health professionals should also be 
made aware of the findings through presentations and publications in peer-reviewed 
journals. 
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Appendix 1 
Smoking and Socioeconomic group 
Data from the 1998 General Household Survey (UK) 
Prevalence of cigarette smoking by sex and socio-economic group: 1976 to 1988, 
adults aged 16 and over in the UK 
Year 1976 1986 1990 
Men % 
SEG 1 25 18 16 
SEG2 38 28 24 
SEG3 40 28 25 
SEG4 51 40 36 
SEG 5 53 43 39 
SEG6 58 43 48 
Women 
0/0 
SEG 1 28 19 16 
SEG2 35 27 23 
SEG3 36 27 27 
SEG4 42 36 32 
SEG5 41 35 36 
SEG6 38 33 36 
SEG 1 - Professional occupations 
SEG 2 - Employers/Manager 
SEG 3 - Intermediate/Junior/non-manual 
1992 
14 
23 
25 
34 
39 
42 
13 
21 
27 
31 
35 
35 
SEG 4 - Skilled manual/own account non-professional 
SEG 5 - Semi-skilled manual/personal service 
SEG 6 - Unskilled manual 
1994 1996 1998 
16 12 15 
20 20 21 
24 24 23 
33 32 33 
38 41 38 
40 41 45 
12 11 14 
20 18 20 
23 28 24 
29 30 30 
32 36 33 
34 36 33 
/ 
Data from Scottish Health Survey, 1998 
Prevalence of cigarette smoking in Scotland, by sex and socioeconomic group: 
1995 and 1998, adults aged 16-64 
Men 0/0 1995 1998 
Professional Occupations 17 14 
Managerial/technical 24 27 
Skilled non-manual 27 36 
Skilled manual 38 40 
Partly skilled occupations 46 53 
Unskilled occupations 58 48 
Women % 1995 1998 
Professional occupations 19 9 
Managerial/technical 24 26 
Skilled non-manual 35 29 
Skilled manual 40 36 
Partly skilled occupations 47 51 
Unskilled occupations 54 59 
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I write to inform you that your protocol for the clinic research project has been 
approved by the Area Dental Ethics Committee subject to: 
• an assurance of compliance with the Data Protection Act; 
• amendment to the information sheet deleting the word "may" in the sentence 
commencing "you may already need some blood"; 
• there should be clarification of the time required for sampling. 
The Committee would be grateful if you would inform them of the results of your 
project and any ethical problems encountered when the project is complete. 
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Appendix 3 
University of Glasgow Dental School 
Information Sheet to Patients 
Here at Glasgow Dental Hospital and School we are looking at measuring patients' 
exposure to tobacco smoke in a study entitled: 
"The Validation of Self-Reported Smoking Status by Analysing Systemic Cotinine 
Levels in Blood, Urine and Saliva". 
F or this we require patients, both smokers and non-smokers. If you agree to take 
part, you will be asked some questions about your contact with cigarette smoke and 
requested to provide two saliva samples and some scrapings from your cheek,- this 
procedure will be performed painlessly. In addition, we will also require a sample of 
urine and blood. You may already need some blood to be taken for routine 
examination today, and in this case, a small amount extra will be taken. 
Each of these samples will take only a few minutes to collect. They will then be sent 
to a laboratory, and the level of nicotine compounds measured. Patient confidentiality 
with regard to this study is assured. 
If you have any questions about this study or require further details, please contact 
one of the principal investigators: 
Mrs V. Binnie 
Dr J Gibson 
Dr L. Macpherson 
telephone number: 0141-211-9688 
telephone number: 0141-211-9833 
telephone number: 0141-211-9751 
In addition the staff and students conducting this study will be able to answer any 
queries. 
/ 
Consent Form 
1 ______________________________________________________ _ 
of 
-----------------------------------
freely and voluntarily agree to participate in a clinical study entitled: 
The Validation of Self-Reported Smoking Status by Analysing Systemic Cotinine 
Levels in Blood, Urine and Saliva 
I have read the accompanying information sheet. The nature and purpose of the study 
have been explained to me by 
Dr 
-------------------
I have had the opportunity to ask questions and I fully understand what is proposed. 
I recognise that I may receive no benefit from the study. I accept that there may be 
other risks procedure which are not directly attributable to negligence on the part of 
those undertaking the procedures. 
I understand that I am free to withdraw my consent at any time without prejudice to 
me or my medical and dental care. 
I have been assured that any information obtained from me will not be disclosed 
without my permission to any third party in a manner which will reveal my identity. 
Signature ________________________ _ 
Date: 
I confirm that I, Dr have explained the 
nature and purpose of the clinical research study and the procedures in respect on 
which consent has been given by the above named. 
Signature _______________ __ Date 
-------------
Appendix 4 
SMOKING QUESTIONNAIRE 
Name: 
Age: yrs I 
Gender: Male 0 Female o 
Occupation: 
Post Code: 0000 000 
Do you smoke cigarettes? Yes 0 No o 
Smokers 
What do you smoke? Cigarettes 0 
Cigars 0 
Pipe 0 
How many cigarettes do you smoke per day? <10 0 
10-20 0 
>20 0 
What brand of cigarettes do you smoke? 
What is the tar level of the cigarettes you smoke? High 0 
Middle 0 
Low to Middle 0 
Low 0 
Varied 0 
Do you inhale the smoke? Not at all 0 
Slightly 0 
Medium 0 
Deeply 0 
How many hours since your last cigarette? hrsl 
/ 
Are you using any nicotine replacement therapy? 
If yes, are you using nicotine: 
Non-Smokers 
Does anyone in your household smoke around you? 
Does anyone in your work place smoke around you? 
Yes D 
Patches 
Gum 
Inhaler 
Yes D 
Yes D 
No 
No 
No 
How many hours of passive smoking have you been exposed to per day in the last 
week? 
Have you been exposed to any passive smoking during the past 24 hours? 
None D <1 hour D 1-5 hours 
Are you using any nicotine replacement therapy? 
If yes, are you using nicotine: 
Time of Data Collection: 
D >5 hours 
Yes D No 
Patches 
Gum 
Inhaler 
D 
D 
D 
D 
D 
D 
hrsi 
D 
D 
D 
D 
o 
Patient Acceptability Questionnaire 
How acceptable did you find the collection of the different samples? 
Sample Very Moderately Tolerable Not at all 
Acceptable Acceptable Acceptable 
Saliva drool D D D D 
Saliva-cotton roll D D D D 
Blood D D D D 
Urine D D D D 
,} 
Appendix 5 
Training of Staff Hygienists involved in the Intervention 
Basic Smoking Cessation Training 
• Two 3-hour sessions 
• delivered by Ms Fiona Campbell, 
Smoking Concerns 
Nicotine Replacement Therapy Training 
• One 3-hour session 
• delivered by Ms Fiona Campbell, 
Smoking Concerns 
Smoking Cessation Trial Methodology 
• One 3-hour session 
• delivered by Mrs V. Binnie 
• Basic epidemiology of nicotine 
addiction and diseases caused with 
regards to smoking 
• Role of nicotine and nicotine 
dependence 
• Basic smoking cessation skills 
including how to give 'brief advice' 
• Assessing a client's readiness to 
change including 'Cycle of 
Change' 
• Discussing ways of motivating a 
quit attempt. Information on how to 
support a client's quit attempt 
• Information about resources 
available such as carbon monoxide 
monitors 
• Nicotine withdrawal 
• Use of nicotine replacement 
therapy products including 
cautions and side-effects 
• Relevant clinical guidelines on the 
use ofNRT 
• Demonstration of NRT products 
and their usage 
• Use of Zyban, contraindications, 
cautions and side-effects (for 
information only) 
• Additional information on the oral 
health aspects of tobacco use and 
smoking cessation 
• Information on trial methodology, 
including collection of data and 
use of questionnaires 
• 'SA's methodology 
• Salivary cotinine sampling 
methodology 
• Use of CO monitors 
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Miss V Binnie 
Lecturer in Oral Health Promotion 
Post Graduate Centre 
9th Floor 
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Dear Miss Binnie 
Secretary (0141 ) 211 9796 
PROTOCOL "SMOKING RELATED BEHAVIOUR CHANGE IN PERIODONTAL PATIENTS WHO ARE 
GIVEN 'BRIEF' SMOKING CESSATION ADVICE, DELIVERED BY DENTAL HYGIENISTS - A 
RANDOMISED CONTROL TRIAL" 
I refer to the above Protocol which was submitted to the last Ethics Committee meeting on 15 January 
2001. 
This protocol is approved. 
Yours sincerely 
,/, ... , 
/; " \ {{- (' <' '(. \ 
o Kinane 
Chainnan 
Appendix 7 
STOPPING SMOKING STUDY 
Smoking weakens gums and, therefore, smokers have more severe gum infection than non-
smokers. Patients who give up smoking during the course of their treatment are more likely 
to achieve healthy gums. We explain this to all our patients and recommend that they should 
give up smoking. 
Smokers who require professional help to give up smoking will usually be able to obtain it 
from their doctor or pharmacist. However, we would like to know whether smokers are more 
likely to quit if skilled help is made available in our department during the course of their 
gum treatment, and we have designed a project to find out. An outline of this project is given 
below. 
We are inviting smokers, whether or not they want to quit, to complete a questionnaire about 
their smoking habits and to give us a sample of saliva. Patients will then be divided into two 
groups: 
Group 1 - Patients in group 1 will receive gum treatment without any help to stop 
smoking 
Group 2 - Patients in group 2 will receive advice on how to stop smoking and will be 
offered free nicotine replacement therapy (gum or patches). 
You will have an equal chance of being placed in either group. Of course, those who are 
placed in group 1, which is scheduled not to receive additional advice or nicotine replacement 
therapy can, if they wish, ask their doctor for this assistance or obtain help elsewhere. 
Patients in group 2 will be given advice to stop smoking by their dental hygienist. This advice 
will be given to all patients in group 2 even if they have no intention of giving up. All the 
dental hygienists have been specially trained to do this, and the advice will be given during 
normal treatment visits. 
In a few months, patients in both groups will be asked for a further sample of saliva and 
asked whether their smoking habits have changed. 
If, having read this information, you decide that you do not wish to be part of this study, 
please be reassured that you can decline without prejudice to your dental care. All 
information that you provide will be totally confidential. If you require any information about 
this study, please contact one of the individuals below: 
Mrs V Binnie - Glasgow Dental School, tel: 0141-211-9802 
Dr W Jenkins - Glasgow Dental Hospital, tel: 0141-211-9857 
/ 
Consent Form 
1 ______________________________________________________ ___ 
of 
------------------------------------------------------------
freely and voluntarily agree to participate in a clinical study entitled: 
Smoking-related Behaviour Change in Periodontal Patients who are given 'Brief' 
Smoking Cessation Advice/ NRT, delivered by Dental Hygienists- a randomised control 
trial. 
I have read the accompanying information sheet. The nature and purpose of the study have 
been explained to me by 
I have had the opportunity to ask questions and I fully understand what is proposed. 
I recognise that I may receive no benefit from the study. 
I understand that I am free to withdraw my consent at any time. 
I have been assured that any information obtained from me will not be disclosed without my 
permission to any third party in a manner which will reveal my identity. 
Signature _____________________________________ _ 
Date: 
I confirm that I, have explained the nature and 
purpose of the clinical research study and the procedures in respect on which consent has 
been given by the above named. 
Signature ______________________________ Date ____________ _ 
Glasgow Dental Hospital & School 
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GDH numberOOOOOOO Study numberOOOO 
Hygienist Initials Date _______ _ 
SMOKING QUESTIONNAIRE - BASELINE 
Name: 
Age: yrsl 
Gender: MaleO Female 0 
Occupation: 
Post Code: 0000 000 
Please Tick 
How many cigarettes do you smoke per day? 10 or less 
11-20 
21-30 
31 or more 
Can you give us an exact number per day 00 
How soon after you wake up do you smoke your first cigarette? 
Within 5 minutes 
6-30 minutes 
31-60 minutes 
Longer than that 
Which cigarette would you hate most to give up? 
First in the morning 
Any of the others 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
Do you smoke more frequently during the first hours after waking than during the rest of the 
day? 
YES 
NO 
Do you smoke when you are so ill that you spend most of the day in bed? 
YES 
NO 
Do you find it difficult to refrain from smoking in public places where it was 
forbidden eg cinema, on airplanes, public buildings etc? 
YES 
NO 
o 
o 
o 
o 
o 
D 
How many years have you smoked? 
What brand of cigarettes do you smoke? 
What tar level? 
How often do you inhale the smoke? 
Never 
Sometimes 
Always 
Does anyone in your household smoke around you? YES 
D 
Does anyone in your work place smoke around you? YES 
D 
Would you give up smoking altogether, if you could do so easily? 
Yes, definitely Yes, probably Possibly Probably not 
D D D D 
How much do you want to stop altogether? 
Not at all Slightly Moderately Quite strongly 
D D D D 
Please tick ./ 
D 
D 
D 
NO 
D 
NO 
D 
Definitely not 
D 
Very strongly 
D 
If you want to stop, what are your main reasons? (Please tick"; ALL that apply) 
Your health YESD NoD 
The expense YEsD NoD 
Not fair on other people YESD NoD 
Don't like being addicted YESD NoD 
Some other reason YEsD NoD 
What do you think your biggest problem will be in stopping smoking? 
And finally, which of the three statements below best describes you? 
Please tick 0/ only ONE. 
YES 
Are you a smoker at the moment and not thinking about giving up? D 
Are you concerned about your smoking and thinking about giving up D 
in the next 6 months? 
Are you ready to stop smoking and are thinking about giving up in the D 
next 30 days? 
And about your quit attempts in the last year? 
Have you tried quitting in the last year? 
If you answered YES to the above question, 
Could you answer the two questions below. 
Have you had two or more quit attempts? 
Had a quit attempt lasting a week or more? 
YES NO 
D 
D 
D 
D 
D 
D 
Thank you for your help in answering this questionnaire. 
Carbon Monoxide Level D D 
Cotinine sample D Time of sample 
---
Time of last cigarette __ _ 
:? ) 
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Smoking Cessation 5As Protocol 
Study NumberOOO 
Visit numberOO Date 
Case Number 00000000 
Patient Name 
---- ---------
ASK (can refer to questionnaire) 
Smoking History 
• How long has patient smoked? 
• How many at present? 00 
• Patient smoke regularly throughout day or mainly evening? 
• What products are used? ______________ _ 
ADVISE 
• Advice to be clear, strong and personalised. 
• 'I believe that it is important for you to quit smoking for your oral 
health as well as your general health and we can help you ........ . 
• emphasise the perio aspect of smoking as well as oral cancer. 
ASSESS 
willingness to quit 
• patient willing to make a quit attempt ___ ASSIST 
• patient unwilling to make a quit attempt ___ 5R's 
• patient willing to make some change in smoking behaviour 
(Risk Reduction) 
ASSIST 
• SET QUIT DATE (ideally within 2 weeks) 
• tell family and friends about quitting 
• identify likely problems and solutions, 
o 
o 
o 
o 
o 
o 
o 
o 
D 
o 
e.g. other smokers, use of alcohol 
• plan how to cope with increase in food and drink 
• infonnation about NRT 
• prescribe NRT? See NRT sheet 
• Infonnation about Zyban 
• Give quit pack 
• Telephone help line number 
5 Rs 
D 
D 
D 
D 
D 
D 
o 
• Emphasise the relevant benefits for the patient 0 
• Emphasise the risks of continuing to smoke D 
• list the rewards from stopping 0 
• discuss the roadblocks to quitting (withdrawal symptoms, lack of support) 0 
• emphasise that repeat attempts are more successful 0 
Risk Reduction 
• thinking about reducing number of cigarettes 
• reduce cigarettes to less than half of consumption 
• Thinking about making a quit attempt of 24 hours or more. 
Arrange Follow -up 
• Arrange next appointment 
• At next visit reinforce the 5 A's. 
Comments 
o 
o 
o 
D 
D 
2 
CO level DD 
Prescription for NRT 
Nicotine Patches (high, ISmg) D 
Nicotine Patches (med, 10 mg) D 
Nicotine Patches (low, Smg) D 
Nicotine Gum (high) - 4mg D 
Nicotine Gum (low) - 2mg D 
No of packs D 
No ofpacksD 
No ofpacksD 
No of packs D 
No ofpacksD 
3 
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CaseRecord D D D D D D D Date----- 3 6 
Study number D D D 
FOLLOW-UP SMOKING QUESTIONNAIRE 
Name: 
Age: 
Gender. Male D Female D 
Occupation: 
Post Code: DDDD DDD 
Please tick where required 
Are you currently a smokerD ------------------ - please go to section 2 (page 2) 
Are you currently not smoking D ----------------- please answer section 1 
Section 1- Ex-Smokers 
If you are an ex-smoker, when did you give up? ___________ _ 
Did you use any Nicotine Replacement Therapy (gum/patches) ? YES D 
If yes, what did you use? 
Did you use Zyban? 
If YES, for how long? 
What else helped you? 
YEsD NOD 
NoD 
Section 2 - Smokers 
Have you made any changes in smoking habit, if you are still smoking: 
Have you made any quit attempts in the last 3 months YES D NO D 
Have you had two or more quit attempts? YES D NO D 
Have you had a quit attempt of 24 hours or longer? YES D NO D 
Have you had a quit attempt of one week or longer? YES D NO D 
Have you managed to delay smoking for longer than 
five minutes after waking YES D NO D 
Have you managed to reduce smoking: 
Reduce number of cigarettes YES D NO D 
If YES. can you tell us from __ cigarettes to __ cigarettes. 
Inhale Less YES D NoD 
Smoke less of a cigarette before stubbing out 
YESD 
Changed to a low-tar brand 
Any other changes in smoking habits: 
How many cigarettes do you smoke per day? 
Can you give us the exact daily number DO 
YEsD 
10 or less 
11-20 
21-30 
31 or more 
NoD 
NoD 
D 
D 
D 
o 
) 
-.-
How soon after you wake up do you smoke your first cigarette? 
Within 5 minutes 
6-30 minutes 
31-60 minutes 
Longer than that 
Which cigarette would you hate most to give up? 
First in the morning 
Any if the others 
D 
D 
D 
D 
D 
D 
Do you smoke more frequently during the first hours after waking than during the rest ofthe 
day? 
YES 
NO 
Do you smoke when you are so ill that you spend most of the day in bed? 
How many years have you smoked? 
What brand of cigarettes do you smoke? 
What tar level? 
Do you inhale the smoke? 
Never 
Sometimes 
Always 
YES 
NO 
Does anyone in your household smoke around you? 
Does anyone in your work place smoke around you? 
YEsD 
YESD 
D 
o 
D 
D 
Please tick 
NO D 
NoD 
D 
D 
D 
Would you give up smoking altogether, if you could do so easily? 
Yes, definitely Yes, probably Possibly Probably not Definitely not 
D D D D D 
How much do you want to stop altogether? 
Not at all Slightly Moderately Quite strongly Very strongly 
D D D D 
And finally, which of the three statements below best describes you? 
Please tick only ONE. 
D 
YES 
Are you a smoker at the moment and not thinking about giving up? D 
Are you concerned about your smoking and are thinking about giving up D 
in the next 6 months? 
Are you ready to stop smoking and are thinking about giving up D 
in the next 30 days? 
Did you find the advice on stopping smoking from the dental staff helpful? 
YEsD NO D 
Any further comments regarding any aspects of this study? 
Thank you for answering this questionnaire. COLevel DO 
Cotinine o Time taken ___ _ Time of last Cigarette __ _ 
Appendix 11 
1 year Telephone Reviews in Smoking Cessation Trial 
Name 
---------------------------
Log number 000 
Allocation I c 
Hygienist EW VG PJ 
Date of Baseline Questionnaire. 0 0 0 0 0 0 
Have you smoked a cigarette, even a puff, in the past 7 days? 
YES 0 
If yes, do you consider yourself to be a regular smoker YES 0 
If yes, how many cigarettes per day? 0 0 
If no, describe your smoking habits 
NO 0 
NO 0 
If you are a smoker, or have started smoking again, have you tried any further 
quit attempts, or feel more able to try a further quit attempt. 
YES 0 NO 0 
Why do you think you smoke the same or more than you did a year ago? 
(DO NOT PROMPT) 0 
Wasn't ready to give up 0 
Related to stress 0 
Patches didn't work 
Too hard to give up 0 
Changed my mind 0 
Individual problems/circumstances 0 
Other (please specify) 
Total Cessation/Occasional smoker/regular smoker/unreported 
Occasional - less than 5 cigarettes per week. 
/ 
Log number 
Please fill in the questionnaire below 
1. Have you smoked a cigarette, or even a puff in the past 7 days? 
Yes D No D 
2. If yes, do you consider yourself to be a regular smoker? 
Yes D No D 
3. If yes, how many cigarettes per day? D 
4. If no, please describe your smoking habits 
5. If you are a smoker, or have started smoking again, have you tried any 
further quit attempts, or feel more able to try a further quit attempt. 
Yes D No D 
6. Why do you think you still smoke? 
Thank You for taking the time to complete this questionnaire 
Appendix 12 
I 
I 
Rates of abstinence for six months or longer compared 
with will-power or placebo alone 
I nten ell! ion 
Wr tten self hel matenals 
-.-
Telephone counsellin~ 
Brief opportunistic advice from a GP or outpatient doctor to stop 
Face to face intensive behavioural support from a specialist 
Various forms ofNRT with limited or intensive behavioural support 
Bupropion (300 mglday sustained release) with intensive behavioural support 
l' Ired 
sIZe 
I , 
, lYo 
2% 
2% 
4-7% 
5-12% 
9% 
Adapted from Smoking Cessation Guidelinesfor Health Professionals: an update (West 
et a/., 2000). The effect size is the difference in>6 month abstinence rate between 
intervention and control/placebo in the studies. Studies were mainly Cochrane meta-
analyses. 
/ 
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Lancaster BSDR Meeting, 2000 
Passive smoking and it's effects on cotinine levels 
V. Binnie, S. McHugh, K. Malik, K. Moir, L. MacPherson, W. Borland l 
University of Glasgow, Scotland, I Glasgow Royal Infirmary 
Cotinine can be used to quantify exposure to environmental tobacco smoke (passive 
smoking). The aim of this study was to examine reported levels of nicotine exposure 
due to passive smoking and relate this to the levels of cotinine found in different body 
fluids. 33 non-smokers participated, with each being asked to provide samples of 
blood, urine and both stimulated and unstimulated saliva, together with information 
on their environmental exposure to smoke either in the home or workplace. 33% of 
participants were exposed to smoke at home and 18% were exposed to smoke in the 
workplace. In the 24 hours prior to providing the fluid samples, 64% of participants 
had no exposure to smoke and 36% had been exposed to smoke. The mean cotinine 
levels of serum, urine (corrected for concentration using the cotinine/creatinine ratio), 
stimulated and unstimulated saliva in participants with no exposure to smoke in the 
previous 24 hours were 3.1, 1.8 1.4 and 0.4 ng/ml, respectively, whilst the mean 
cotinine levels in non-smokers who had been exposed to smoke were 34.0, 10.8, 12.5 
and 7.6 ng/ml respectively. However, due to the relatively small number of 
participants, no statistical significant difference was found between the mean cotinine 
levels of non-smokers who were and were not exposed to smoke, for each of the four 
types of sample (all p-values >0.05). 
This study suggests that there may be a difference in the cotinine levels of non-
smokers who have and have not been exposed to smoke and further work with a 
larger sample is indicated. 
Lancaster BSDR Meeting, 2000 
The effect of nicotine exposure on the cotinine levels in smokers 
K. Malik, V. Binnie, K. Moir, L. MacPherson, W. Borland l , S. McHugh 
University of Glasgow, Scotland, IGlasgow Royal Infirmary 
Determination of a smoker's degree of exposure to nicotine, can be assessed by 
measuring the level of cotinine in various biological fluids. The aim of this study was 
to relate reported smoking habits to the levels of cotinine found in a group of 
smokers. Participants were asked about the number of cigarettes smoked per day, tar 
level and inhalational habits. A total of 52 smokers took part (24 males). The 
participants were asked to contribute four different biological samples: blood, urine 
and samples of both stimulated and unstimulated saliva. With regards to the serum 
levels, those smoking <10 cigarettes a day had a mean cotinine level of 261 ng/ml, 
which was significantly lower than the mean cotinine level of 395 ng/ml for those 
smoking >20 cigarettes/day (p=0.04). The mean cotinine level measured from the 
urine samples was 142 ng/ml for participants smoking <10 cigarettes a day. This was 
significantly lower than both the mean cotinine level of those smoking 10-20 
cigarettes/day (357 ng/ml) and those smoking >20 cigarettes/day (522 ng/ml) 
(p<0.01). Similar patterns were found from both the saliva samples, with the mean 
levels of cotinine found in the stimulated sample (chewing on a cotton wool roll) 
being significantly lower than those found in the unstimulated (drool) sample 
(p<O.OI). There was little relationship found between either the tar level and cotinine 
levels or the inhalational habits and the cotinine levels, in the four fluids from the 
smokers. 
This study reveals that a dose-response can be elicited for smoking habits and this is 
consistent in all four biological fluids. Levels of cotinine in saliva are dependent 
upon the method of salivary collection used, with a significantly higher level of 
cotinine being found in unstimulated saliva. 
Lancaster BSDR Meeting, 2000 
Cotinine estimation in biological fluids - patient acceptability 
K. Moir, V. Binnie, K. Malik, L. MacPherson, W. Borland1, S. McHugh 
University of Glasgow, Scotland, lGlasgow Royal Infirmary 
Cotinine, a metabolite of nicotine, can be used for determining exposure to nicotine 
via various biological fluids. In this study, participants were recruited via a dental 
hospital Oral Medicine department. They were asked to provide four biological 
samples: saliva collected via chewing on a cotton wool roll, a sample of unstimulated 
saliva as well as blood and urine specimens. The subjects were also asked about the 
acceptability of the differing methods of sample collection. Samples were analysed 
using an immunoassay kit (Cozart). Data were collected from 85 subjects: 52 
smokers and 33 non-smokers. Using a cut-off point of 20ng/ml, correct classification 
of smoking status was achieved for 98%, 96%, 96% and 94% of the smokers, and 
94%,97%,94% and 94% for the non-smokers, using the cotinine measurements from 
serum, urine, stimulated and unstimulated saliva, respectively. There was a significant 
difference between the percentages of participants who found each of the four 
methods 'very acceptable' (p<O.OI), with 67% and 65%, respectively rating the blood 
and urine collection methods as being very acceptable, whilst only 49% and 45% 
(respectively) rated the unstimulated and stimulated saliva very acceptable. 8% of 
participants rated stimulated saliva as 'not acceptable' (1% thOUght unstimulated 
saliva was not acceptable, whilst none of the participants found the blood or urine 
collection methods 'not acceptable'. 
This study reveals that cotinine levels, as determined by an immunoassay kit. are a 
good indicator of a subject's smoking status, but while cotinine estimation using 
saliva is often the method of choice, being a non-invasive technique, this may not be 
the method which is most acceptable to the patient. 
Cardiff PEF Meeting 2002 
Nicotine dependence and cotinine & carbon monoxide levels in smokers 
V.1. Binnie, S. McHugh, L.M. MacPherson, W. Jenkins, W. Borland 
(Glasgow Dental Hospital & School, lDept of Biochemistry, Gartnavel General 
Hospital, Glasgow) 
There is increasing recognition of the role that dental health professionals including 
hygienists can play in promoting smoking cessation. Baseline characteristics were 
examined in 86 smokers recruited to a smoking cessation trial in a periodontal clinic. 
Participants were asked to complete a questionnaire examining smoking habits and 
readiness to quit. Patients were also asked to provide a salivary sample for cotinine 
(COT) analysis and an exhaled air sample for carbon monoxide (CO) analysis, to 
determine baseline exposure to nicotine. The mean age of the participants was 41 yrs, 
with 69% (59) being female. The majority smoked between 11 and 20 cigarettes with 
a mean of 19 cig/day. When assessing nicotine dependence the mean Heaviness of 
Smoking (HSI) was 3.3, with the mean Fagerstrom Test for Nicotine Dependence 
(FTND) being 4.8. Of the participants, 15% (13) were not interested in stopping 
smoking, 44% (38) were concerned about their smoking, and 40% (35) were 
interested in trying to stop within the next month. The mean level of CO for the 
participants was 22ppm, and the mean level of COT was 244ng/ml. There was a 
statistically significant positive correlation of 0.51 between CO and COT levels. The 
mean COT for the highly dependent group (FTND ~6, n=34) was 281ng/ml, which 
was significantly higher than that of the less dependent group (FTND<6, n=52, mean 
COT 220nglml). A similar relationship was also found between CO levels in the two 
dependency groups (27ppm and 18ppm, respectively). 
Significant associations between COT and CO were found in relation to the level of 
dependency as measured by FTND; this may be an important predictor of likelihood 
of quitting. 
Gothenburg IADR Meeting, 2003 
Dental Hygienists' Delivery of Smoking Cessation: 3-month Outcomes 
V. Binniel, S. McHughl, L.M. MacPhersonl, W. Jenkins2, W. Borland3 
lUniversity of Glasgow, United Kingdom, 2Glasgow Dental Hospital, United 
Kingdom,3Gartnavel General Hospital, Glasgow, United Kingdom 
Objectives: To examine the feasibility and efficacy of a smoking cessation 
intervention, delivered by dental hygienists, in a cohort of patients attending a 
specialist periodontal department in a dental hospital. 
Methods: One hundred and eighteen new patients were recruited into a randomised 
controlled smoking cessation trial. Dental hygienists offered those patients allocated 
to the intervention group smoking cessation advice based on the 5As and free nicotine 
replacement therapy, in addition to their periodontal treatment. The patients in the 
control group were only given brief advice at point of recruitment. At baseline, all 
participants were asked to complete questionnaires assessing their smoking habits and 
readiness to quit, as well as providing a salivary sample for cotinine analysis. Follow-
up information and questionnaires were available for 103 (87%) of the participants at 
3 months. 
Results: The mean age of the participants was 41 years (SD 10), with 70% being 
female. In the intervention group, 17% of the participants quit, compared with 12% of 
the control group (biochemically validated). With regards to secondary outcomes in 
smokers, a significantly greater percentage of participants in the intervention group 
claimed to have reduced their smoking than in the control group (79% vs 47%, 
p=0.002). There was a significantly higher mean percentage reduction in cigarettes 
per day in the intervention group (32%) than in the control group (19%) (p=0.013, 
95%CI (3, 23)%). When asked about their quit attempts, 36% of the intervention 
group claimed to have had a quit attempt of 1 week or more, compared with 18% of 
the control group (p=0.059). 
Conclusion: There is increasing recognition of the role that dental health 
professionals including hygienists can play in promoting smoking cessation. Dental 
hygienists in a hospital setting can deliver effective smoking cessation advice as part 
of their contribution to treatment. 
Gothenburg IADR Meeting, 2003 
Prediction of Primary and Secondary Outcomes in a Smoking Cessation Trial 
S. McHugh!, V. Binnie!, L.M. MacPherson!, W. Jenkins2, W. Borland3 
!University of Glasgow, United Kingdom, 2Glasgow Dental Hospital, United 
Kingdom,3Gartnavel General Hospital, Glasgow, United Kingdom 
Objective: To identify significant factors in predicting changes in smoking behaviour 
of participants in a smoking cessation trial. 
Methods: One hundred and eighteen participants were recruited into a randomised 
controlled trial which aimed to compare the delivery of smoking cessation advice and 
nicotine replacement therapy, delivered by dental hygienists, with brief advice alone 
given at the recruitment visit. Participants completed questionnaires at baseline 
eliciting smoking habits and readiness to quit. Potential predictors extracted from the 
baseline data included demographics, smoking habits, level of physiological 
dependency on nicotine, as defined by the Fagerstrom Test for Nicotine Dependence 
(FTND) and the Heaviness of Smoking Index (HSI), motivation and intention to quit 
(Cycle of Change), together with the allocated group. After 3 months, the primary 
outcome of smoking status and the secondary outcomes of quit attempt of 31 week and 
reduction in number of cigarettes smoked were examined (data available for 103 
participants). Classification trees were used to identify significant factors in predicting 
both primary and secondary outcomes. 
Results: In predicting the primary outcome of quitting smoking at 3 months, a 
combination of low HSI and preparing to quit (Stage 3 of Cycle of Change) at 
baseline identified the only subgroup of participants predicted to quit smoking. 
However, this model only correctly identified 6/15 quitters. More successful models 
were obtained for predicting secondary outcomes, with both models having sensitivity 
of approximately 75% and specificity of approximately 85%. The allocated group was 
a significant factor in predicting both secondary outcomes, as were the measures of 
nicotine dependence, smoking habits and motivation at baseline. 
Conclusion: Classification trees can be used to produce informative models in 
predicting 3 month outcomes of a smoking cessation trial; these were most efficient 
with regard to the secondary outcomes. 
Oral Diseases (2004) 10, 287-293 
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Clinical Biochemistry 
The validation of self-reported smoking status 
by analysing cotinine levels in stimulated and unstimulated 
saliva, serum and urine 
V Binnie!, S McHugh!, L Macpherson!, B Borland2, K Moir3, K Malik4 
iGlasgOlI' Dental School, Glasgow, UK; 2Department of Biochemistry, North Glasgoll' NHS Trust, GartnGl'el General Hospital, 
Glasgow, UK; 3 Royal Dental Hospital of Melbourne, Melbourne, Australia; 4Birmingham Dental School, Birmingham, UK 
OBJECTIVES: Cotinine, a nicotine metabolite, can be 
used to measure exposure to tobacco smoke. The aim of 
this study was to compare cotinine levels in different 
biological fluids collected from both smokers and non-
smokers and to relate the findings to self-reported smo-
king status. Data were also collected concerning the 
acceptability of the differing methods of sample collec-
tion. 
MATERIAL AND METHOD: Patients recruited to the 
study were asked to provide samples of urine, blood and 
saliva (both stimulated and unstimulated). Data collected 
from patients by questionnaire included information on 
smoking behaviour such as daily number of cigarettes and 
environmental exposure to smoke. After the sample 
collection, patients were asked to rate the acceptability 
of each sampling method. Samples were analysed using 
enzyme immunoassay (EIA) kits. 
RESULTS: In total, 80 patients participated, with 49 
being smokers and 3 I being non-smokers. There was 
clear differentiation between smokers and non-smokers 
(P < 0.00 I) for all the different samples in terms of coti-
nine. A significant relationship was seen between cotinine 
and daily number of cigarettes for both salivas and urine 
(all P < 0.00 I) but not for serum. Participants found ser-
um and urine collection methodologies 'very acceptable' 
(67 and 66%, respectively) whereas 9% found collection of 
stimulated saliva 'not at all acceptable'. 
CONCLUSION: Cotinine, whatever the collection 
method and analysed by EIA kits, shows good differenti-
ation between smokers and non-smokers. Salivary sam-
ples have the advantage of being non-invasive, although 
collection methodology is important, as cotinine levels 
may vary. 
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Introduction 
Tobacco use is the single biggest contributor to ill 
health, and is the most important preventable cause of 
death in the UK (Callum, 1998). There is growing 
awareness and interest in the role that dental health 
professionals can play in helping their patients quit the 
tobacco habit, whether in secondary or primary care 
(Chestnutt and Binnie, 1995; McCann et aI, 2000; 
Warnakulasuriya 2002; Watt and Daly, 2003), 
In addition to being implicated in coronary health 
disease, lung and other cancers, smoking also has a 
profound effect on the oral tissues. Cigarette smoking is 
associated with increased prevalence and severity of 
periodontitis and smokers suffer from more tooth loss 
(KralI et ai, 1997; Tonetti, 1998). In addition, the risk of 
oral cancer and potentially malignant lesions is higher 
amongst smokers compared with those who have never 
smoked, Patients who smoke have a sixfold increased 
risk of developing oral leukoplakia compared with non-
smokers (Baric et aI, 1982). There is some evidence that 
if patients with such lesions can be encouraged to quit 
the tobacco habit, such lesions will regress (Gupta et ai, 
1986; Chad Martin et aI, 1999), However, neither of 
these studies used biochemical validation to monitor 
changes in tobacco exposure. 
When evaluating the effectiveness of tobacco cessa-
tion advice, it is important that some form of biochemi-
cal validation is used. The most commonly used means 
of evaluating tobacco exposure is the measurement of 
carbon monoxide in an exhaled air sample. Although 
advantages of this method include cost and ease of use, 
disadvantages include non-specificity and a short half-
life of 3-6 h, which can lead to false negatives, One 
biochemical marker that is able to determine exposure 
to tobacco smoke over a longer timeframe, with a half-
life of 20 h, is cotinine, This compound is a metabolite 
of nicotine and can be measured in a number of 
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biological fluids including blood, saliva, cervical exu-
date, semen and urine (Etzel, 1990; Vine et ai, 1993; 
Poppe et ai, 1995). Cotinine is sufficiently sensitive to be 
detected also in the body fluids of those individuals 
exposed to passive or environmental tobacco smoke 
(Cummings et ai, 1990). 
Most studies using cotinine assays have relied on 
serum samples, which can be problematic in field 
settings. Urine is non-invasive to collect, but requires 
access to facilities for its collection. 
Salivary samples, taken for use in cotinine analysis, 
also have the benefit of being non-invasive, and have 
been shown to be stable if sent by post, thus enabling 
their use in outreach studies (Greeley et ai, 1992; Smith 
et ai, 1998). Salivary cotinine has also been used exten-
sively to determine exposure to smoke in large popula-
tion studies, such as the health surveys in Scotland and 
England (Shaw et aI, 2000; Bajekal et ai, 2003). 
Most previous studies using saliva have failed to 
specify exactly how the saliva is collected although it has 
been suggested that levels of cotinine can vary depend-
ing on whether the saliva collected is stimulated or 
unstimulated. However, one study has examined the 
relationship between cotinine levels and collection 
method and found that stimulated samples had lower 
levels of cotinine than those found in unstimulated 
saliva (Schneider et ai, 1997). 
Traditionally, cotinine has been measured using a 
number of techniques including radioimmunoassay, gas 
liquid chromatography or liquid chromatography (Fey-
erabend and Russell, 1990). However, more recently, a 
microplate enzyme immunoassay (EIA) has become 
available in the UK. An advantage of these kits is that 
large, expensive equipment is not required, but to date 
the kits are relatively unevaluated in the UK. 
With regards to the patient's perspective, no pub-
lished work has previously investigated patient accepta-
bility of the different sampling methods used to collect 
biological samples for cotinine analyses. 
The main aim of this study was to measure and 
compare cotinine levels using the microplate EIA 
technique in a variety of biological fluids, collected 
from a group of patients, both smokers and non-
smokers, recruited in an outpatient oral medicine 
department. Further aims were to: 
(a) Correlate self-reported smoking exposure data with 
the biochemical determination of cotinine levels in 
the various body fluids; 
(b) Compare the patient acceptability of the differing 
methods of sample collection. 
Material and method 
Following approval from the Greater Glasgow Area 
Dental Ethics Committee, recruitment was via patients 
attending the oral medicine outpatient clinic at Glasgow 
Dental Hospital and School. Initially, smokers were 
invited to participate and non-smokers were then 
recruited, in an attempt to match age and gender to 
the case group. Data were collected over a 3-month 
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period in early summer, by two student researchers and 
one academic researcher. A convenience sample was 
used, with as many patients recruited as possible within 
the available timeframe. 
The age range for the participants was 16-75 years. 
Exclusion criteria included medical conditions such as 
an incipient diagnosis of oral carcinoma or medication 
affecting salivary function. For smokers, only those who 
used cigarettes were included in the study: those 
individuals who smoked a pipe or used cigars were 
excluded, as were any individuals currently using nico-
tine replacement therapy. 
Participating patients were asked to fill in a question-
naire about their tobacco smoke exposure. The ques-
tionnaire sought information on daily number of 
cigarettes smoked, time of first cigarette of the day, 
inhalational habits and brand and tar levels of current 
cigarettes used. The time elapsed since the most recent 
smoking occasion was also noted. 
For non-smokers, information on exposure to tobacco 
smoke both at home and in the workplace was collected. 
Additionally, details relating to tobacco smoke exposure 
in the last 24 h was recorded. 
Samples were then collected from each patient in the 
following order: 
1. An unstimulated sample of saliva was collected by 
asking the patient to drool into a universal container 
(minimum volume = 3 ml). 
2. A sample of stimulated saliva was collected by asking 
the patient to chew the cotton wool roll from a 
Salivette collection device (Sarstedt Aktiengesellsc-
haft & Co., Numbrecht, Germany). When saturated, 
this was removed from the mouth and placed into the 
salivette. 
3. A sample of blood (5 ml) was collected in a plain 
container using standard venepuncture techniques. 
4. A sample of urine (25 ml) was collected in a plain 
universal container. 
Patients were then asked to fill in a short question-
naire concerning the acceptability of the four different 
methods of sample collection. A four-point Likert scale 
was used which asked the respondents to rate the sample 
collection from 'completely unacceptable' to 'completely 
acceptable' . 
Blood samples were stored in a fridge overnight, to 
allow clotting before the serum was separated and 
stored at -20°C. Stimulated saliva samples collected 
using the Salivette devices were centrifuged at 1200 g for 
10 min. The supernatant was then removed and stored 
at -20°e. The unstimulated saliva and urine samples 
were stored at -20°e. On the day of analysis, the 
unstimulated saliva was thawed and centrifuged and the 
supernatant transferred to inert plastic tubes. 
Cotinine concentrations were measured using a micro-
plate EIA (Cozart Biosciences Ltd, Abingdon, UK). 
Different versions of the assay, with appropriate stand-
ards, are available for each of the three biological 
matrices. Quality control material was prepared by 
spiking cotinine-free serum, urine and saliva with coti-
nine standard (Sigma Chemicals) to give two levels, low 
and high within each standard range for each matrix. 
Where required. dilutions of the patients' samples were 
made using cotinine-free serum, urine and in the case of 
saliva, deionized water. Serum and salivary cotinine 
concentrations are expressed as ng ml- 1. Urine creatinine 
was measured by the Olympus kinetic Jaffe reaction on an 
Olympus 640 analyser (Olympus UK Ltd. Southall, UK). 
To take account of urine dilution, all urine cotinine 
results were expressed as a ratio (ng mmol- 1 creatinine). 
A cut-off of IS ng ml- 1 of cotinine was used to 
differentiate smokers from non-smokers in serum and 
saliva, whilst for the urine sample analysis, a cut-off of 
50 ng mmol- 1 of cotinine was used to determine smok-
ers (SRNT Subcommittee on Biochemical Verification, 
2002). 
Statistical analysis 
For smokers and non-smokers separately, the cotinine 
levels were approximately normally distributed. When 
comparing smokers and non-smokers, it was necessary 
to logarithmically transform the data, due to greatly 
differing variances in the cotinine levels. Subsequent 
analysis was performed on the transformed data and 
reported confidence intervals to compare smokers and 
non-smokers are for the ratios of the geometric means. 
Similar analysis was required when comparing non-
smokers who were exposed/not exposed to smoke. 
For smokers and non-smokers separately, a repeated 
measures analysis of variance was used to determine 
whether there were any significant differences between 
the four collection methods in terms of mean cotinine 
levels. Subsequent follow-up multiple comparisons were 
carried out to identify which methods differed signifi-
cantly. Generalized linear models were used to identify 
which self-reported factors, for smokers and non-
smokers separately, had a significant effect on the 
cotinine levels, again with suitable follow-up multiple 
comparisons where necessary. 
Results 
In total, 80 patients were recruited. Of the participants, 
49 (25 male, 24 female) were smokers (61 %) and 31 (15 
male, 16 female) were non-smokers (39%). The mean 
age of the smokers was 44 years (s.d. 18 years) and for 
the non-smokers 47 years (s.d. 17 years). Thirty-eight 
(48%) of the participants were from relatively affluent 
backgrounds, i.e. residing in DEPCAT 1-4 areas (21 
smokers and 17 non-smokers). 
Comparison of smokers vs non-smokers 
The mean cotinine level for the four fluids, for smokers 
and non-smokers separately, is shown in Table I 
together with the 95% confidence interval for the rati~ 
of the geometric mean cotinine levels (smokers/non-
smokers). Corresponding P-values from the two-sample 
t-tests of equal mean levels of cotinine in smokers and 
non-smokers are also given. 
A clear differentiation between the smokers and non-
smokers was seen (with P < 0.001 for all fluids) with 
confidence intervals illustrating the much greater mean 
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Table I Mean levels of cotinine for smokers and non-smokers for each 
sampling method 
Serum (ng ml-!) 
Stimulated saliva 
(ng ml-!) 
Unstimulated 
saliva (ng ml-!) 
Urine 
(ng mmol-!) 
Smokers 
(n = 49), 
mean (s.d.) 
328.4 (207.5) 
194.3 (122.5) 
314.0 (171.9) 
302.5 (244.0) 
Non-smokers 95% Cf' 
(n = 31). (smokers/ 
mean (s.d.) non-smokers) P-value 
3.6 (2.8) 59.7 Ill.? <0.001 
2.0 (0.9) 28.5 105.4 <0.001 
1.6 (1.2) 120.8 235.5 <0.001 
l.l (1.9) 224.9 776.3 <0.001 
"CI is for ratio of geometric mean of smokers to geometric mean of 
non-smokers. 
cotinine level of smokers. The mean level of cotinine in 
non-smokers in all the fluids was below 10 ng ml- 1• 
whereas the mean level of cotinine in the smokers varied 
from 194 ng ml- 1 in stimulated saliva to 328 ng ml- 1 in 
serum. 
Comparison of collection methods 
Repeated measures ANOV A indicated that there were 
significant differences in the mean cotinine levels 
between the four collection methods, for both smokers 
and non-smokers (both P < 0.001). Subsequent multi-
ple comparisons indicated that for smokers the cotinine 
levels in serum, urine and unstimulated saliva were 
significantly greater on average than the levels found in 
stimulated saliva (Table 2). For non-smokers, where 
cotinine is being measured in very small amounts, there 
were significant differences between the serum and all 
o.the.r types of .sample, with the mean serum level being 
slgmficantly higher. When comparing the urine and 
stimulated saliva in non-smokers, the mean level in the 
stimulated saliva was significantly higher. This last 
finding is the opposite relationship to that found with 
these two samples in smokers, where the mean level of 
cotinine in urine is higher than that found in the 
stimulated saliva. 
Relationships between self-reported data and cotinine 
levels for smokers 
Results from generalized linear models, incorporating 
number of cigarettes smoked per day « 10, 10-20 or 
Table 2 MUltiple comparisons of sampling methods for smokers and 
non-smokers 
Fluid fluid 
Serum ·stimulated saliva 
Serum ·unstimulated saliva 
Serum-urine 
Urine··stimulated saliva 
Urine unstimulated saliva 
Unstimulated saliva 
stimulated saliva 
95% Simultaneous CI for 
difference in average cotinine levels 
Smokers 
(n = 49) 
59.7217.7 
-63.793.2 
-52.0-103.9 
33.7191.8 
-89.7-67.3 
44.4 203.5 
Non-smokers 
(n = 31) 
0.9 2.5 
1.2 2.8 
1.83.4 
-1.7-0.1 
- J.3.'().3 
-1.2.'{).4 
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Figure 1 Boxplots of levels of cotinine by number of cigarettes smoked per day for each collection method, Boxplots illustrating dose response 
relationship between cotinine and number of cigarettes smoked per day (median trace of cotinine level across NOeS) 
> 20), tar level of cigarettes smoked (low, medium or 
high) and inhalational habits (slightly, moderately or 
deeply) for each of the collection methods separately, 
suggested that the only factor having a significant 
influence on the smokers' cotinine levels was number 
of cigarettes smoked per day (NOeS). The boxplots 
shown in Figure I show a cotinine dose-response 
relationship with NOeS. This dose-response relation-
ship between cotinine level and NOeS was statistically 
significant for stimulated saliva (Figure Ib), unstimu-
lated saliva (Figure Ic) and urine (Figure Id) (all 
P < 0.001) but was not statistically significant for 
serum (P = 0.291) (Figure la). 
For stimulated saliva, the mean cotinine level for < 10 
cigarettes day-l was significantly lower than that for 10-
20 and > 20 cigarettes day-I, but there was no signifi-
cant difference between the mean cotinine level for 10-
20 and that for> 20 cigarettes day-I. For unstimulated 
saliva, there was a significant difference between each of 
the three categories of NOeS. For urine, there was no 
significant difference between the average levels of 
cotinine for < 10 and 10-20 cigarettes day-I, but both 
of these had on average lower levels of cotinine than the 
> 20 cigarettes day-I category. 
Relationships between self-reported data and cotinine 
levels for non-smokers 
For non-smokers, generalized linear models were used 
to determine which of the three factors - exposed to 
passive smoke at home (yes or no), at work (yes or no) 
and exposed to passive smoke in the previous 24 h (yes 
or no) - had a significant influence on the mean cotinine 
level, for each of the four collection methods in turn (see 
Table 3). 
For each of the fluids, the most dominant factor was 
exposure to smoke at home. This factor had a significant 
effect on the average cotinine levels of stimulated saliva, 
unstimulated saliva and urine (all P < 0.05). For each 
of these fluids exposure to smoke at home significantly 
increased on average the mean level of cotinine, 
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Table 3 Mean levels of cotinine for non-smokers for each sampling 
method by exposure to smoke a t home 
Exposed 10 NOI exposed 
smoke 10 smoke al 95% Ct' 
al home home (exposed/ 
( n = 10), (n = 21), nol 
mean (s.d .) mean (s.d.) exposed ) P-value 
Serum (ng ml - I ) 5.4 (4.7) 2.9 (0 .8) 0.4- 1.4 0.25 
Stimulated 
sa liva (ng ml - I ) 
2.7(1.4) 1.7 (0.4) 0.5-0.9 0.02 
0.04 Unstimulated 2.5 (1.9) 1.3 (0.4) 0.4-1.0 
sa liva (ng ml- I ) 
< 0.01 Urine (ng mmol- I ) 2.3 (2 .0) 0.6 (1.5) 0.1- 0.5 
aCI is for ratio of geometric mean of exposed to geometric mean of not 
exposed. 
compared with the mean level of cotinine of participants 
not exposed to smoke at home. 
Patient acceptability of each collection method 
Figure 2 gives the percentages of patients who found 
each of the four collection methods 'very acceptable', 
'moderately acceptable', 'tolerable' and 'not at all 
acceptable'. There was no difference between the 
patterns of acceptability of smokers and non-smok~rs . 
High numbers of patients found both serum and urme 
collection methodologies 'very acceptable' (67 and 66% , 
respectively), significantly greater than that for the 
stimulated saliva collection (45%). No participant rated 
the serum or urine collection methods as being 'not at all 
acceptable', whilst almost one in 10 (9%) found collec-
tion of the stimulated saliva 'not at all acceptable'. The 
unstimulated saliva fared better than the stimulated 
saliva, with 51 % of the participants rating the former 
collection method as 'very acceptable' and only I % 'not 
at all acceptable'. 
Discussion 
For monitoring purposes within a smoking cessation 
trial , usually only one type of biological sample would 
be collected. Choice of sample type depends upon the 
sampling means available and the setting in which the 
sample is collected. 
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Figure 2 Barcharts of patient acceptability for each collection method. 
Percentage of patients finding serum, stimulated saliva, unstimulated 
saliva and urine collection methods 'very acceptable', 'acceptable', 
'moderately acceptable', and 'not at all acceptable' 
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This study aimed to compare cotinine levels and 
patient acceptability in four different collection methods 
within an oral medicine setting. It is acknowledged that 
the utilization of a convenience sample may have 
resulted in participants not being necessarily represen-
tative of the typical oral medicine patient population. 
Although a reasonable number of participants were 
recruited, the matching of non-smokers and smokers 
was incomplete due to time constraints, resulting in an 
unequal number of patients in the two groups. 
In this study, using the appropriate microplate EIA 
kit for each type of sample, good differentiation was 
obtained between smokers and non-smokers. Levels of 
cotinine varied among the different samples collected in 
the study. The half-life of cotinine in saliva and serum is 
approximately the same, and cotinine concentrations in 
these two matrices have previously been found to be 
correlated. Bernert et at (2000) reported that levels of 
cotinine in salivary samples (collected via salivette 
devices) were predictive of serum cotinine levels by 
± 10%. However, in the present study, serum levels were 
found to be more closely correlated with unstimulated 
than stimulated saliva: for smokers the serum cotinine 
was on average 4 and 41 % greater than the unstimu-
lated and stimulated salivas, respectively. 
In this study, the mean level of cotinine in smokers was 
found to be greater in the unstimulated (314 ng ml- I ) 
compared with the stimulated (194 ng ml- I ) saliva. These 
findings were consistent with those of Schneider et at 
(1997), who postulated that the reason for the difference 
may lie in the pH changes which alter with the flow rate. 
Cotinine has a pKa close to the pH of saliva and 
plasma. As the pH of unstimulated saliva is less than 
that of stimulated saliva, a basic compound such as 
cotinine would be influenced by the flow. Under more 
acidic conditions such as those produced by unstimulated 
saliva, there would be higher concentrations available 
of cotinine. Thus, as flow rate is increased with stimula-
tion, less of the substance would be captured for 
measurement. 
A cotinine dose-response relationship to nicotine 
exposure is important as it helps to quantify the relative 
risk that patients are undergoing. In this study, the two 
salivary samples and urine samples were able to differ-
entiate between categories of light, medium and heavy 
smoker, whereas serum samples were not able to exhibit 
this finding. Machacek and Jiang (1986) found similar 
findings, with poor correlation between cotinine con-
centrations in plasma and number of cigarettes smoked. 
With regards to saliva and cotinine levels, Etter et at 
(2000) found cotinine concentration to be moderately 
associated with the number of cigarettes per day. 
Given the reported relationship between cotinine 
concentrations and cigarettes per day, it may be possible 
to use this analysis in longitudinal studies to differentiate 
between smokers who report they have reduced smoking 
but who continue to compensatory smoke by inhaling 
more deeply (i .e. cotinine levels will be maintained), and 
smokers who actually cut down smoking exposure prior 
to quitting totally. This is an area requiring further 
investigation. 
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Patient acceptability of the different methods of 
sample production provided some unexpected findings. 
It was postulated that patients might rate venepuncture 
least favourably because of the invasive nature of the 
technique. However, surprisingly they rated the stimu-
lated saliva collection most negatively. Some partici-
pants found the chewing of the cotton wool roll an 
unpleasant sensation and, in extreme cases, felt nause-
ous, which may have led to a poor acceptability rating 
being recorded. From a participant's point of view, the 
unstimulated saliva appeared to be the more acceptable 
of the two salivary collection methods, and hence 
would be the choice for any future work within a 
dental setting. Acceptability levels associated with 
alternative means of stimulating saliva would require 
further investigation. 
The high acceptability of the blood sampling meth-
odology may be related to the setting in which this cross-
sectional study took place: a dental hospital oral 
medicine department where venepuncture is often a 
routine part of investigation. It is postulated that work 
carried out in a different dental setting such as general 
dental practice or a periodontal clinical may yield 
differing results in terms of patient acceptability of 
collection methods. 
It is important that any future smoking cessation 
interventions within a dental setting are monitored, and 
that quit rates are biochemically verified. One study 
which took place in a hospital periodontal department, 
found a difference in quit rates between intervention and 
control groups of 7%. However, this information was 
gathered by self-report (Macgregor, 1996). The first UK 
study of smoking cessation in general dental practice did 
use cotinine to biochemically verify those participants 
who reported that they had quit smoking and had a 
success rate of 11 % (Smith et ai, 1998). Whole mouth 
salivary samples were collected for cotinine analysis by 
gas chromatography. 
For future smoking cessation work, baseline verifica-
tion of cotinine levels, followed by cotinine assessment 
once smoking cessation interventions have taken place 
offer a good means of monitoring and evaluating the 
process of smoking cessation interventions as they are 
delivered. For patient motivation and feedback, if this is 
combined with a more immediate means of determining 
exposure, similar to that obtained with an exhaled air 
sample measured using a carbon monoxide monitor, the 
greater may be the benefit for the patients (Murray et ai, 
2002). 
In conclusion, the results of this study show that, with 
the use of EIA kits, any of the four collection methods 
would be appropriate for biochemical validation of 
tobacco exposure. From a practical perspective, saliva 
would be the most appropriate for use by oral health 
staff, and patients' opinions would suggest using an 
unstimulated rather than stimulated collection method. 
References 
Bajekal M, Primatesta P, Prior G (2003). Health survey for 
England. 2001. The Stationery Office: London. 
Oral Diseases 
Baric JM, Alman JE, Feldman RS, Chancey HH (1982). 
Influence of cigarette smoking, removable partial dentures 
and age on oral leucoplakia. Oral Surg Oral Med Oral 
Pathol54: 424-429. 
Bernert JT, McGuffey JE, Morrison MA, Pirkle JL (2000). 
Comparison of serum and salivary cotinine measurements 
by sensitive high-performance liquid chromatography -
tandem mass spectrometry method as an indicator of 
exposure to tobacco smoke among smokers and nonsmok-
ers. J Anal Toxieol24: 333-339. 
Callum C (1998). The UK smoking epidemic: deaths in 1995. 
Health Education Authority: London. 
Chestnutt IG, Binnie VI (1995). Smoking cessation counselling 
- a role for the dental profession? Br Dent J 179: 411--415. 
Cummings KM, Markello SJ, Mahoney M, Bhargava AK, 
McElroy PD, Marshall JR (1990). Measurement of current 
exposure to environmental tobacco smoke. Arch Environ 
Health 45: 74-79. 
Etter JF, Vu DT, Perneger TV (2000). Saliva cotinine levels in 
smokers and nonsmokers. Am J Epidemiol151: 251-258. 
Etzel RA (1990). A review of the use of saliva cotinine as a 
marker of tobacco smoke exposure. Prev Med 19: 190--197. 
Feyerabend C, Russell MA (1990). A rapid gas-liquid chro-
matographic method for the determination of cotinine and 
nicotine in biological fluids. J Pharm Pharmacol 42: 450--452. 
Greeley DA, Valois RF, Bernstein DA (1992). Stability of 
salivary cotinine sent through the U.S. mail for verification 
of smoking status. Addict Behav 17: 291-296. 
Gupta PC, Mehta FS, Pindborg JJ et al (1986). Intervention 
study for primary prevention of oral cancer among 36 000 
Indian tobacco users. Lancet 21: 1235-9. 
Krall EA, Dawson-Hughes B, Garvey AJ, Garcia RI (1997). 
Smoking, smoking cessation, and tooth loss. J Dent Res 76: 
1653-1659. 
Macgregor ID (1996). Efficacy of dental health advice as an aid 
to reducing cigarette smoking. Brit Dent J 180: 292-296. 
Machacek DA, Jiang NS (1986). Quantification of cotinine in 
plasma and saliva by liquid chromatography. C/in Chern 32: 
979-982. 
Martin CG, Brown JP, Eifler CW, Houston GD (1999). Oral 
leucoplakia status six weeks after cessation of smokeless 
tobacco. J Am Dent Assoc 130: 945-54. 
McCann MF, Macpherson LM, Binnie VI, Stephen KW 
(2000). A survey of primary care dental practitioners' oral 
cancer-related practices and training requirements. Comm 
Dent Health 17: 24-30. 
Murray RP, Connett JE, Istvan JA, Nides MA, Rempel-
Rossum S (2002). Relationship of cotinine and carbon mon-
oxide to self-reported smoking in a cohort of smokers and 
ex-smokers followed over 5 years. Nicotine Tob Res 4: 287-294. 
Poppe WA, Peeters R, Daenens P, Ide PS, Van Assche FA 
(1995). Tobacco smoking and the uterine cervix: cotinine in 
blood, urine and cervical fluid. Gynecol Obstet Invest 
39:110--114. 
Schneider NG, Jacob P III, Nilsson F, Leischow SJ, Benowitz 
NL, Olmstead RE (1997). Saliva cotinine levels as a function 
of collection method. Addiction 92: 347-351. 
Shaw A, McMunn A, Field J (2000). Scottish health survey 
1998. The Stationery Office: Edinburgh. 
Smith SE, Warnakulasuriya KA, Feyerband C, Belcher M, 
Cooper DJ, Johnson NW (1998). A smoking cessation 
programme conducted through dental practices in the UK. 
Br Dent J 185: 299-303. 
SRNT Subcommittee on Biochemical Verification (2002). 
Biochemical verification of tobacco use and cessation. 
Nicotine Tab Res 4: 149-159. 
Tonetti MS (1998). Cigarette smoking and periodontal 
diseases: etiology and management of disease. Ann Period-
ontal 3: 88~ I 0 1. 
Vine MF, Hulka BS. Margolin BH et al. (1993). Cotinine 
concentrations in semen, urine, and blood of smokers and 
nonsmokers. Am J Publ Health 83: 1335~1338. 
The validation of self· reported smoking status 
V Binnie et 01 
Warnakulasuriya S (2002). Effectiveness of tobacco counsel-
ling in the dental office. J Dent Edu 66: 1079~1O87. 
Watt R, Daly B (2003). Prevention. Part 1: Smoking advice 
within general dental practice. Brit Dent J 194: 665-668. 
293 
Oral Dileases 
Tobacco and Smoking Cessation. 
Peer-reviewed Pu blications 
Chestnutt, I.G., Binnie, V.1. (1995): Smoking Cessation counselling - A role for the dental 
profession? British Dental Journal, 179, 411-415. 
Chestnutt, I.G., Binnie, V.1. (1996): La Lutte contre Ie tabagisme. Information Dentaire, 
21,1553-1558. 
Chestnutt, I.G., Binnie, V.1. (1996): Training in the provision of smoking cessation advice in 
United Kingdom Dental Schools and Schools of Hygiene. International Journal of Health 
Education, 34, 109-111. 
McCann, M, Macpherson, L.M., Binnie, V.I, Stephen, K.W. (2000): A survey of Scottish 
Primary Care Dental Practitioners' oral cancer-related practices and training requirements. 
Community Dental Health 17, 24-30. 
Conway, D.I., Macpherson, L., Gibson, J. and Binnie, V.1. (2002): Oral Cancer Prevention 
and Detection in Primary Dental Care. Primary Dental Care 9, 119-123 
Macpherson, L.M., McCann, M., Gibson, 1., Binnie, V.I. and Stephen, K.W. (2003): The 
role of Primary Health Care Professionals in Oral Cancer Prevention and Detection. British 
Dental Journal 195, 277-28 
Binnie, V., McHugh, S., Macpherson, L., Borland, 8., Moir, K. and Malik, K. (2004): The 
validation of self-reported smoking status by analysing cotinine levels in stimulated and 
unstimulated saliva, serum and urine. Oral Diseases 10: 287-293. 
Other 
Macpherson LMD, Gibson J, Binnie VI, Stephen KW. (2000). Oral Cancer: Prevention & 
Detection for the Primary Care Dental Team. University of Glasgow, Glasgow. 
Macpherson LMD, Gibson J, Binnie VI, Conway D. (2003). Oral Cancer Prevention and 
Detection: a guide for the primary care team. 2nd Ed. NHS Health Scotland/University of 
Glasgow. Edinburgh. 
Tobacco-related Research Abstracts 
BSDR Lancaster 2000 
Passive smoking and the effect on cotinine levels 
V. Binnie, S. McHugh, K. Malik, K. Moir, L. Macpherson, W. Borland l 
(University of Glasgow, Scotland, IGlasgow Royal Infmnary) 
The effect of nicotine exposure on the cotinine levels in smokers 
K. Malik, V. Binnie, K. Moir, L. Macpherson, W. Borland l , S. McHugh 
(University of Glasgow, Scotland, !Glasgow Royal Infirmary) 
Cotinine estimation in biological fluids - patient acceptability 
K. Moir, V. Binnie, K. Malik, L. Macpherson, W. Borland!, S. McHugh 
(University of Glasgow, Scotland, IGlasgow Royal Infirmary) 
Cardiff PEF Meeting, 2002 
Nicotine dependence and cotinine & carbon monoxide levels in smokers 
V.1. Binnie, S. McHugh, L.M. Macpherson, W. Jenkins, W. Borland 
(Glasgow Dental Hospital & School, IDept of Biochemistry, Gartnavel General 
Hospital, Glasgow) 
Gothenburg IADR Meeting, 2003 
Dental Hrgienists' Delivery of Smoking Cessation: 3-month Outcomes 
V. Binnie, S. McHughl, L.M. Macpherson I , W. Jenkins2, W. Borland3 
(lUniversitl of Glasgow, United Kingdom, 2Glasgow Dental Hospital, United 
Kingdom, Gartnavel General Hospital, Glasgow, United Kingdom). 
Prediction of Primary and Secondary Outcomes in a Smoking Cessation Trial 
S. McHugh!, V. Binnie!, L.M. Macpherson!, W. Jenkins2, W. Borland3 
(IUniversi7. of Glasgow, United Kingdom, 2Glasgow Dental Hospital, United 
Kingdom, Gartnavel General Hospital, Glasgow, United Kingdom). 
Research Grants in Smoking Cessation 
Scottish Office(1995) : Smoking Cessation and the Dental Team: £4000 
ASH ScotlandIP A TH (2003) : Preventing Oral Cancer an intervention in a dental 
setting: £130, 113 
Invited Lectures 
Viv also lectures on Tobacco and Smoking Cessation to various oral health 
professionals including undergraduates and dentists, dental hygienists and dental 
nurses, as part of the NHS Education CPD and PCD continuing education 
programmes. Courses have been held so far, in Glasgow, Edinburgh, Dundee and 
Inverness. Viv has also lectured on the topic at Emerging Trends in Oral Care, Philips 
Oral Healthcare Symposium 2004, Paris. 
